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Classification of benign and malignant soft tissue tumours
Soft tissue sarcomas are rare malignant tumours originating from the 
mesenchymal or neuroectodermal tissues, comprising less than 1% of all 
cancers. The annual incidence of soft tissue sarcomas is around 5 (4.74) per 
100,000 with a 5-year survival rate of around 49% (1, 2). Nevertheless, there 
are more than 50 different histological subtypes described, which differ in 
biology and are characterized by a unique clinical behaviour and prognosis 
and therefore require specialized treatment (3). This emphasizes the pivotal 
importance of a correct diagnosis, which can be challenging for pathologists as 
these tumours are rare and due to the numerous different histological subtypes 
of which some have overlapping features. Uniform classification of bone and 
soft tissue sarcomas is performed on the international consensus guidelines of 
the World Health Organisation (WHO)(3). The biological potential of tumours 
varies and four main groups can be discerned: benign, locally aggressive, rarely 
metastasizing and malignant.
Soft tissue sarcomas can be grouped based on their line of differentiation, 
thus, based on the normal tissue that the tumour most closely resembles, 
including for example adipocytes, smooth muscle cells, striated muscle cells, 
fibroblasts, histiocytes, pericytes, endothelial cells, perineurial-like cells and 
Schwann cells. Some soft tissue tumours are composed of a combination 
of two or more cell types and there is also a group of tumours of uncertain 
differentiation. Mesenchymal tumours can occur anywhere in the body, 
although the majority is located in the extremities (up to 75%), the trunk wall 
(around 10%) and the retroperitoneum (10%). Some subtypes even have a 
strong predilection site, for instance, two-third of the myxoid liposarcomas 
develop in the thigh. Moreover, the age of patients is important to consider 
as some sarcomas have an age-related incidence, for example, embryonal 
rhabdomyosarcoma is encountered almost exclusively in young children while 
alveolar soft part sarcoma is most frequently detected in young adults and 
soft tissue leiomyosarcoma and undifferentiated pleomorphic sarcoma occur 
mainly in elderly patients (3). The overall male to female ratio is 1.1/1 for soft 
tissue sarcomas. In the subgroup of visceral sarcomas, including gastrointestinal 
stromal tumour (GIST), a female preponderance is observed (1.4/1) (4). 
On the other end of the spectrum of malignant soft tissue tumours, 
are the benign mesenchymal lesions. This group of neoplasms is also 
43717 Marieke de Graaff 100% ZW.indd   10 30-12-16   11:46
General Introduction
11
1
heterogeneous and consists of multiple diff erent histological subtypes. 
The incidence of some of these lesions is relatively high, and is estimated to 
outnumber sarcomas by a factor of minimal 100. A well-known example of 
a benign soft tissue tumour is a conventional lipoma, responsible for around 
30% of all benign soft tissue tumours (3, 5). Conventional lipomas are most 
frequently located subcutaneously or in the deep soft tissues on the trunk 
or extremities. Generally they are maximum a few centimetres in diameter, 
macroscopically well circumscribed and histologically composed of lobules 
of mature adipocytes without cytonuclear atypia (3). Other common benign 
neoplasms are for example leiomyomas, which will be discussed in more detail 
below, nodular fasciitis and schwannoma (3).
Histological classifi cation and grading of soft tissue 
neoplasia
As mentioned before, soft tissue sarcomas, comprises a rare group of 
malignancies and accurate diagnosis is challenging for pathologist who are 
not familiar with the broad range of histological subtypes, therefore the risk of 
initial diagnostic error ranges from 8-25% (3, 4, 6). This has been investigated 
by performing a second opinion on diagnosed cases of soft tissue sarcomas by 
expert pathologists. In the majority of the cases there is either a full agreement 
on the diagnosis or a partial agreement, situation in which both pathologists 
diagnosed a sarcoma but with diff erent histopathological grade, between the 
fi rst and expert pathologist. Other examples of major discrepancies are cases in 
which benign lesions are mistaken for a sarcoma (10%) or the other way round, 
a sarcoma is mistaken for a benign neoplasm (4%)(4). Expert pathologists have 
extensive experience with these rare tumours and knowledge of and access 
to the latest molecular diagnostic tools like immunohistochemistry, FISH and 
(Next Generation) Sequencing. In a large series <10% of initial diagnoses 
were considered major misdiagnoses which were related to histological type 
or tumour grade (6). The correct diagnosis is crucial for determination of the 
right treatment, especially for tumours with novel targeted treatments, as 
this infl uences patient outcome. Therefore referral to a specialized sarcoma 
center is often advised for diagnostics and to make appropriate decisions on 
treatment. These multidisciplinary teams often include surgeons, pathologists, 
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radiologists, medical oncologists, radiation therapists and when applicable 
organ-based specialists.
The most widely used grading system of sarcomas and also advised by 
the WHO is the system of the Fédération Nationale des Centres de Lutte Contre 
le Cancer (FNCLCC)(3, 7). This system is reproducible and the grade is assessed 
based on three independent histological parameters: tumour differentiation, 
mitotic activity and necrosis. Tumour differentiation indicates how closely the 
tumour resembles normal mesenchymal tissue. Poorly differentiated sarcomas, 
like for example rhabdomyosarcoma, synovial sarcoma and clear cell sarcoma, 
are scored as undifferentiated per definition (3, 7).
Clinical features and diagnosis
Most soft tissue sarcomas present as slowly growing, painless masses that 
are detected incidentally and do not, at first instance, interfere with the daily 
function or general health. Especially at certain locations, as for example the 
retroperitoneum, tumours can become quite large before they are detected. 
Due to this seemingly innocent behaviour tumours are often in the beginning 
characterized as benign lesions. Patients with a superficial lesion of >5 cm in 
diameter or with a deep soft tissue mass should preferably be directed to a 
referral center with a multidisciplinary team for diagnosis and treatment (2, 3). 
Imaging of soft tissue neoplasia is important as it will provide key 
information on size of the tumour and relation with other structures, and 
specialized radiologists might give a good differential diagnosis on the 
images. Conventional X-ray is often performed in the first place and although 
it is not detailed it might be helpful in ruling out a primary bone tumour 
extending in the surrounding soft tissues. Also calcifications in a soft tissue 
mass, as seen in myositis ossificans, will be detected. Magnetic resonance 
imaging (MRI) is able to give detailed information on tumour size, tumour 
components like fat, necrosis, cystic degeneration, haemorrhage and 
oedema, and relation with surrounding structures, including for example 
bone and neurovascular bundles. The use of T1-weighted and T2-weighted 
images might help to discriminate between tumours with a high fat or blood 
content (high signal on T1W) and fibrous tumours (high signal on T2W). CT-
scans are in some instances performed to detect deposition of calcifications 
43717 Marieke de Graaff 100% ZW.indd   12 30-12-16   11:46
General Introduction
13
1
and baseline chest CT might be performed for accurate staging at time of 
diagnosis (2, 3). 
Following adequate imaging, the next step in the work-up is taking of 
multiple core needle biopsies of the soft tissue mass. In case of a deep seated 
lesion this might be done with image-guidance. The biopsy location must be 
chosen in deliberation with the surgeon in such a way that complete resection 
of the biopsy tract can be achieved during defi nitive surgery of the tumour (2, 3).
Genetic classifi cation of mesenchymal tumours
Next to the histopathological classifi cation, soft tissue neoplasms can be 
divided based on the molecular biology of the tumours. From the molecular 
genetic perspective, tumours are classifi ed in accordance to their genomic 
profi le. Development of cytogenetic and molecular techniques have resulted 
in the discovery of recurrent genetic aberrations in a large subset of soft 
tissue tumours. The identifi cation of specifi c genetic alterations have led to an 
increased understanding of the biological mechanisms and cellular pathways 
that have a role in the tumorigenesis.
From a genetic point of view soft tissue tumours can be classifi ed in 
three main categories: tumours with a specifi c, reciprocal translocation and 
often a near-diploid karyotype, tumours with specifi c mutations (activating or 
inactivating mutation or gene amplifi cation) in a variable genomic background 
and tumours with an instable genome and as a consequence a complex 
karyotype (Table 1) (3, 8). Of the 117 soft tissue tumours listed in the WHO 
Classifi cation of Tumours of Soft Tissue and Bone of 2013, approximately 45% 
harbour a recurrent cytogenetic or molecular aberration (3, 9). However, it is 
not inconceivable that this number will increase in the future with the ongoing 
development of molecular genetic techniques.
The overall fraction of soft tissue tumours with a reciprocal translocation 
is estimated at ~20% (3, 9, 10). The occurrence of a chromosomal translocation 
is considered a crucial genomic event for a cell and often plays an important 
role in tumorigenesis. A chromosome translocation is formed in a complex 
one-step event and is infl uenced by several factors, including for example the 
occurrence of double strand breaks (DSB), the concentration of repair proteins 
around the broken chromosome ends and the three-dimensional location of 
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chromosomes with DSB in the interphase nucleus (11, 12). Dependent on the 
exact location of the breakpoints and the resulting composition of the fusion 
product, translocations can have several consequences, it can form a chimeric 
fusion protein in case the coding sequence of two genes are fused, it can 
disrupt a tumour suppressor gene or it can place a tumour-promoting gene 
behind the promoter of a transcriptional active gene (promotor swapping). In 
all these three cases the cell can experience a proliferative advantage and this 
can subsequently lead to tumorigenesis (11, 13). An example of a soft tissue 
sarcoma with a chimeric fusion gene is myxoid liposarcoma characterized 
by an FUS-DDIT3 or EWSR1-DDIT3 translocation; which was first described at 
cytogenetic level in 1986 and the involved genes were identified more than six 
years later (3, 14, 15). Translocations and point mutations are not exclusively 
found in malignant tumours as also multiple benign neoplasm harbour 
recurrent cytogenetic aberrations (16). The translocations found in aneurysmal 
bone cyst (ABC), a locally aggressive neoplasm, are caused by juxtaposition 
of the USP6 gene to any of the highly transcriptional active promotors of the 
CDH11, COL1A1, OMD, TRAP150 or ZNF9 genes (12, 17). A subset of lipomas 
show rearrangements at 12q14.3, leading to deregulation of the high-mobility 
group AT-hook 2 (HMGA2) gene and several partner genes of HMGA2 have been 
identified (3).
The second category consist of tumours with specific in- or activating 
mutations or gene amplifications which often lead to alterations in important 
signalling pathways. A well-known example is gastrointestinal stromal tumour 
(GIST) characterized by oncogenic, activating mutations in KIT, PDGFRA or 
BRAF, resulting in a continuous signalling of the KIT pathway (8). These tumours 
might harbour a variation in secondary genetic changes and in some cases 
DNA copy number changes seem to be related to the occurrence of metastasis 
(18).
The last group comprise tumours with an instable genome and as a 
consequence a complex karyotype, these tumours often contain multiple 
non-recurrent numerical and structural chromosome alterations (3, 8). These 
alterations can accumulate gradually over time during cancer development, 
although complex rearrangements can also develop in a single catastrophic 
event of reshuffling of chromosomes, known as chromothripsis (19). 
Leiomyosarcoma, pleomorphic liposarcoma and undifferentiated pleomorphic 
sarcoma (UPS) are examples of karyotypically complex sarcomas (3).
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The discovery of specifi c, recurrent translocations or mutations in certain 
soft tissue neoplasms are unique features that discriminates them from other 
lesions and have contributed signifi cantly to the classifi cation of mesenchymal 
neoplasms. The presence of a pathognomonic molecular genetic alteration 
has also proven to be of tremendous value in the diagnostic process (9). 
Molecular genetic techniques provide a helpful diagnostic tool, especially 
in discriminating tumours with similar histology, but diff erent biological 
behaviour or clinical outcome (9, 10). Due to the ongoing development of 
genetic profi ling techniques, for example the broad spectrum of sequencing 
options, including RNA, whole genome and transcriptome sequencing, 
tumours that are now classifi ed under the same diagnosis, might in the future 
be split in diff erent molecular subtypes. The seemingly ‘ever increasing’ number 
of molecular subtypes will inevitably lead to a discussion between the ‘splitters’ 
and the ‘lumpers. It is important to focus on those molecular subtypes that 
diff er in clinical prognosis or that have alterations in molecular pathways which 
might be candidates for targeted therapies. 
Table 1. The molecular genetic subtypes of soft tissue tumours.
Genetic profi le Example
Specifi c translocation and 
relatively simple karyotype
Myxoid liposarcoma: t(12;16)(q13;p11) or t(12;22)(q13;q12)
Synovial sarcoma: t(X;18)(p11;q11)
Specifi c mutation in variable 
genomic background
Gastrointestinal stromal tumour: KIT, PDGFRA, BRAF
Dediff erentiated liposarcoma: amplifi cation MDM2, CDK4
Complex karyotype without 
recurrent aberration 
Leiomyosarcoma of soft tissue
Myxofi brosarcoma
Therapeutic strategies in soft tissue sarcomas
The cornerstone of the treatment of soft tissue sarcomas is surgery with a wide 
tumour resection with negative margins, which implies that the tumour needs to 
be surrounded by a rim of normal tissue or the tumour may not cross anatomical 
borders like muscular fasciae or epineurium. Radiation and chemotherapy, 
neo-adjuvant or adjuvant, are frequently part of the treatment regimen and 
the decision of these therapies are made in a specialised multidisciplinary 
team by taking into account several variables, including: specifi c sarcoma 
subtype, chemosensitivity of histological subtype, resection margins (if 
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possible to operate at all), tumour location,  tumour size, tumour grade, stage 
of the disease (especially localized versus advanced and/or metastatic disease), 
patient’s general condition, relevant comorbidities, previous chemotherapy 
and treatment goal (2, 20-22). The first-line chemotherapy of choice is the 
anthracycline doxorubicin, often used as monotherapy but individual cases 
might benefit from the combination with ifosfamide (2, 23). Over the past 
years several trials have compared these two chemotherapeutic regimens in 
soft tissue sarcomas and there is no evidence that multi-agent chemotherapy 
leads to a statistical significant longer overall survival compared to doxorubicin 
alone, although in some studies a higher regression rate was observed (23, 24). 
The specific alterations that have been identified in the genomes of 
sarcomas over the past years, can be used to develop molecular targeted 
therapy. In particular tumours with a pathognomonic genetic aberration are 
good candidates for targeted therapy. The most well-known example is GIST, 
which can be targeted by the KIT kinase inhibitor imatinib, which gives a 
partial response or stable disease in around 77% of patients with advanced 
or metastatic GIST (25). Other targeted (tyrosine kinase) inhibitors are being 
investigated in several sarcoma types. A thorough understanding of the 
different mechanisms of pathogenesis in soft tissue tumours is of pivotal 
importance in the search for novel therapeutic targets. Most translocation-
associated sarcomas are characterized by gene-fusions which act as aberrant 
transcription factors, thereby influencing the expression of a multitude of 
genes promoting oncogenesis. In this way the chimeric transcription factor 
dysregulates downstream signalling of several cellular pathways. As a result, 
specific targeting of only one affected signalling pathway might have a 
limited effect in individual cases. Secondary changes occurring during tumour 
progression might serve as a potential target as well. For instance,  ~18% of 
myxoid liposarcomas, characterized by FUS-DDIT3 fusion products, harbour 
additional PIK3CA mutations resulting in altered signalling of the mammalian 
target of rapamycin (mTOR) pathway. However, targeting the mTOR pathway 
alone might not be sufficient in myxoid liposarcoma, since the tumour cells are 
likely to show disturbances in other pathways as well due to altered signalling 
caused by the aberrant transcription factor (26).  Occasionally, a translocation 
may lead to receptor or ligand activation leading to aberrant receptor 
tyrosine kinase signalling that more often have specific, inhibitory  small 
molecules. An example of this type of translocation-associated sarcomas is 
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dermatofi brosarcoma protuberans. This locally aggressive neoplasm harbours 
a COL1A1-PDGFB chimeric fusion gene and the fusion product is processed 
to the normal PDGFB ligand (3, 27). Tumour cells carry the membrane kinase 
receptor, resulting in autocrine signalling and stimulating tumorigenesis. This 
autocrine growth signalling loop can be disrupted by the PDGFR inhibitor 
imatinib.
Recently, the fi eld of cancer immunology has become more important and 
several immunotherapeutic approaches, like cytokine-based immunotherapy, 
immune checkpoint inhibitors, tumour vaccines and adoptive T-cell therapy, 
are under investigation (8, 28). The family of cancer-testes antigens constitute 
more than 200 proteins which are by defi nition expressed in the primitive 
spermatogonium of the testis, but not in other adult tissues (29). They have 
immunogenic properties, but as they are separated and protected by the 
blood-testis barrier, no natural immune response is provoked. There are 
diff erent subgroups and some are more immunogenic than others. Well-known 
examples of cancer-testes antigens are MAGE, PRAME, GAGE and SSX2. New 
York oesophageal squamous cell carcinoma (NY-ESO-1) or CTAG1B belongs to 
the CTA family and was fi rst detected in an oesophageal carcinoma. It is also 
highly expressed in the majority of myxoid liposarcomas and synovial sarcomas 
(30-32). Therefore it is regarded as an attractive target for immunotherapy. 
NY-ESO-1 can be targeted by dendritic vaccine based strategies resulting in 
CD8+ and CD4+ T-cell responses. Since the direct cytotoxic eff ect of CD8+ T-cells 
against tumour cells is the most important, another option is adoptive cell 
therapy, involving the transfer of autologous cytotoxic T-cells or natural killer 
(NK-)cells which are genetically engineered to express T-cell receptors directed 
against NY-ESO-1 (28).
Smooth muscle tumours
Leiomyomas
Benign smooth muscle tumours are quite frequently encountered in the 
smooth muscle tissue of the uterus. Uterine fi broids have an estimated 
incidence of ~70% of women in reproductive age and often more than one 
lesion is present (33, 34). The tumours are usually well-circumscribed and have 
a slight varying cell density of a population of uniform long spindle cells with 
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eosinophilic cytoplasm and elongated blunt-ended nuclei without substantial 
cytonuclear atypia. 
Genetically, uterine leiomyomas can be classified in at least four 
different groups. The majority, around 70%, of the tumours harbour a mutation 
in mediator complex subunit 12 (MED12), located on chromosome Xq13.1 
(33). Germline mutations in this gene were first described in patients with FG 
syndrome (Opitz-Kaveggia syndrome)(35). MED12 is a member of the mediator 
complex which is involved in regulation of transcription of RNA polymerase II-
dependent genes. The molecular pathogenesis responsible for tumorigenesis 
in MED12 mutated fibroids is still not completely elucidated, but it has been 
postulated that interaction with β-catenin and increased canonical WNT 
signalling; and loss of repressor element 1 silencing transcription factor (REST) 
and increased signalling of PI3K/AKT/mTOR might have an important role (34, 
36). Nuclear β-catenin is also known to directly interact with MED12, resulting 
in transcription of target genes of the canonical Wnt-signalling pathway. 
Markowski et al found high expression of wingless-type MMTV integration 
site family, member 4 (WNT4), also a member of the Wnt pathway, of which 
expression is regulated by estrogen in Müllerian mesenchymal tissues (37). 
Multiple chromosomal alterations have been described in leiomyomas, and 
the most frequent recurrent translocation is the t(12;14)(q15;q24), fusing high-
mobility group AT-hook 2 (HMGA2) gene to the RAD51L1 gene (38). This is the 
second most common genetic aberration found in uterine leiomyomas. A 
small percentage of leiomyomas harbour a fumarate hydratase (FH) mutation 
or deletions affecting collagen, type IV, alpha 5 (COL4A5) and collagen, type IV, 
alpha 6 (COL4A6) (39). The HMGA2, FH, COL4A5-COL4A6 and MED12 alterations 
are mutually exclusive, while some other genetic aberrations including HMGA1 
alterations and 7q deletions can co-occur with MED12 mutations (37, 40, 
41). An interesting observation is the occurrence of complex chromosomal 
rearrangements in some MED12 mutated and MED12 wild-type leiomyomas 
(40). The complex chromosomal rearrangements fulfil to the criteria of 
chromothripsis, which was first thought to be exclusively associated with 
malignant tumours, but is also encountered in genomes of some benign 
lesions and congenital disorders (42, 43).
Less frequently leiomyomas appear in the cutis, named cutaneous or 
piloleiomyomas, and these can occur either sporadic or in association with 
an inherited disorder. The most well-known is Reed’s syndrome or hereditary 
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leiomyomatosis and renal cell cancer (HLRCC), an autosomal dominant 
disease, in which patients are predisposed to develop cutaneous and uterine 
leiomyomas and papillary renal cell cancer. HLRCC is caused by a heterozygotic 
germline mutation in the gene encoding the Krebs cycle enzyme fumarate 
hydratase (FH), located at 1q43 (44, 45). The accumulation of high levels of 
fumarate leads to abberant succination of proteins by forming a chemical 
modifi cation of cysteine residues to S-(2-succino)-cysteine (2SC) (46). In 
addition to HLRCC cutaneous leiomyomatosis has been associated with several 
other syndromes and conditions (47).
Leiomyosarcomas
Leiomyosarcomas are malignant tumours with features of smooth muscle 
diff erentiation and responsible for around 10 to 20% of all soft tissue sarcomas 
(3, 48, 49). Tumours are most frequently encountered in the 5th to 6th decade and 
are slightly more common in women compared to men. Based on the anatomic 
site the tumours can be classifi ed in fi ve major groups:  leiomyosarcomas 
originating in the deep soft tissues, retroperitoneum, uterus, blood vessels and 
superfi cial dermis (3). Tumours confi ned to the dermis have an indolent clinical 
course and rarely metastasize, and are therefore better designated “atypical 
intradermal smooth muscle neoplasm” (50, 51).
Uterine leiomyosarcomas are considered as a separate entity, as they 
have a Müllerian origin and often express estrogen receptor (ER), progesterone 
receptor (PR) or Wilms tumour protein (WT1), supporting derivation of the 
genitourinary tract (52, 53). These tumours are not graded according to the 
FNCLCC, instead the Federation of Gynaecology and Obstetrics (FIGO) staging 
system is applied. The prognosis of uterine leiomyosarcoma is often poor and 
depends on the tumour stage. The 5-year overall survival (OS) rate is 40% (54).
Leiomyosarcomas of the deep soft tissues and the retroperitoneum are 
often large (>10 cm) at the moment of presentation (55). Histologically lesions 
are characterized by a population of long spindle cells with eosinophilic, fi brillar 
cytoplasm, arranged in intersecting bundles (Figure 1A and B). The cells contain 
cigar-shaped nuclei with often remarkable pleomorphism and hyperchomasia. 
Bizarre tumour giant cells, a high mitotic rate and necrosis can be present. 
Tumours are graded according to the FNCLCC system. Immunohistochemically, 
tumours frequently express smooth muscle actin (SMA), actin (HHF35) and 
vimentin. In addition, for the diagnosis of leiomyosarcoma focal expression of 
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at least one of the two smooth muscle markers, desmin and heavy-caldesmon, 
is more supportive for the diagnosis (3). Tumour depth, tumour size (>5cm), 
high histological grade, age >60 years and metastasis at presentation are 
indicators of a poor prognosis (48, 55, 56). The overall disease-specific 5-year 
survival rate is around 54-64% (48, 55). 
As mentioned above, leiomyosarcomas pertain to the sarcomas with an 
instable genome and complex karyotype (Figure 1C). Although no common 
cytogenetic aberrations have been identified in these tumours, over the past 
decades several genes were found to be mutated. Mono-allelic or bi-allelic 
TP53 alterations are found in up to 50% of leiomyosarcomas and p53 pathway 
inactivation is encountered in a minority of leiomyosarcomas by p14 loss (57, 
58). Also loss of the tumour suppressor genes PTEN and RB1 is frequently found 
(59, 60). Myocardin (MYOCD), a transcriptional cofactor regulating smooth 
muscle differentiation, is amplified in a subset of soft tissue and retroperitoneal 
tumours (61). ATRX mutations, ROR2 overexpression and MYC overexpression 
are correlated with poor clinical outcome (58, 62, 63). Deregulation of the 
apoptosis pathway can occur under influence of MYC which affects death-
associated protein (DAP) kinase or via high expression of anti-apoptotic 
proteins of the Bcl family (64).
More recently, molecular profiling including gene expression profiling 
and array comparative genomic hybridization (array-CGH) identified three 
molecular subtypes of leiomyosarcoma (49). One subtype demonstrated high 
expression of multiple muscle-associated genes and is regarded as the ‘muscle-
enriched’ group. This subtype can be identified immunohistochemically 
with the smooth muscle marker leiomodin 1 (LMOD1) and is associated with 
an improved disease specific survival (49, 65). High expression of ARL4C, a 
member of the GTP-binding proteins, can distinguish the leiomyosarcomas 
of the second molecular genetic subtype, which are associated with a worse 
disease specific survival (65). The third group had an intermediate outcome 
and until now no specific marker is discovered to differentiate this group (65).
Leiomyosarcomas are treated with the conventional chemotherapeutics 
used for most soft tissue sarcomas. Single-agent doxorubicin is the 
treatment of choice in soft tissue sarcomas and although the combination of 
doxorubicin with ifosfamide or with dacarbazine has been suggested, there 
is no randomized trial that proves the effect of these drug combinations in 
leiomyosarcoma. Docetaxel plus gemcitabine is active in uterine and soft 
43717 Marieke de Graaff 100% ZW.indd   20 30-12-16   11:46
General Introduction
21
1
tissue leiomyosarcomas (66). Trabectedin alone has been used as second-
line treatment. The combination of doxorubicin with trabectedin is being 
investigated, but has not been approved for fi rst-line treatment yet (67, 68). 
As the driver mechanism responsible for leiomyosarcoma genesis is poorly 
understood and only a limited number of functional studies have been 
performed, at present, no targeted therapy is present for leiomyosarcomas.
Figure 1. Histology and molecular cytogenetic representation of leiomyosarcoma. 
(A) H&E stained section of a soft tissue leiomyosarcoma, grade II, with characteristic elongated spindle 
cells with fi brillar and eosinophilic cytoplasm arranged in bundles. A moderate variation in size and 
chromasia is observed and several mitotic fi gures are present. Inset shows desmin positivity in the 
majority of the tumour cells. (B) Grade III leiomyosarcoma of soft tissue with increased cytonuclear 
pleomorphism and atypical mitotic fi gures (inset). (C) Hypotetraploid karyotype of leiomyosarcoma 
with multiple translocations.
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Liposarcomas
Different subtypes of liposarcomas
Liposarcomas are malignant mesenchymal neoplasms characterized by 
a varying degree of  lipogenic differentiation and can be classified into 
three subtypes, each with a distinctive histopathology, genetic profile and 
clinical behaviour (3). The most common subtype is the well-differentiated/
dedifferentiated liposarcoma, consisting of areas resembling well-
differentiated fat with an often abrupt transition to high-grade, non-lipogenic 
areas. This subtype is characterized by amplification of various segments 
of 12q most consistently involving the amplification of MDM2 and CDK4 
genes, located herein (69). Pleomorphic liposarcoma is rare and resembles 
histologically an undifferentiated high grade sarcoma with varying amounts of 
lipoblasts. Genetically this tumour has a complex karyotype without recurrent 
aberrations (3, 69). Myxoid liposarcoma is responsible for around 20-30% of the 
liposarcomas and 5% of all soft tissue sarcomas (3). 
Myxoid liposarcomas
Myxoid liposarcomas most commonly arise in the deep soft tissues of 
the thigh (two-third of the cases). The peak age is between the 3rd and 5th 
decade an no gender predilection is observed (3). Tumours are histologically 
composed of a variably cellular proliferation of stellate spindle cells with 
some signet-ring lipoblasts intermingled and embedded in a myxoid matrix 
with a characteristic plexiform, “crow’s feet”, vascular network (Figure 2A and 
B). Areas of undifferentiated small blue round cells with scarce cytoplasm and 
no matrix might be present and if they compose more than 5% of the total 
tumour volume, the tumor is considered high grade (round cell variant) and is 
associated with a higher metastatic potential and a worse prognosis (70-75). 
The presence of necrosis, male gender, increasing age and multifocal disease 
are other poor prognostic factors (76-78). 
The cytogenetic hallmark of myxoid liposarcoma is the reciprocal 
translocation t(12;16)(q13;p11) which generates a fusion transcription factor 
oncogene by fusing FUS (fused in sarcoma; also known as TLS) on 16p11 with 
DDIT3 (DNA-damage-inducible transcript 3; also known as CHOP) on 12q13. To 
date, twelve different fusion transcripts have been described (Figure 2C)(79, 
80). In less than 5% of the cases a t(12;22)(q13;q12) is identified resulting in an 
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EWSR1-DDIT3 fusion, of which 4 diff erent transcripts are known (81). The fusion 
type in myxoid liposarcoma does not impact clinical outcome, which is similar 
to the translocation-associated sarcomas Ewing and synovial sarcoma (77, 81-
83).
The exact mechanism via which the chimeric fusion product exerts its 
oncogenic potential remains to be elucidated, however it is postulated that it 
functions as an aberrant transcription factor by stimulating proliferation while 
inhibiting adipogenic diff erentiation (84, 85). The fusion product interferes 
with heterodimerization of DDIT3 with CCAAT/enhancer-binding protein-β 
(C/EBPβ). FUS-DDIT3 represses the promotors of C/EBPα and PPARγ, resulting 
in inhibition of the adipocyte diff erentiation program in mesenchymal cell 
progenitors (85). Investigation of C/EBPα and PPARγ at mRNA and protein level 
revealed under- and overexpression, respectively in myxoid liposarcoma tumour 
samples, which might be explained by the fact that both factors exert their 
eff ect at another stage of the diff erentiation process. Additionally, the fusion 
protein stimulates expression of eIF4E, which is able to downregulate the afore 
mentioned C/EBPα pathway and further inhibits adipogenic diff erentiation 
(85). In line with these data, the mRNA expression profi le of myxoid liposarcoma 
is consistent with an immature adipogenic status (86). The fusion product also 
interacts with NF-kappa-B inhibitor zeta (NFKBIZ), which could contribute to 
oncogenesis through deregulation of nuclear factor-kB-controlled genes (87, 
88). The expression of the FUS-DDIT3 oncogene is tightly regulated at both the 
mRNA and protein levels. Also the level of the aberrant transcription factor has 
shown to diff er between individual tumour cells. This once more illustrates that 
tumorigenesis is a complex process and not all regulatory mechanisms and 
role of downstream targets are understood yet (89).
MicroRNAs (miRNAs) are small, non-coding RNAs that are able to 
negatively regulate expression of target genes and they are associated with 
various cellular processes as diff erentiation and proliferation. In myxoid 
liposarcoma the FUS-DDIT3 fusion product is found to suppress miR-486 
resulting in increase of cell growth (90). The miR-135b is higher expressed in 
the round cell component and associated with worse prognosis (91, 92).
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Figure 2. Histology of myxoid liposarcoma. (A) low grade, hypocellular area of stellate spindle cells set 
in a myxoid background. The fine branching vascular network (crow’s feet) is visible. (B) moderate cell 
rich area with characteristic pools of myxoid matrix. (C) high grade area with closely packed round cells. 
(D) partial karyotype of myxoid liposarcoma with t(12;16).
Biomarker analysis of myxoid liposarcoma specimens has identified 
alterations in the IGF/Akt/mTOR axis, involved in crucial cellular processes 
such as cell survival, proliferation and growth. Overexpression of the receptor 
tyrosine kinases RET and IGF1R, and the ligand IGF1, are negative prognostic 
biomarkers known to stimulate the PI3K/Akt pathway (86, 93). PIK3CA, the 
catalytic subunit of phosphatidylinositol 3-kinase (PI3K), harbours activating 
mutations in 14-18% of the tumours. Loss of PTEN expression, a negative 
regulator of PI3K, is found in 12% of the cases and is mutually exclusive from 
PIK3CA mutations (94, 95). Increased PI3K/Akt signalling has been demonstrated 
by high expression of downstream targets like phosphorylated 4EBP1, PRAS40 
and S6. The PIK3CA mutation rate, IGF1R expression and loss of PTEN were 
higher in tumors with a round cell component suggesting that this pathway 
might be involved in round cell transformation and tumor progression (86, 93). 
Also TP53 mutations and reduced protein expression of p16INK/p14ARF have 
been identified in a subset of the tumors, especially in round cell areas (93). 
Hotspot mutations in the TERT (telomerase reverse transcriptase) promoter 
region were recently reported to be recurrent in myxoid liposarcoma, as well as 
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in several other solid tumours like for example glioblastomas, melanomas and 
urothelial carcinomas (96-99). These mutations lead to increased TERT mRNA 
and protein expression and have been implicated in telomerase dysregulation 
and the resultant proliferative capability of tumor cells (100). In summary, most 
of the above listed biomarkers are progression markers rather than myxoid 
liposarcoma specifi c markers, again highlighting the need for further research 
to identify tumour specifi c, targetable, alterations.
Surgery or a combination of surgery with radiotherapy is an eff ective 
treatment for localized disease, however 25-50% of patients develop recurrence 
or metastases (73, 74, 78, 101). The metastatic pattern is unconventional with 
spread to sites in soft tissue or bone (retroperitoneum, abdominal wall, thoracic 
wall, spine) occurring before the tumour metastasizes to the lungs (3, 73, 101). 
The 5-year disease specifi c survival rate depends on the histology and is for purely 
myxoid tumours higher than for tumours with a round cell component (around 
91-100% versus 73-79%) (70, 71, 73, 74, 77, 78, 101, 102). Cases with advanced 
disease at time of diagnosis have a worse disease specifi c survival of 8% (75). 
Compared to other soft tissue sarcomas, myxoid liposarcoma is quite 
sensitive to radiotherapy and chemotherapy. In the search for new therapeutic 
agents the pure form of the natural tetrahydroisoquinolone alkaloid was 
isolated from the Caribbean tunicate Ecteinascidia turbinata in 1986. This 
substance, known as trabectedin or ET-743 was found to be a DNA alkylating 
agent, it binds the DNA minor groove in GC-rich sequences and the adducts 
are reversible upon DNA denaturation (103). Trabectedin was shown to 
block the cell cycle in late S and G2 phases and it is able to disorganize the 
microtubule network in the cell (104). In vitro and in vivo studies demonstrated 
a potent antitumour activity at a relatively low dose in several solid tumours 
(104, 105). The fi rst, phase 1, clinical trial with advanced, pretreated sarcoma 
patients revealed an eff ect of treatment in patients with soft tissue sarcomas 
(106). Over the past decade several trials were conducted and especially 
myxoid liposarcoma patients do respond well to treatment with trabectedin 
(107-109). Therefore, next to doxorubicin also trabectedin has been approved 
for the treatment of unresectable or metastatic myxoid liposarcoma or 
leiomyosarcoma (110). In the European Union trabectedin has been approved 
in 2007 and in the USA the Food and Drug Administration approved the 
use of trabectedin in 2015 after a large phase III trial trabectedin (67, 111). It 
was postulated that the drug is able to dislocate the oncogenic FUS-DDIT3 
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transcription factor from the DNA (112). Interestingly trabectedin has shown 
to have an effect in other translocation-associated sarcomas as well, such 
as alveolar rhabdomyosarcoma and mesenchymal chondrosarcoma (113). 
Worth-mentioning is that trabectedin also demonstrates antitumour activity 
in leiomyosarcoma and platinum-sensitive ovarium cancer, which are both, as 
far as we know yet, not characterized by an oncogenic chimeric transcription 
factor (67, 114). The exact mechanism of trabectedin has been subject of 
multiple studies over the past years and is currently not entirely elucidated, 
ongoing research demonstrated that the mechanism of action of trabectedin 
is complex and involves multiple aspects: binding to DNA-minor groove, 
interaction with homologous recombination and transcription-coupled 
nucleotide-excision repair (TC-NER), modulation of transcription regulation 
and induction of micro-environment changes (115). Recently eribulin has been 
registered for the treatment of liposarcomas (116).
Table 2. Clinico-pathological characteristics of leiomyosarcoma and myxoid liposarcoma.
Features Leiomyosarcoma of soft tissue Myxoid/round cell liposarcoma
Age range 5th - 6th decade 3rd - 5th decade
Frequency 10%-20% of soft tissue sarcomas ~5% of soft tissue sarcomas
Preferential location Retroperitoneum and other deep 
soft tissues
Deep soft tissues of extremities (2/3 
in thigh)
Survival 5-years survival 54%-64% 5-years survival ~10%-90%
Histomorphology Spindle cells in intersecting 
bundles
Stellate cells in myxoid matrix with 
“crow’s feet” vasculature
Histological grading FNCLCC Myxoid: low grade; >5% round cell: 
high grade
Immunohistochemistry Desmin, h-caldesmon No specific stain
Normal counterpart Smooth muscle Adipose tissue
Genomic profile Complex karyotype with multiple 
non-recurrent aberrations
t(12;16)(q13;p11) or t(12;22)(q13;q12)
Cell line models LMS04, LMS05, IB133, IB140 402-91, 1765-92, DL-221
Aim and outline of the thesis 
The aim of this thesis is to gain more insight in the molecular pathology of 
soft tissue sarcomas, especially leiomyosarcoma and myxoid liposarcoma. As 
mentioned above, the group of soft tissue sarcomas constitute a large number 
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of diff erent, mostly rare, neoplasms, each with their own histopathology, 
genetic profi le and clinical features. Here we focus on two diff erent tumours, 
on one hand the leiomyosarcomas characterized by a complex genetic profi le 
and on the other hand the myxoid liposarcoma with one well-defi ned recurrent 
translocation. Over the past decade, we have gained increasing insight into the 
molecular pathogenesis of leiomyosarcoma and myxoid liposarcoma; however, 
translating this knowledge into specifi c therapies has been challenging. Here we 
focus on the molecular profi le of these two soft tissue tumours and performed 
studies to identify potential targets for specifi c therapeutic strategies.
Part 1. Leiomyosarcoma
To study leiomyosarcomas we used collected tumour specimens, primary 
tumour cultures and four well-established cell lines (LMS04, LMS05, IB133 and 
IB140) that were available through our international collaborators. 
In chapter 2 we investigate the presence of MED12 exon 2 mutations in both 
benign and malignant smooth muscle tumours of soft tissues as well as the 
mutation rate in uterine smooth muscle tumours. Also the possible role of the 
Wnt-signalling pathway in the pathogenesis of these tumours is investigated 
by use of β-catenin immunohistochemistry.
In chapter 3 primary cell cultures of soft tissue leiomyosarcomas are 
characterized in depth by array-based comparative genomic hybridization 
and COBRA-FISH karyotyping in order to investigate the genetic alterations in 
leiomyosarcomas and to search for a common molecular genetic aberration. 
This might improve the understanding of this malignant tumour and identify 
candidate targets for future therapeutic regimens.
In chapter 4 we investigated whether the anti-apoptotic Bcl family 
proteins play a role in the responsiveness to conventional chemotherapy in 
leiomyosarcomas. The expression of the Bcl proteins in a large patient series is 
investigated. Next, we determined whether the Bcl-2 pathway inhibitor ABT-
737 sensitises leiomyosarcoma cells to chemotherapy in vitro. 
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Part 2. Myxoid liposarcoma
The studies on myxoid liposarcoma were performed within an international 
consortium, encouraged and partly funded by the Liddy Shriver Sarcoma 
Initiative, and led by Dr. T. Nielsen, University of British Columbia, Vancouver. 
Chapter 5 is a large, multicenter, validation study in which we investigate 
the immunohistochemical expression of the cancer-testis antigen NY-ESO-1 
(CTAG1B) in myxoid liposarcomas as well as multiple other soft tissue and bone 
neoplasms. The aim is to identify tumour subtypes with a high expression rate, 
which might benefit from NY-ESO-1 targeted immunotherapy.
Chapter 6 reports the detailed molecular cytogenetic profile, phenotypic 
properties and xenograft properties of a newly established myxoid liposarcoma 
cell line (DL-221). Reliable in vitro and in vivo models are of pivotal importance 
to investigate novel therapies, and to study the mechanisms of action and 
causes of resistance. Although myxoid liposarcoma is a relatively common soft 
tissue sarcoma subtype, only few model systems are available to study the 
disease. Thus far only two cell lines were available (402-91 and 1765-92), both 
of which are immortalized by transfection with the SV40 large T-antigen. One 
of the goals of the consortium was to increase the number of available models. 
We were able to establish one new cell line (DL-221) with xenograft model, 
which is so far the only spontaneously immortalized cell line model of myxoid 
liposarcoma.
In chapter 7 we use this newly established cell line, in addition to the two cell 
lines that were already available, to perform a high-throughput drug screen 
exploring the effectivity of 273 different drugs. Our aim is to identify auspicious 
candidate targets which might serve as a new therapeutic option for myxoid 
liposarcoma.
Finally, chapter 8 summarizes and discusses the results of the studies described 
in the preceding chapters.
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Abstract
Recently heterozygous mutations in exon 2 of the mediator complex subunit 
12 (MED12) gene have been described in 50-70% of uterine leiomyomas; 
the recurrent nature of these mutations suggests an important role in 
their pathogenesis. MED12 is involved in regulation of transcription 
and Wnt-signaling. So far, little is known about the pathogenesis of the 
different subtypes of extra-uterine leiomyomas and leiomyosarcomas. 
We performed mutation analysis of MED12 and immunohistochemistry 
for β-catenin, using 69 tumors of 64 patients including 19 uterine-, 6 
abdominal-, 9 angio-, 5 piloleiomyomas, 7 uterine- and 23 soft tissue 
leiomyosarcomas. In line with previous observations, 58% of uterine 
leiomyomas carried a MED12 mutation. However, all other extra-uterine 
leiomyomas were negative with the exception of one abdominal 
leiomyoma with a likely primary uterine origin. Of the 30 leiomyosarcomas, 
only one uterine tumor harbored a mutation. A new observation is the 
identification of three tumors with a homozygous mutation; a monosomy 
X or interstitial deletion was excluded. β-catenin immunohistochemistry 
showed nuclear positivity in only 55% of the MED12 mutated uterine 
leiomyomas suggesting the involvement of pathways other than 
canonical Wnt-signaling in tumorigenesis. Interestingly, 80% of MED12 
wild type sporadic piloleiomyomas displayed nuclear β-catenin positivity 
indicating its involvement in this leiomyoma subtype. The lack of MED12 
mutations in extra-uterine leiomyomas and leiomyosarcomas indicate 
that these tumors arise through a different pathway, emphasizing the 
genetic heterogeneity of smooth muscle tumors.
Keywords: 
β-catenin, leiomyoma, leiomyosarcoma, MED12 mutation, Wnt-pathway.
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Introduction
Leiomyomas are benign tumors (fi broids) consisting of a proliferation of smooth 
muscle cells. The majority of these tumors arise in the uterus and by age 45 60% 
of women has at least one leiomyoma [1]. The tumors can reach a substantial 
size and multiple tumors are often present; leading to a considerable morbidity. 
Surgery is the mainstay of treatment to relieve symptoms [1,2]. At histological 
examination the lesions are composed of interlacing fascicles of spindle shaped 
cells with eosinophilic cytoplasm and blunt-ended cigar shaped nuclei [3].
An identical histology can be seen in smooth muscle tumors in the 
abdomen and in the dermis (piloleiomyoma), although these leiomyomas are 
far less frequent compared to the uterine lesions. In angioleiomyomas smooth 
muscle cells spin off  from vessel walls, presenting as a small and painful mass 
located in the subcutis of the lower extremities. Simple surgical excision is an 
adequate treatment for symptomatic cases [4-6]. 
Uterine leiomyomas are genetically heterogeneous since approximately 
30-50% of the tumors display chromosomal aberrations involving (balanced) 
translocations of chromosomes t(6;14) or t(12;14) and deletions of chromosome 
7 [7-9]. The HMGA1 and HMGA2 genes mapping to chromosome 6p21.31 and 
12q14.3 respectively are frequently involved in the breakpoints; and as no 
partner gene on chromosome 14 has been identifi ed so far, the deregulation 
of HMGA1/2 is believed to be important for tumor development [10-12]. 
Mäkinen et al. recently identifi ed MED12 mutations in 70% (159 of 225) of 
uterine leiomyomas of 80 diff erent patients in a study using next generation 
sequencing [13]. All mutations were heterozygous and resided in exon 2 and 
each tumor only contains one mutation, suggesting that these alterations 
contribute to tumorigenesis. MED12 changes and 12q14 rearrangements 
turned out to be mutually exclusive [14]. In fi ve consecutive studies mutation 
rates of 52.2% (35/67), 58.8% (47/80), 66.6% (6/9), 67% (100/148) and 50% 
(14/28) were identifi ed, including a study with African patients [14-18]. The 
occurrence of MED12 mutations in other leiomyoma subtypes has not been 
investigated. 
MED12 consists of 45 exons and is located at chromosome Xq13.1. It is a 
subunit and activator of the CDK8-module, which includes in addition to MED12 
also MED13, CCNC and CDK8. The CDK8-module associates with 25 other 
complexes in the highly conserved Mediator complex, which is responsible 
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for the transcription of all RNA polymerase II dependent genes and functions 
as a transcription factor [19-21]. The CDK8-module controls global and gene 
specific transcription and regulates specific transcription of members of the 
Wnt-pathway. MED12 is involved in the binding of transcription factors to the 
Mediator complex and it is crucial for activation of the CDK8 histone kinase 
[20-22]. Moreover, MED12 interacts directly with β-catenin, a member of the 
Wnt-pathway, and mediates β-catenin-activated transcription [23]. 
Leiomyosarcomas are malignant tumors originating from smooth muscle 
cells. They account for 10-15% of the soft tissue sarcomas and predilection 
sites are the retroperitoneum, the large blood vessels and the soft tissues of 
the lower extremities [6,24]. They can also arise in the uterus with an estimated 
incidence of 0.40 per 100,000 women per year [25]. Although leiomyomas of 
the uterus are quite common, uterine leiomyosarcoma is very rare. There is 
not much known about the pathogenesis of this group of highly malignant 
tumors. Cytogenetic analysis reveals often complex karyotypes with multiple 
non-recurrent genetic aberrations, probably resulting from genetic instability 
[6,26,27]. A tumor progression model has been postulated for leiomyoma 
and leiomyosarcoma as both originate from smooth muscle cells; with an 
estimated frequency of <0.1%, however such a relation is still controversial as 
no convincing evidence is present [26]. In a recent study, mutations in MED12 
have been found in 2 of 10 uterine leiomyosarcomas [17], while the occurrence 
in leiomyosarcoma of soft tissue has, so far, not been investigated.
To determine a possible role for MED12 mutations both in benign and 
malignant extra-uterine smooth muscle tumors, we evaluated the presence 
of mutations in different smooth muscle tumor subtypes occurring in the soft 
tissues. As MED12 has both direct and indirect interactions with β-catenin we 
performed immunohistochemistry for β-catenin to study activity of canonical 
Wnt-signaling and correlate expression to mutation status. 
Materials and Methods
Tissue samples
A total of 69 formalin fixed paraffin embedded (FFPE) tissue samples of smooth 
muscle tumors from 64 different patients were selected for DNA extraction 
and mutation analysis and were retrieved from the archives of the department 
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of Pathology at Leiden University Medical Center (Leiden, The Netherlands); 
including 6 abdominal leiomyomas, 9 angioleiomyomas, 5 piloleiomyomas, 19 
uterine leiomyomas, 7 leiomyosarcomas of the uterus and 23 leiomyosarcomas 
of soft tissue (Table 1). Of one patient, three diff erent uterine leiomyomas were 
included as well as a leiomyosarcoma of the femoral artery; another patient 
underwent surgical removal of an abdominal leiomyoma and shortly thereafter 
leiomyoma-related hysterectomy, both tumors were included. 
Tissue microarrays (TMAs) were constructed from a panel of FFPE tumors 
including 7 uterine leiomyomas, 53 leiomyosarcomas (30 of which were 
also used for mutation analysis), 14 myxofi brosarcomas, 4 pleomorphic 
liposarcomas, 2 rhabdomyosarcomas, 6 undiff erentiated spindle cell sarcomas 
and 24 undiff erentiated pleomorphic sarcomas. The TMAs were constructed 
using a semi-automated TMA apparatus (TMA Master, 3DHistech, Budapest, 
Hungary) to transfer tumor punches to the recipient block. A biopsy needle of 
1.5 mm was used resulting in a surface area of 1,767 mm2 per core; all tumor 
samples are present in triplicates. Cores from colon, liver, placenta, prostate, 
skin and tonsil were included for control and orientation purposes. Using a 
tape-transfer system (Instrumedics, Hackensack, NJ, USA), 4-μm sections were 
transferred to coated glass slides. For 12 of the uterine leiomyomas and 20 
extra-uterine leiomyomas regular tissue sections were obtained from paraffi  n 
blocks, as the amount of tissue was too low to punch three tissue cores.
The histological diagnosis of all samples was confi rmed by reviewing the 
hematoxylin and eosin (HE) stained slides by a bone and soft tissue tumor 
specialist (JVMGB). At least one of the smooth muscle markers h-caldesmon 
or desmin was positive in the smooth muscle tumors. Malignant tumors 
were graded according to the FNCLCC grading system [6]. All samples were 
handled in a coded fashion, and all procedures were performed according to 
the ethical guidelines, ‘‘Code for Proper Secondary Use of Human Tissue in the 
Netherlands’’ (Dutch Federation of Medical Scientifi c Societies). 
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Table 1. Patient characteristics per group, including results of MED12 mutation analysis and ß-catenin 
immunohistochemistry.
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Abdominal 
leiomyoma
6 2 : 4 62.3 (42-80) 5.8 (0.5-17.0) 1/6 0/6 (0%) 6/6 (100%)
Angioleiomyoma 9 5 : 4 52.8 (36-70) 1.6 (0.2-5.2) 0/9 0/9 (0%) 9/9 (100%)
Piloleiomyoma 5 3 : 2 44.6 (19-62) 0.8 (0.4-1.1) 0/5 4/5 (80%) 5/5 (100%)
Uterine 
leiomyoma
19 0 : 19 48.7 (34-71) 6.5 (1.5-20.0) 11/19 6/19 (31.6%) 18/19 (94.7%)
LMS soft tissue 23 9 : 14 58.6 (30-86) 7.3 (1.1-23.5) 0/23 3/23 (13.0%) 22/23 (95.7%)
Uterine LMS 7 0 : 7 58.0 (39-76) 12.1 (5.0-23.0) 1/7 0/7 (0%) 7/7 (100%)
LMS TMA 23 9 : 14 58.7 (23-80) 8.0 (1.0-23.0) NA 7/23 (30.4%) 22/23 (95.7%)
Pl LPS TMA 4 2 : 2 67.5 (53-82) 10.5 (4.5-26.5) NA 1/4 (25%) 4/4 (100%)
MFS TMA 14 6 : 8 67.9 (47-91) 9.8 (2.2-20.0) NA 3/14 (21.4%) 12/14 (85.7%)
RMS TMA 2 2 : 0 56.5 (55-58) 5.2 (5.0-5.3) NA 1/2 (50%) 2/2 (100%)
USCS TMA 6 4 : 2 72.3 (46-89) 5.7 (2.5-8.3) NA 6/6 (100%) 6/6 (100%)
UPS TMA 24 16 : 8 64.9 (36-94) 8.4 (2.4-17.0) NA 9/24 (37.5%) 23/24 (95.8%)
LMS: leiomyosarcoma; Pl LPS: pleomorphic liposarcoma; MFS: myxofibrosarcoma; RMS: 
rhabdomyosarcoma; USCS: undifferentiated spindle cell sarcoma; UPS: undifferentiated pleomorphic 
sarcoma; TMA: tissue microarray; NA: not available.
MED12 mutation analysis
Representative tumor areas from FFPE samples were selected to punch 3 
cores of 0.6 mm in diameter for DNA isolation, whereas microdissection was 
performed on small tumors; using a total of five 10-µm thick hematoxylin 
stained sections for each case. A tumor percentage of >90% was achieved for all 
tumors. Genomic DNA was isolated using NucleoSpin tissue kit from Macherey-
Nagel (Düren, Germany). DNA concentration was measured using a Nanodrop 
ND-1000 spectrophotometer (Thermo Scientific, Breda, The Netherlands). 
Oligonucleotide primers were designed to amplify exon 2 of MED12 (NCBI 
gene ID: 9968; ChrX:70,338,406-70,357,793 [GRCh37/hg19]) with the use 
of Primer3 program (http://frodo.wi.mit.edu/). Primers included forward: 
AACAACTAAACGCCGCTTTC and reverse: TGTCCCTATAAGTCTTCCCAACC with 
the addition of universal M13-tails (M13 forward: TGTAAAACGACGGCCAGT 
and M13 reverse: CAGGAAACAGCTATGACC) to facilitate standardization of 
PCR and subsequent sequencing. PCR was performed on 10 ng of genomic 
DNA in combination with iQ SYBRgreen supermix (Bio-Rad, Veenendaal, The 
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Netherlands) using a CFX96 Real-Time PCR Detection System (Bio-Rad). All PCR 
products were purifi ed with the QIAquick PCR purifi cation kit (Qiagen GmbH, 
Hilden, Germany). Purifi ed PCR products were electrophoresed using a 0.8% 
agarose gel in order to separate amplifi ed fragments as a quality control. Direct 
sequencing of both the forward and reverse PCR products was performed by 
Macrogen (Macrogen Corporation, Amsterdam, The Netherlands) and analysis 
of the sequence graphs was performed both manually and with the computer 
program Mutation Surveyor V4.0.4 (Softgenetics, State College, PA, USA).
Immunohistochemistry
Immunohistochemistry (IHC) was performed using the β-catenin antibody 
(clone 14, Becton Dickinson Transduction Laboratories, San Diego, CA, USA) in 
a 1:4000 dilution, following antigen retrieval by heating in citrate buff er. Signal 
detection was performed with Envision+ (DAKO Cytomation, Carpinteria, CA, 
USA) and the chromogen 3,3’-diaminobenzidine according to manufacturer’s 
instructions. Nuclear and cytoplasmatic or membranous staining were 
separately scored on a 0-7 scale based on the staining intensity (1=weak, 
2=moderate, 3=strong) added to the percentage of positive cells (1=0-24%, 
2=25-49%, 3=50-74% and 4=75-100%) by two independent observers and a 
score of >0 was considered positive [28]. IHC pictures were taken using the 
Pannoramic MIDI scanner (3DHistech).
Fluorescence in situ hybridization (FISH)
In order to determine the copy number status of MED12 loci on the X 
chromosome, a two color interphase FISH was performed using a probe mix 
containing bacterial artifi cial chromosome (BAC) RP11-523P2 clone labeled 
with Biotin-dUTP and detected with streptavidin conjugated to Cy3 (Roche 
diagnostics GmbH, Mannheim, Germany); a direct labeled centromere X probe 
(FITC-dUTP) (Roche) was used as a reference. Probes were hybridized on a 4 µm 
thick FFPE section from cases with a detected homozygous MED12 mutation. 
Probe labeling and hybridization reaction were performed using standard 
protocols published earlier [29].
Statistical analysis
The PASW 18.0 for Windows software package (SPSS Inc., Chicago, IL, USA) was 
used to analyze the results. The statistical signifi cance of diff erences between 
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two groups was assessed by the independent-samples t-test and the one-way 
ANOVA-test was used for comparisons of more than two groups, a p-value of 
<0.05 was considered statistically significant.
Results
MED12 mutation analysis
Mutations were absent in all extra-uterine leiomyomas with the exception 
of abdominal leiomyoma L4041 in the pelvic region of a 42-year-old female 
harboring a homozygous c.[130G>A];[130G>A] base substitution. The tumor 
cells expressed the estrogen receptor alpha, suggesting an uterine origin of the 
tumor. The patient underwent hysterectomy due to a large uterine leiomyoma 
a few months earlier and this tumor L3981 showed a heterozygous c.131G>C 
mutation (Figure 1a-c; Supplementary Table 1). Interphase FISH showed the 
presence of two copies of both the centromere X signal (green) and the RP11-
523P2 probe signal (red) in the majority of the cells (Figure 1e) excluding the 
possibility of a hemizygous deletion of one allele leading to the detected 
homozygous mutation.
Figure 1. Histological and molecular cytogenetic results in leiomyomas.
Sequence chromatogram of homozygous c.130G>A mutation in codon 44 of the MED12 gene in 
abdominal leiomyoma L4041; the altered base is indicated by a red arrow (a). Sequence graph showing 
a heterozygous c.131G>C alteration in the uterine leiomyoma L3981 of the same patient (b). HE stained 
slide of L4041 (c) and immunohistochemical staining of β-catenin showing staining of the cytoplasm 
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but no nuclear localization of the protein (d). FISH performed on a tissue section of mutated abdominal 
leiomyoma with centromere X probe (green) and BAC-probe RP11-523P2 (red) close to the MED12 locus 
showing two signals in the majority of the nuclei, thereby excluding a deletion of chromosome X or the 
region around the MED12 gene (e, inset). 
Of the 19 uterine leiomyomas, 11 (57.9%) revealed a mutation in exon 
2 of MED12, among which one substitution was homozygous as is confi rmed 
with FISH. All detected base changes were missense mutations occurring at 
the hot spot positions of base pairs 130 and 131. Four diff erent mutations were 
observed of which c.130G>A was the most frequent with an incidence of 36.4% 
(4/11) followed by c.131G>A and c.131G>C which were both responsible for 
27.3% (3/11) of the MED12 alterations. The c.130G>C alteration was only found 
once (9.1%) (Supplementary Table 1). From sample L3984 having multiple 
uterine leiomyomas three tumors were included, two of three leiomyomas 
showed a c.131G>A substitution, while c.131G>C was found in the third 
leiomyoma. A mutation was absent in the vascular leiomyosarcoma of the 
same patient. 
Of the 30 leiomyosarcomas, only 1 of 7 (14.3%) uterine tumors harbored 
a homozygous c.[133_144del];[133_144del] deletion leading to a deletion of 
four amino acids p.F45_Q48del. The homozygous change was not caused by an 
allelic loss as interphase FISH revealed retained copies of both X chromosomes 
and MED12 loci. This tumor was graded as high grade based on the nuclear 
pleomorphism, the mitotic index of 32 mitoses per 10 high power fi elds and 
necrotic fi elds [6,30]. All 23 soft tissue leiomyosarcomas were MED12 exon 2 
wild type (Table 1). 
Correlation of MED12 mutation status to clinicopathological data
Uterine leiomyomas harboring a mutation in exon 2 of MED12 were signifi cantly 
smaller compared to MED12 wild type leiomyomas (p=0.013) with a mean size 
of 4.1 cm for the mutated tumors versus 9.9 cm in the MED12 wild type lesions. 
We found no association between the c.130G>A and c.131G>A transitions 
and larger size (p = 0.708), which was reported previously by others [14]. No 
correlation was observed between the age at hysterectomy and the mutation 
status (p = 0.364) (Table 2) [13,14]. 
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Table 2. Clinicopathological data of uterine leiomyomas in MED12 mutated and wild type cases.
MED12 wild type MED12 mutation Statistical 
significance
Median age (range) 51.5 (36-71) 46.7 (34-66) p = 0.364
Median size (range) 9.9 (1.5-20.0) 4.1 (1.5-7.0) p = 0.0131
β-catenin nuclear score (range) 0.0 (0.0) 1.7 (0.7-6.0) p = 0.0421
β-catenin cytoplasmic score (range) 2.8 (0.0-5.0) 4.2 (2.7-7.0) p = 0.0501
P-values marked with a 1 are statistically significant.
β-catenin immunohistochemistry
Nuclear β-catenin staining was present in 80% (4/5) of the piloleiomyomas 
(p=0.0001) and semi-quantitative analysis revealed a mean 
immunohistochemical score of 4.0, while the nuclei of all other extra-uterine 
leiomyomas were negative (score 0) (Figure 2a-c). All extra-uterine leiomyomas 
expressed β-catenin in the cytoplasm, however the cytoplasmic staining was 
most intense in the piloleiomyomas but not statistically significant compared 
to the other two subtypes (p=0.087). Nuclear staining of β-catenin was found 
in 54.5% (6/11) of the uterine leiomyomas carrying a MED12 mutation with 
a mean immunohistochemical score of 1.7, while the nuclei of all wild type 
uterine leiomyomas were negative (score 0) (p=0.042) (Figure 2a). Cytoplasmic 
staining of β-catenin was found in 94.7% (18/19) of the uterine leiomyomas 
with a considerably higher expression in the mutated tumors (p=0.050), 
membranous staining was absent. Nuclear staining was found in 18.9% (10/53) 
of all leiomyosarcomas present on the TMAs. Three of 23 (13%) soft tissue 
leiomyosarcomas expressed β-catenin in the nucleus while the nuclei of all 
uterine leiomyosarcomas were negative. Cytoplasmic (96%; 51/53) as well as 
membranous (22.6%; 12/53) staining was however frequently observed in 
leiomyosarcomas. Variable nuclear expression of β-catenin was observed in 25% 
(1/4) of pleomorphic liposarcomas, 21.4% (3/14) of myxofibrosarcomas, 100% 
(6/6) of undifferentiated spindle cell sarcomas, 50% (1/2) of rhabdomyosarcomas 
and 37.5% (9/24) of undifferentiated pleomorphic sarcomas (Table 1).
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Figure 2. Nuclear ß-catenin expression in diff erent leiomyoma subtypes.
Results for ß-catenin immunohistochemistry. Dot plot presenting results of immunohistochemical 
nuclear ß-catenin expression in abdominal leiomyomas, angioleiomyomas, piloleiomyomas and 
MED12 wild type and mutated uterine leiomyomas, demonstrating a high expression in 80% of 
the piloleiomyomas and a high expression in the majority of the uterine leiomyomas with a MED12 
mutation. The abdominal leiomyoma with a mutation is marked with a red dot (a). HE stained slide (b) 
and positive nuclear ß-catenin labeling in one piloleiomyoma (c).
Discussion
Heterozygous mutations in exon 2 of the mediator complex subunit 12 (MED12) 
gene have been described in the majority of uterine leiomyomas [13-18], and 
their recurrent nature suggests an important role in the pathogenesis of these 
lesions. Since the role of MED12 mutations in extra-uterine leiomyomas, and 
in leiomyosarcomas is currently unclear, we investigated the occurrence of 
mutations in these lesions. Moreover, since MED12 is involved in regulating 
Wnt-signaling, we evaluated the expression pattern of β-catenin, as a read-out 
for canonical Wnt-signaling. 
We demonstrated that MED12 mutations were absent in all 
angioleiomyomas, piloleiomyomas and in 5 of 6 investigated abdominal 
leiomyomas. One patient presented with both an abdominal and uterine 
leiomyoma, and we identifi ed a homozygous mutation in the abdominal 
tumor (Figure 1). Monosomy X or an interstitial deletion of the MED12 locus was 
excluded using interphase FISH. The uterine leiomyoma of the same patient 
revealed a diff erent mutation, confi rming that both tumors developed from 
a diff erent cellular clone, however, a primary uterine origin of the abdominal 
tumor is likely considering the expression of estrogen receptor [31]. 
None of the 23 soft tissue leiomyosarcomas harbored a 
MED12 exon 2 alteration. Interestingly, we identifi ed a homozygous 
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c.[133_144del];[133_144del] deletion in one of seven (14.3%) uterine 
leiomyosarcomas. This mutation has been described previously in an uterine 
leiomyoma [16]. Including our cases, in total 22 uterine leiomyosarcomas have 
been studied [15,17]. Two other uterine leiomyosarcomas were identified 
by Pérot et al. to harbor a heterozygous missense mutation at the hot spot 
region of codon 44 [17]. Thus, while MED12 mutations are found in 50-70% 
of uterine leiomyomas, only 13.6% (3/22) of uterine leiomyosarcomas carry 
MED12 mutations. This may suggest a decreased propensity of MED12 mutated 
leiomyomas to progress to malignancy, however, it is still under debate whether 
uterine leiomyosarcomas are primary or arise secondarily within a preexisting 
benign leiomyoma, as only in sporadic cases progression from a leiomyoma 
towards leiomyosarcoma is confirmed [26]. Probably, only a small subset of 
leiomyosarcomas arise in a preexisting leiomyoma, while the majority arise 
primary. Alternatively, the benign tumor may create an environment which 
facilitates wild type smooth muscle cells to acquire more genetic aberrations 
and become invasive, analogous to what has been described for EXT mutated 
osteochondroma, in which wild type cells progress to secondary peripheral 
chondrosarcoma [32].
The detected mutation rate of 57.9% in the group of uterine leiomyomas 
is consistent with previous reports, in which the percentage of mutation 
positive tumors ranges between 50 and 70% [13-18]. The c.130G>A, c.131G>A 
and c.131G>C base substitutions are responsible for 84.6% (11/13) of all 
identified alterations in our series, consistent with those of Markowski et al. 
who also detected these three alterations in the majority of the cases [14]. Of 
note, different mutations were found in multiple leiomyomas of one patient, 
thereby supporting the existing evidence for the independent clonal origin of 
uterine leiomyomas [13,14]. None of the tumors harbors a second mutation 
as expected in case of pathogenic mutations. Mutated uterine leiomyomas 
were significantly smaller compared to wild type lesions, no other statistical 
significant differences were found between the groups (Table 2) [13].
Interestingly, while so far all reported mutations are heterozygous, we 
report for the first time homozygous mutations in three cases: in an abdominal 
leiomyoma, an uterine leiomyoma and in an uterine leiomyosarcoma. MED12 
has a transcriptional repressive and chromatin modifying function and 
McGuire et al. hypothesized that the gene acts as a tumor suppressor gene 
[16,21]. However the absence of nonsense mutations, the presence of in-frame 
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deletions and the existence of hot spot mutations might be regarded as data 
supporting the hypothesis of activating mutations [13,17]. As the MED12 locus 
is localized on the X chromosome, the predominant inactivation of the wild 
type allele [13] leads to the same eff ect as a homozygous mutation. Others 
have confi rmed that MED12 mutated leiomyomas predominantly express 
the mutated allele [13,14,16,17]. The biological relevance of the observed 
homozygous mutation remains to be elucidated. 
Mäkinen et al. observed signifi cant alterations of three pathways in 
MED12 mutated leiomyomas, namely extra-cellular matrix receptor interaction, 
focal adhesion and Wnt-signaling [13]. Under normal conditions β-catenin is 
tightly regulated by the tumor suppressor gene APC and the membrane bound 
E-cadherin, which mediates contact inhibition and suppresses tumor invasion, 
disruption of this equilibrium can result in uncontrolled growth [33]. After 
stabilization β-catenin travels to the nucleus and interacts with MED12 of the 
Mediator complex stimulating transcription of target genes of the canonical 
Wnt-signaling pathway [23]. We investigated the β-catenin expression pattern 
by immunohistochemistry to see if activation of this pathway can be confi rmed. 
As 80% of the piloleiomyomas displayed nuclear β-catenin, this strongly 
suggests that activation of the Wnt-pathway is an important mechanism in 
the development of these cutaneous smooth muscle tumors. However, since 
we showed MED12 mutations to be absent, other mechanisms are probably 
involved for which alterations in β-catenin, APC or E-cadherin but also 
members of the CDK8 subcomplex are possible candidates. Our data suggest 
that angioleiomyomas develop through a diff erent, MED12 and Wnt-signaling 
independent mechanism, as no nuclear β-catenin staining or MED12 mutation 
was found. Thus, our data confi rm that despite morphological similarities, 
smooth muscle tumors at diff erent locations arise through diff erent genetic 
mechanisms.
Pérot et al. found membranous β-catenin staining of MED12 mutated 
uterine leiomyomas in 66.7% (4/6) suggesting that the canonical Wnt-pathway 
is not activated and subsequently not responsible for uterine leiomyoma 
development [17]. However, a mouse model that expresses constitutively 
activated β-catenin in the mesenchyme of the uterus results in the development 
of leiomyoma-like tumors in 100% of the mice [34]. We identifi ed in 54.5% of the 
mutated leiomyomas concurrent nuclear β-catenin positivity, indicating that 
activation of the Wnt-pathway might be important in a subset of these tumors. 
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Moreover, Markowski et al. identified high expression of wingless-type MMTV 
integration site family member (WNT4) in MED12 mutated uterine leiomyomas 
which is a member of the Wnt-pathway. Expression of WNT4 is stimulated by 
estrogen in tissues originating from mesenchyme of the Müllerian duct [35]. 
They hypothesized that MED12 and estrogen cooperate in the pathogenesis of 
uterine leiomyomas, which is consistent with our results as MED12 mutations 
are exclusively found in uterine tumors and are absent in extra-uterine smooth 
muscle tumors. Since these extra-uterine leiomyomas are quite rare in contrast 
to the high incidence of uterine leiomyomas, and also occur in males being 
insensitive to female steroid hormones, we postulate that they might develop 
through a different mechanism.
In conclusion, we investigated the presence of MED12 mutations in 
benign and malignant extra-uterine smooth muscle tumors to obtain insight 
in their pathogenesis. We demonstrate the absence of MED12 mutations in 
angioleiomyomas, piloleiomyomas and in 5 of 6 abdominal leiomyomas, and 
conclude that MED12 is not involved in the development of benign smooth 
muscle tumors outside the uterus. Nuclear ß-catenin staining indicative of 
active canonical Wnt-signaling was found in only half of the MED12 mutated 
uterine leiomyomas. Intriguingly, a high proportion of ß-catenin activation 
was observed in piloleiomyomas, indicating an important role for MED12 
independent activation of Wnt-signaling in this subtype. Our results confirm 
the hypothesis that smooth muscle tumors are a heterogeneous group of 
tumors which arise through different mechanisms.
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Supplementary Information
Supplementary Table 1. Patient data and somatic MED12 mutations observed in the series of 69 smooth 
muscle tumors.
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L3980 41 LM uterus 7.0 missense exon 2 c.130G>A p.G44S
L3871 46 LM uterus 4.0 missense exon 2 c.131G>C p.G44A
L3872 49 LM uterus 5.9 missense exon 2 c.130G>C p.G44R
L3875 40 LM uterus 7.0 missense exon 2 c.130G>A p.G44S
L3983 46 LM uterus 2.3 missense exon 2 c.131G>A p.G44D
L3985 66 LM uterus 1.5 missense exon 2 c.130G>A p.G44S
L3974 34 LM uterus 2.0 missense exon 2 c.[130G>A]; 
[130G>A]
p.G44S
L3984-G1 50 LM uterus 1.7 missense exon 2 c.131G>A p.G44D
L3984-I1 50 LM uterus 2.5 missense exon 2 c.131G>C p.G44A
L3984-J1 50 LM uterus 5.5 missense exon 2 c.131G>A p.G44D
L39812 42 LM uterus 5.2 missense exon 2 c.131G>C p.G44A
L40412 42 LM abdomen 17.0 missense exon 2 c.[130G>A]; 
[130G>A]
p.G44S
L3976 50 LMS uterus 17.0 deletion exon 2 c.[133_144del]; 
[133_144del]
p.F45_Q48del
The three and two samples marked with 1 and 2 respectively belong to the same patients.
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based comparative genomic 
hybridization characterization.
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Abstract
Leiomyosarcomas are malignant mesenchymal tumors recapitulating 
smooth muscle cell differentiation. Tumors are characterized by a genetic 
heterogeneity with complex karyotypes without a tumor-specific genetic 
aberration. Their pathobiology is still poorly understood and no specific 
targeted treatment is currently available for these aggressive tumors. For 
six leiomyosarcomas cells were cultured and analyzed by COBRA-FISH 
karyotyping. A t(6;14)(p;q) was identified in two cases. FISH breakpoint 
mapping of case L1339 reveals a breakpoint at chromosome 6p21.31 close 
to HMGA1 and a small deletion was observed on the distal side of the gene. 
A small homozygous deletion was also found in the breakpoint region of 
chromosome 14q24.1 involving ACTN1. The second case revealed a der(6)
t(6;14)(p21.1;q21.3), with a duplication adjacent to the breakpoint at 
chromosome 6. Confirmatory FISH revealed a second leiomyosarcoma with 
an aberration at 14q24.1. Alterations at this locus are found in 5% (2/39) of the 
leiomyosarcomas in this study. The other identified breakpoints appear to be 
non-recurrent, as they were not detected in other leiomyosarcomas, uterine 
leiomyomas, undifferentiated spindle cell sarcomas or undifferentiated 
pleomorphic sarcomas. 
Keywords: 
Leiomyosarcoma, soft tissue sarcoma, translocation, FISH, array-CGH, 
HMGA1. 
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Introduction
Leiomyosarcomas are malignant tumors originating from smooth muscle cells 
and responsible for 10-15% of adult soft tissue sarcomas. Tumors show a varying 
degree of smooth muscle diff erentiation which is inversely proportional to tumor 
grade. Histologically low grade tumors are composed of sharply demarcated 
bundles of spindle cells intersecting at right angles, whereas high grade lesions 
might contain poorly diff erentiated regions with nuclear pleomorphism and 
atypical mitoses. Areas of myxoid change, epithelioid morphology, fi brosis, 
hemorrhage or necrosis can be present. Smooth muscle diff erentiation can 
be detected with desmin and h-caldesmon immunohistochemistry. The 
retroperitoneum is the most common location but the large blood vessels, 
with a predilection for the vena cava inferior, the uterus and other soft tissue 
sites as the lower extremities are also frequently involved [1]. Lesions of 
the retroperitoneum and blood vessels are encountered more frequently 
in women; no gender predilection is present for other soft tissue locations. 
Leiomyosarcomas are responsible for a substantial morbidity and mortality since 
they are characterized by aggressive behavior, with a 5-year overall survival (OS) 
of 64% [2;3]. A high tumor grade, deep tumor location and large tumor size (>5 
cm) were independent adverse prognostic factors for metastatic disease and 
overall survival [2-4]. Wide surgical excision remains the mainstay of treatment 
often in combination with radiation or conventional chemotherapy. No specifi c 
targeted treatment against leiomyosarcomas is at the moment available as the 
pathophysiology remains still poorly understood [5].
Genetically leiomyosarcomas are characterized by complex karyotypes 
with numerous reported non-recurrent and non-specifi c aberrations which 
result from a high degree of genetic instability [1;6;7]. Although gains and 
losses of many diff erent chromosomes have been reported and the inter-
tumor heterogeneity is extensive, also some similarities are described. Both 
cytogenetic and array-based comparative genomic hybridization (array-CGH) 
analyses have revealed recurrent involvement of losses of 1p, 2p, 10q, 11q, 13q, 
16q and 17p and gains of 17q and 17p [2;8]. The main objective of this study 
is to investigate the genetic alterations in leiomyosarcomas and to search for a 
common molecular genetic aberration in order to improve the understanding 
of this malignant tumor and to identify prognostic factors or candidate targets 
for future therapeutic regimens. We identifi ed two cases with t(6;14) by using 
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state-of-the-art molecular karyotyping tools and fine mapped breakpoint 
regions were tested on a tissue microarray (TMA) consisting of a large panel of 
leiomyosarcomas, uterine leiomyomas, undifferentiated spindle cell sarcomas 
and undifferentiated pleomorphic sarcomas using interphase fluorescence in 
situ hybridization (FISH).
Materials and Methods
Cell culture and COBRA-FISH
Tumor specimens were collected directly after surgery and manually dissected 
in small fragments. After the addition of IMDM, supplemented with 10% 
FBS and 1% penicillin/streptomycin (Gibco, Life Technologies, Bleiswijk, The 
Netherlands), they were placed in a humidified 5% CO
2
 incubator at 37°C. Cells 
were cultured for several passages and harvested after 25 min incubation with 
Calyculin A (Sigma-Aldrich, Zwijndrecht, The Netherlands). Subsequently cells 
were placed in a hypotonic 0.075 M KCl solution followed by three fixation steps 
of methanol/glacial acetic acid (4:1). Slides with metaphase spreads were made 
in a conditioned chamber (25°C, 50% humidity; Thermotron, Holland, MI, USA).
Combined binary ratio labeling fluorescence in situ hybridization 
(COBRA-FISH) karyotyping was performed on slides with metaphase spreads 
of six leiomyosarcomas, no conventional G-banding studies were performed. 
A detailed protocol on the pre- and post-hybridization treatments has been 
published earlier [9]. A DMRA (Leica Microsystems, Rijswijk, The Netherlands) 
fluorescence microscope was used to capture images, which were analyzed 
with the in house developed software tool ColorProc (LUMC, Leiden, The 
Netherlands). Karyotypes were described according to the International 
System for Human Cytogenetic Nomenclature (ISCN, 2013)[10]. In three 
leiomyosarcomas no detectable cytogenetic abnormalities were found 
in the analyzed cells. Tumor cells and fibroblasts show a similar, spindle 
cell morphology in vitro, thereby making it difficult to discriminate them 
morphologically. The leiomyosarcomas with a seemingly normal karyotype 
might have contained a mix in which fibroblast have overgrown the tumor 
cells, these three cases are therefore excluded for further analysis.
43717 Marieke de Graaff 100% ZW.indd   58 30-12-16   11:46
Translocation t(6;14) in leiomyosarcomas
59
3
FISH breakpoint mapping
Two-color FISH was performed to investigate the exact breakpoints of 
chromosomes 6p and 14q of two selected leiomyosarcoma cases. To detect 
possible rearrangements of the region of HMGA1 on chromosome 6p21 
bacterial artifi cial chromosomes (BAC) clones, RP3-349A12, proximal to the 
breakpoint, and RP11-936A3, distal to the breakpoint, were selected. BAC 
clones used in the fi ne mapping of the deletion breakpoints on chromosome 
6 are RP11-175A, RP5-1077I5, RP3-468B3 and RP11-974K1. On region 14q24, 
around the ACTN1 gene, RP11-204K16 was selected proximal and BAC clone 
RP11-486O13 was located distal from the breakpoint. Other BAC clones used 
in the fi ne mapping of the breakpoint on chromosome 14 are RP11-226F19 
and RP11-565I3. All BAC clones were obtained from Wellcome Trust, Sanger 
Institute. Probes were directly labeled with FITC or Cy3 using nick translation 
labeling reaction. Probes were hybridized overnight on metaphase slides using 
a protocol otherwise identical to the COBRA-FISH protocol as described above.
Table 1: Clinicopathological and COBRA-FISH karyotyping results of three leiomyosarcoma cases.
Case Age/
Sex
Tumor 
grade
Tumor 
size (cm)
Location Histological 
features
Karyotype
L1091 70/M 3 8x7x7 Gastrocnemius 
muscle
Myxoid 46,XY,t(6;7)(p;p)
[3]/46,XY[15]*
L1339 39/F N/A 9x7 Uterus Regular/
Spindle cell
45,XX,der(1;13)t(1;13)
(q10;q10), t(2;10)
(q;q),t(6;14)(p21.31;q24.1-
24.2),der(13)t(6;13)
(q?;q10),-14[6]
L1814 56/F 3 10.5x5x4.3 Hamstring 
muscle
Epithelioid 81,XXXX,del(X)(q),der(1;10)
(q10;q10),der(1)t(1;9)
(p10;p?),der(3;6)
(q10;p10),+der(3)t(3;17)
(q10;p10),-4,der(5)t(5;8)
(q10;p10)x3, t(5;16)
(q;p),+der(5)t(5;16)(q;p),-
6,der(6)t(6;14)(p21.1;q21.3)
hsr(6)(p?), der(7) t(6;7)
(q?;q?) ,i(8)(q10)x2,der(8) 
t(8;22)(q10;q10), 
der(8),der(9)t(8;9)(q;p)
x2,-10,-10,-11, der(11) 
t(1;11) (p;p),-13,+der(14)
t(8;14)(q10;q10),-
15,der(15)t(15;18)(p10
;p?),-16,-18,-18,-19,-20,-22, 
der(22)t (8;9;22)(q;p;q)[3]
Abbreviation: N/A (not applicable). Uterine leiomyosarcomas are not FNCLCC-graded according to the 
WHO.
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Array-Comparative Genomic Hybridization Analysis
Genomic DNA was isolated from frozen tumor sections of the two selected 
cases with a Nucleospin DNA extraction protocol (Macherey-Nagel, Düren, 
Germany).  Tumor content was confirmed to exceed 80-90% by histologic 
evaluation. DNA labeling and purification were done according to the BioPrime 
Total Genomic Labeling System (Invitrogen); labeling efficiency was calculated 
with a Nanodrop ND-1000 spectrophotometer measuring A
260
 (DNA), A
550
 
(Cy3) and A
649
 (Cy5). Array-based comparative genomic hybridization was 
performed using oligonucleotide-based human genome CGH microarray 
4x44 k (Agilent Technologies, Santa Clara, CA, USA) at 65°C for 40 hr. Slides 
were washed according to the manufacturer’s protocols and scanned using a 
Agilent microarray scanner with a 5 µm scan resolution. Images were imported 
to Feature Extraction Software and Genomic Workbench (Agilent) with human 
reference genome and standard settings for analysis. Commercially available 
healthy male or female DNA (Promega, Madison, WI, USA) was used as reference 
DNA. Test and reference samples were hybridized as a gender mismatch to 
illustrate the dynamic range of hybridization at the X and Y chromosomes.
Tissue microarray 
A TMA with a broad selection of soft tissue tumors diagnosed at the Department 
of Pathology of the Leiden University Medical Center (LUMC), was used for 
confirmatory FISH analysis [11]. In this study the evaluable cases included 37 
leiomyosarcomas, 17 undifferentiated pleomorphic sarcomas, 4 undifferentiated 
spindle cell sarcomas and 4 uterine leiomyomas. The histological diagnosis 
of all samples was confirmed by reviewing the hematoxylin and eosin (H&E) 
stained slides by a specialized bone and soft tissue tumor pathologist (JVMGB, 
PCWH). At least one of the smooth muscle markers h-caldesmon or desmin was 
positive in the leiomyosarcomas. The included leiomyosarcomas were negative 
for HMB45, which is a marker positive in PEComas. Soft tissue sarcomas were 
graded according to the FNCLCC grading system as accepted by the WHO 
classification [1]. Exclusion criteria were pretreatment with neoadjuvant 
chemotherapy or radiotherapy and radiation-induced sarcomas. All samples 
were handled in a coded fashion and all procedures were performed according 
to the ethical guidelines, ‘‘Code for Proper Secondary Use of Human Tissue in 
the Netherlands’’ (Dutch Federation of Medical Scientific Societies). 
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Confi rmatory TMA FISH and scoring
Four diff erent sets of BAC clones were used to screen the samples on the 
tissue microarray for a recurrent breakpoint as that of the two index cases 
(Supplementary Table 1). For the interphase FISH on TMA sections probes were 
labeled with biotin-dUTP or digoxigenin-dUTP using a nick translation labeling 
reaction. Biotin and digoxigenin labeled probes were visualized by indirect 
detection with Cy3-labeled streptavidin (1:500; Sigma), FITC-labeled mouse 
antidigoxigenin antibody (1:250; Sigma) and FITC-labeled rabbit anti-mouse 
antibody (1:1000; Sigma). A detailed protocol of two-color FISH on formalin-
fi xed, paraffi  n-embedded (FFPE) tissue sections has been published previously 
[12]. For digital archiving and annotation, all slides used for various staining 
procedures were scanned with the Pannoramic MIDI scanner (3DHistech, 
Budapest, Hungary) using brightfi eld or fl uorescent settings for H&E sections 
or interphase FISH staining, respectively. Scanned images were visualized 
using the Pannoramic Viewer (v15.0), scoring was performed visually. For the 
TMA slides, at least 50 nuclei were evaluated per core with retained tissue and 
good signals.
Results
Clinicopathological data and COBRA-FISH karyotyping
In this study cultured tumor cells from three leiomyosarcoma patients were 
suitable for cytogenetic analysis. Two patients were diagnosed with a high 
grade, grade 3 according to the FNCLCC grading system, leiomyosarcoma of 
soft tissue located in the muscles of the lower limb. One patient presented with 
a uterine leiomyosarcoma, which was staged according to the FIGO criteria 
[13;14]. All tumors expressed desmin using immunohistochemistry (Table 1).
The uterine leiomyosarcoma L1339 harbored a diploid karyotype 
with translocations involving several chromosomes: 45,XX,der(1;13)t(1;13)
(q10;q10),t(2;10),t(6;14)(p21.31;q24.1-24.2),der(13)t(6;13)(q?;q10),-14[6]. Soft 
tissue leiomyosarcoma L1814 displayed a complex, hypotetraploid karyotype 
with multiple chromosomal rearrangements and whole chromosome gains 
and losses: 81,XXXX,del(X)(q),der(1;10)(q10;q10),der(1)t(1;9)(p10;p?),der(3;6)
(q10;p10),+der(3)t(3;17)(q10;p10),-4,der(5)t(5;8)(q10;p10)x3,t(5;16)
(q;p),+der(5)t(5;16)(q;p),-6,der(6)t(6;14)(p21.1;q21.3)hsr(6)(p?),der(7)t(6;7)
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(q?;q?),i(8)(q10)x2,der(8)t(8;22)(q10;q10),der(8),der(9)t(8;9)(q;p)x2,-10,-
10,-11,der(11)t(1;11)(p;p),-13,+der(14)t(8;14)(q10;q10),-15,der(15)t(15;18)
(p10;p?),-16,-18,-18,-19,-20,-22,der(22)t(8;9;22)(q;p;q)[3] (Figure 1). 
Figure 1. Histology and molecular cytogenetic results of two leiomyosarcoma cases. 
H&E stained section of uterine leiomyosarcoma L1339 showing intersecting bundles of spindle cells, 
inset shows immunoreactivity for h-caldesmon, scale bar represents 100 µm (A). COBRA-FISH karyotype 
of L1339, the balanced t(6;14)(p21.31;q24.1-24.2) is indicated with white arrows (B). H&E stained section 
of grade 3 leiomyosarcoma L1814 with nuclear pleomorphism and multiple mitotic figures. Tumor cells 
exhibit epithelioid morphology with eosinophilic cytoplasm, inset shows a focal strong positive desmin 
staining (C). Hypotetraploid karyotype of L1814 with several translocations, including the der(6)t(6;14)
(p21.1;q21.3) indicated by an arrow (D).
FISH breakpoint mapping and array-CGH profile
A seemingly balanced translocation was observed in case L1339. The breakpoint 
regions on chromosomal arms 6p and 14q were compatible with translocation 
breakpoint regions described in uterine leiomyoma involving the HMGA1 and 
the RAD51L1 genes on chromosome 6 and chromosome 14, respectively [15]. 
FISH mapping of the translocation regions was performed using probe sets 
depicted in Figure 2. Clones RP3-349A12 and RP11-936A3, proximal of and 
partly overlapping with the HMGA1 locus respectively, demonstrated a split 
43717 Marieke de Graaff 100% ZW.indd   62 30-12-16   11:46
Translocation t(6;14) in leiomyosarcomas
63
3
apart in which the RP3-349A12 signal was retained on chromosome 6 while 
the signal of RP11-936A3 was translocated to the derivative chromosome 14. 
Fine mapping of this region revealed a deletion of clones RP11-175A4 and 
RP3-468B3 and the retention of RP5-1077I5 and RP11-974K1 bracketing this 
region on chromosome 6p. Breakpoint mapping on chromosome 14 using BAC 
clones located proximal (RP11-204K16) and distal (RP11-486O13) to ACTN1 on 
chromosome 14q24, showed split signal and the distal clone was located on the 
derivative chromosome 6. The mapping also revealed a homozygous deletion 
of clones RP11-226F19 and RP11-565I3 (Figure 2B), covering the ACTN1 gene. As 
secondary rearrangements at or around translocation breakpoint regions have 
been observed more often, we further characterized these regions by using a 
high resolution array-CGH approach. The array-CGH profi le of L1339 detected 
a 603 kb deletion on 6p21.31-21.32, located 333 kb distal of HMGA1 without 
the involvement of the HMGA1 locus itself (Figure 2A). TAPBP was overlapping 
with the last distal deleted probe and might be involved in the deletion 
breakpoint. No copy number alteration was identifi ed at the translocation 
breakpoint proximal to HMGA1. On chromosome 14q24.1 a 449 kb deletion 
was observed involving the ACTN1 and WDR22 genes (Supplementary Table 2). 
A second, 77 kb deletion was detected inside the distal part of RAD51L1, close 
to the locus of the BAC clone RP11-204K16 which is retained to chromosome 
14 in the translocation. These deletions on chromosome 14 resulted in a 
homozygous loss of the involved chromosomal regions as monosomy 14 
was observed in all tumor cells. A 7.3 Mb region at 14q21.1-21.3 was retained 
based on the array-CGH and likely was inserted into one of the derivative 
chromosomes containing chromosome 14 as no other regions were stained 
by whole chromosome specifi c paint (wcp) probes in a confi rmatory FISH test 
using wcp 6 and wcp 14 (data not shown). Taking this together with the FISH 
mapping results, a balanced translocation with complex rearrangements at 
translocation breakpoint regions involving the HMGA1 and RAD51L loci can be 
concluded (Figure 2). 
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Figure 2. Schematic representation of breakpoints of leiomyosarcoma L1339 and L1814.
Schematic picture of 6p21 region with location of genes and BAC clones used for fine mapping of the 
translocation and deletion breakpoints of L1339; and the relation of this breakpoint compared to the 
breakpoint of L1814 (A). Schematic diagram of region 14q21-q24 including the genes and BAC clones 
involved in the translocation and deletion breakpoints (B). BAC clones in white boxes represent clones 
deleted in L1339, not to scale. 
The hypotetraploid karyotype of L1814 resulted in a complex array-CGH 
profile in which the copy number varied from two to five or more of certain 
genomic regions. A derivative chromosome 6 involving translocations between 
chromosome 6 and chromosome 14 was detected. Array-CGH profiling showed 
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that the der(6)t(6;14) translocation was complicated with an amplifi cation of 
3.8 Mb in size at locus 6p21.1. The probes spanning the proximal breakpoint of 
the amplicon were 40 kb separated and SUPT3H was located in this region. The 
distance between the two probes spanning the distal amplicon breakpoint was 
52 kb and was overlapping with CR936713. The amplifi cation was located 6.7 
Mb proximal to the HMGA1 locus. On chromosome 14 a gain of 5.3 Mb in size 
was found at 14q24.2-24.3, located 3.7 Mb distal to ACTN1. The proximal and 
distal breakpoints of this gained region were spanning the DPF3 and ADCK1 
loci, respectively. Based on the array-CGH data the translocation breakpoint 
was located at 14q21.3, as a slight change in copy number variation was 
noticed at that location. The proximal probe of the translocation breakpoint 
was corresponding to the MGAT2 locus and the distal probe was overlapping 
with C14orf104. More detailed FISH-based fi ne mapping of the der(14)t(6;14)
(p21.1;q21.3) could not be performed due to a lack of cultured tumor cells.
The unbalanced cytogenetic aberrations identifi ed with COBRA-FISH 
were also confi rmed by the array-CGH profi les of both leiomyosarcoma cases. 
Furthermore, the higher resolution of array-CGH revealed several other small 
deletions and gains in both cases. 
Validation of breakpoints in other soft tissue tumors
A TMA with several soft tissue tumors was used to investigate the 
recurrence of the aberrations by using interphase FISH of four BAC clone sets 
corresponding to the regions of HMGA1 at 6p21.31, TAPBP at 6p21.32, the 
amplicon at 6p21.1 and ACTN1 at 14q24 (Supplementary Table 1). The two 
index cases were also present on the TMA and a split apart at the HMGA1 and 
ACTN1 locus and a deletion around TAPBP was confi rmed in L1339. L1814 
harbored numerous copies of BAC clone RP11-501I18 at 6p21.1, 2 Mb distal 
from SUPT3H, consistent with an amplifi cation of that particular region; the 
tumor cells only contain 2 to 3 copies of centromere 6, which was included 
as a control. The majority of the cells of one leiomyosarcoma (L1566) revealed 
two times co-localization of the signals of the BAC clone set bracketing ACTN1 
and two additional signals of clone RP11-486O13 distal to ACTN1 were present 
indicating an unbalanced translocation of this region. In this series, alterations 
involving a split apart of the signals in the 1.6 Mb region at 14q24.1-24.2 were 
found with FISH in 5% (2/39) of all investigated leiomyosarcomas. Copy number 
alterations with an equal number of the red and green signals were observed in 
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several tumors. None of the investigated loci showed any structural alteration 
in any of the additional evaluable cases including 37 leiomyosarcomas, 
17 undifferentiated pleomorphic sarcomas, 4 undifferentiated spindle cell 
sarcomas and 4 uterine leiomyomas. 
Discussion
Leiomyosarcomas belong to a group of sarcomas with a complex genetic 
profile without a yet identified specific, known genetic aberration. The 
complex karyotypes of most leiomyosarcomas might merely represent 
tumor progression associated changes; however, a causative role of a hidden, 
recurrent chromosomal aberration cannot be excluded in the development 
of these malignancies. In this study COBRA-FISH karyotyping of three tumors 
revealed a translocation t(6;14)(p;q) in two unrelated cases. 
In case L1339 HMGA1 might be involved in the breakpoint. HMGA 
proteins are evolutionary conserved members of the heterogeneous high-
mobility group family of non-histone DNA binding proteins, they bind in the 
minor groove to AT-rich DNA sequences and regulate gene transcription by 
affecting the promotor activity and influencing the accessibility of transcription 
factors to target genes. They are involved in the differentiation and proliferation 
of mesenchymal tissues during embryonic development [16]. Some lipomas, 
angiomyxomas and uterine leiomyomas harbor a translocation involving 
HMGA2, at 12q15, leading to a chimeric fusion product with different partners 
[15;17-19]. Translocations involving HMGA1 are identified in a subset of lipomas 
and uterine leiomyomas including benign uterine metastasizing leiomyoma, 
resulting in an upregulated expression of the chimeric protein [16;20-22]. 
Elevated expression has been encountered in synovial sarcoma and malignant 
peripheral nerve sheath tumor and is correlated with increased tumor grade 
and poor prognosis [23;24]. The molecular mechanism is considerably 
complex, as overexpression of wild type HMGA leads to deregulation of the 
cell cycle machinery and apoptosis in normal cells [25], while overexpression in 
immortalized cells stimulates tumor development [26]. The leiomyosarcomas 
in this study showed no intragenic HMGA1 involvement, but a transregulatory 
effect due to the complex rearrangements cannot be excluded. Previously 
published benign mesenchymal tumors with HMGA1 translocations mostly 
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revealed a break at the 3’-end, instead of an intragenic break; the breakpoint 
in L1339 is located less than 428 kb from the 3’-end. It has been postulated 
that transcriptional upregulation due to the genomic rearrangement is able 
to induce tumor formation [20]. Similarly complex rearrangements, involving 
regulatory sequences upstream of the coding sequence, have been described 
recently in chondromyxoid fi bromas [27]. 
FISH mapping showed that the breakpoint at 14q24.1 in case L1339 
was located at the ACTN1 (α-actinin-1) locus, which is, like other cytoskeletal 
proteins, a member of the spectrin superfamily. This isoform is mainly expressed 
in non-muscular cells and regulates the role of focal adhesions and stress 
fi bers and the association with cell motility [28]. High resolution array-CGH, 
showed a homozygous deletion of the ACTN1 gene, which might be relevant 
for tumorigenesis. RAD51L1, located less than 200 kb to the 14q24 breakpoint, 
has been identifi ed as a fusion partner of HMGA2 in leiomyomas [15;29]. It is 
part of the homologous recombination repair machinery of double-strand 
DNA breaks. Although FISH mapping showed that the probe overlapping 
with RAD51L1 was still retained to chromosome 14, array-CGH revealed a 
small intragenic deletion indicating a more complex rearrangement at the 
translocation breakpoint region with involvement of RAD51L1. In this way both 
fusion and a truncated protein expression might be possible, like mono-allelic 
knockout of the uterus-specifi c RAD51L1-11c splice variant as described in 
leiomyomas [30]. A uterine leiomyoma from a pseudo-Meigs’ syndrome patient 
harbored a fast growing subclone with a deletion of the second RAD51L1 allele 
next to the RAD51L1/HMGA2 fusion [31]. Due to the monosomy 14, L1339 also 
has no normal copies of the gene left; the importance for tumor progression 
remains uncertain. Recently RAD51L1 gene fusions were found in three uterine 
PEComas, it is interesting that these diff erent mesenchymal tumors share 
involvement of the same gene [32]. Further research needs to be done to 
elucidate whether there is a common pathogenetic mechanism in the early 
development of these tumors. However, in our cases PEComa was excluded 
using immune-histochemical markers. 
In L1814 a duplication at 6p21.1 was complicating the translocation 
breakpoint, forming the der(6)t(6;14)(p21.1;q21.3). These breakpoints 
diff er from those in L1339. Confi rmatory FISH on a TMA revealed a second 
leiomyosarcoma with an aberration at 14q24.1, however without involvement 
of the investigated regions on chromosome 6. In this study, alterations at 
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genomic region 14q24.1 were identified in 5% of the leiomyosarcomas. None 
of the other alterations appeared to be recurrent in the investigated soft tissue 
tumors. Nevertheless, an influence of cryptic rearrangements around HMGA1, 
ACTN1 or RAD51L1 cannot be excluded completely as they are expressed in 
smooth muscle cells and play a role in the development of these tumors. 
Both cases harbored several other structural chromosomal aberrations, 
but as no other recurrent translocation was identified, these were not further 
investigated. In one case (L1091) we detected a balanced t(6;7)(p;p), the 
breakpoint region on chromosome 6 might be compatible with the HMGA locus. 
The breakpoint on chromosome 7p is different from the regions described in 
earlier studies [21]. However, as we had no access to more tumor cells, FISH 
mapping experiments could not be performed on this case. The quite simple 
karyotype is remarkable for a high grade leiomyosarcoma, but in the Mitelman 
Database of Cancer 9 out of the 129 reported cases showed a similarly simple 
translocation indicating a genetic subtype of leiomyosarcoma. None of the 
reported cases had translocation breakpoints similar to the one observed by 
us [33]. The case was included on the TMA, but unfortunately few cells were left 
with good signals so this case was not eligible for scoring.
With the currently available techniques it is challenging to identify 
common aberrations in these genetically heterogeneous and instable 
tumors. Improvements in the field of next generation sequencing have led 
to an increased possibility to detect aberrations. Whole-genome sequencing 
of osteosarcomas, a genomically complex and instable bone sarcoma, has 
recently shown that tumors undergo chromothripsis, leading to numerous 
genomic rearrangements due to reshuffling of small chromosome segments 
probably during a crisis-phase [34]. Chromothripsis is also found in 42% of 
uterine leiomyomas and it has been postulated that similar events occur during 
the development of leiomyosarcomas [35]. Modern sequencing techniques 
might be helpful to identify pathogenetic mechanisms responsible for the 
development of these tumors. Amplification of myocardin (MYOCD) at 17p is 
frequently encountered in leiomyosarcomas [36]. Some genetic alterations 
are found in only a subset of tumors indicating that they might be secondary 
rather than the causative, tumor initiating event. Recently mutations in 
dystrophin (DMD) have been identified in high grade mesenchymal tumors 
with certain level of muscle differentiation, including leiomyosarcomas, 
rhabdomyosarcomas and gastrointestinal stromal tumors [37]. In that study a 
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high percentage of the tumors has aberrations in DMD, suggesting that these 
diff erent tumors might develop via a similar way. It will be interesting to study 
the role of DMD as deregulation of this gene might play a role in the early 
tumorigenesis of myogenic sarcomas.
This study reports the identifi cation of a t(6;14)(p;q) in two 
leiomyosarcoma cases. As the translocation breakpoints diff er, a common 
driver alteration for leiomyosarcomas was not found which is consistent with 
the genetic heterogeneity of these tumors. However, we identifi ed genes that 
might be involved in the pathogenesis of these particular leiomyosarcoma 
cases. In the future, next generation sequencing can be a helpful tool in the 
search for a common driver alteration of these malignant tumors. 
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Chapter 4
Inhibition of Bcl-2 family 
members sensitizes soft 
tissue leiomyosarcomas to 
chemotherapy
Marieke A. de Graaff, Marije A.J. de Rooij, Brendy E.W.M. van den Akker, 
Hans Gelderblom, Fréderic Chibon, Jean-Michel Coindre, 
Adrian Marino-Enriquez, Jonathan A. Fletcher, 
Anne-Marie Cleton-Jansen, Judith V.M.G. Bovée
British Journal of Cancer. 2016; 114(11): 1219-1226.
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Abstract
BACKGROUND: Leiomyosarcoma is an aggressive soft tissue sarcoma 
with a 5-year survival rate of 15 to 60%. Treatment options for inoperable 
or metastatic patients are limited due to frequent resistance of tumours 
to chemotherapy and radiation. In this study, we hypothesized that anti-
apoptotic Bcl-2 family proteins might contribute to leiomyosarcoma 
chemoresistance and therefore inhibition of Bcl-2 family proteins might 
sensitize leiomyosarcomas to conventional chemotherapy.
METHODS: Expression of the Bcl-2 family proteins Bcl-xL, Bcl-w and Bcl-
2 was investigated using immunohistochemistry on a tissue microarray 
containing 43 leiomyosarcomas. Furthermore, we investigated whether ABT-
737, a potent BH3 mimetic, sensitises leiomyosarcoma cells to doxorubicin 
treatment in vitro.
RESULTS: Seventy-seven percent, 84% and 42% of leiomyosarcomas 
demonstrated high expression of Bcl-2, Bcl-xL and Bcl-w, respectively. Single-
agent treatment with ABT-737 resulted in a minor reduction of cell viability. 
However, combination treatment of ABT-737 and doxorubicin revealed 
synergism in all four cell lines, by inducing apoptosis. 
CONCLUSION: In conclusion, Bcl-2 family proteins contribute to soft tissue 
leiomyosarcoma chemoresistance. Anti-apoptotic proteins are highly 
expressed in leiomyosarcoma of soft tissue, and inhibition of these proteins 
using a BH3 mimetic increases leiomyosarcoma sensitivity to doxorubicin.
Key words:
sarcoma, leiomyosarcoma, soft tissue tumour, apoptosis, Bcl-2, Bcl-xL, Bcl-w, 
ABT-737, chemoresistance.
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4
Introduction
Leiomyosarcomas are malignant mesenchymal neoplasms displaying smooth 
muscle diff erentiation (1). They occur in patients over a wide age range with the 
highest incidence in the 5th and 6th decade of life. The 5-year survival rates range 
from 15 to 60% depending on the location, size and stage of disease at time of 
diagnosis (1). These low survival rates are in part attributable to low response 
rates to chemo- and radiotherapy (2). 
Overexpression of multidrug resistance (MDR) proteins, like 
P-glycoprotein, only partly explains leiomyosarcoma chemoresistance. In 
addition, overexpression of Bcl-2 family proteins could contribute to chemo- 
and radiotherapy resistance, since chemo- and radiotherapy are DNA 
damaging therapies that provoke tumour regression by the activation of the 
intrinsic apoptotic pathway (3-5). Interestingly, immunohistochemistry shows 
high expression of the anti-apoptotic protein Bcl-2 in soft tissue sarcomas, 
including leiomyosarcoma (6, 7). Bcl family members, like Bcl-2, Bcl-xL (BCL2L1) 
and Bcl-w (BCL2L2) inhibit activation of the intrinsic apoptotic pathway by 
regulating the mitochondrial outer membrane permeabilization. Specifi cally, 
mitochondrial outer membrane pores are formed by dimerization of Bax and 
Bak proteins. These pores release cytochrome c from mitochondria which 
leads to activation of the intrinsic apoptotic cascade (5). By binding of the 
anti-apoptotic proteins Bcl-2/Bcl-xL to the pro-apoptotic family members Bak 
and Bax, the dimerisation of Bak and Bax is prevented and activation of the 
apoptotic pathway is inhibited.
In this study we hypothesized that the Bcl-2 family members play an 
important role in leiomyosarcoma chemoresistance and their inhibition might 
therefore render leiomyosarcoma cells sensitive to treatment with conventional 
chemotherapeutic agents. To explore the role of Bcl-2 family members in 
leiomyosarcoma chemoresistance we fi rst evaluated the protein expression of 
the anti-apoptotic proteins Bcl-2, Bcl-xL and Bcl-w in a large series of soft tissue 
leiomyosarcomas by immunohistochemistry, using clinically-annotated tissue 
microarrays. Subsequently, we determined whether the Bcl-2 pathway inhibitor 
ABT-737 sensitizes leiomyosarcoma cells to chemotherapy. ABT-737 is a potent 
BH3 mimetic that inhibits Bcl-2, Bcl-xL and Bcl-w at the mitochondrial membrane 
by binding to their BH3 domains (8). As chemotherapeutic agent we used 
doxorubicin which is widely used in the treatment of leiomyosarcoma (9, 10). 
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Material and methods 
Tissue samples
Tissue microarrays were previously constructed containing leiomyosarcomas (soft 
tissue n=40, uterine n=3), leiomyomas of the uterus (n=7), myxofibrosarcomas 
(n=16), and undifferentiated pleomorphic/spindle cell sarcomas (n=28). These 
sarcomas all belong to the genetic subcategory of soft tissue sarcomas with 
complex karyotypes. Tissue microarrays (TMAs) were constructed using a 
semi-automated TMA apparatus (TMA Master; 3D Histech, Budapest, Hungary) 
(11). For each case, 1.767 mm2 per core was present in triplicate. All samples 
were handled according to the Dutch code of proper secondary use of human 
material as accorded by the Dutch society of pathology (Federa). The samples 
were handled in a coded (pseudo-anonymised) fashion according to the 
procedures as accorded by the LUMC ethical board. In total, 40 soft tissue 
leiomyosarcomas were included from 39 patients (23 females and 16 males); 
of one patient both the primary tumor and a metastatic lesion were analyzed. 
In addition, three uterine leiomyosarcomas were included. The average age at 
diagnosis was 60 years. Clinicopathological information is shown in Suppl table 
1. Patients were diagnosed between 1989 and 2011 in the LUMC (Leiden, the 
Netherlands). None of the patients received pre-operative chemotherapy or 
radiation therapy.
Compounds
Doxorubicin was obtained from the in-house hospital pharmacy in a 0.9% 
NaCl solution. ABT-737 (Selleckchem, Houston, USA) was dissolved in dimethyl 
sulfoxide (DMSO).
Cell culture
In this study we included four leiomyosarcoma cell lines (LMS04, LMS05, IB133 
and IB140). These cell lines were established from primary tumours and for 
the experiments described herein were used between passages 20-50. LMS04 
was derived from a high grade retroperitoneal metastasis from the uterus and 
LMS05 was derived from a grade 2 soft tissue leiomyosarcoma (Suppl table 2). 
IB140 was derived from a FNCLCC grade 2 leiomyosarcoma from the upper leg 
and IB133 was derived from a FNCLCC grade 3 retroperitoneal leiomyosarcoma. 
TP53 mutation analysis was determined by Sanger sequencing. In addition, the 
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cell lines were screened for hotspot mutations using the Ion AmpliSeqTM Cancer 
Hotspot panel v2 (Thermo Fisher Scientifi c, Bleiswijk, The Netherlands). Fifty 
reads were considered enough to draw reliable conclusions. The coverage of 
identifi ed SNPs was ranging from 50 up to 1995 reads.
The leiomyosarcoma cell lines LMS04 and LMS05 were cultured in 
RPMI1640 medium with 15% FBS and 1% penicillin/streptomycin and the cell 
lines IB140 and IB133 were cultured in RPMI1640 with 10% FBS, 1% glutamax 
and 1% pen/strep. The HeLa cell line was included as a reference and cultured 
in RPMI1640 with 10% FBS and 1% pen/strep. All cell lines were repeatedly 
checked for mycoplasm and authentication of the cell lines was determined by 
short tandem repeat (STR) typing (GenePrint 10 system, Promega, Leiden, The 
Netherlands).
Immunohistochemistry 
To detect the expression of anti-apoptotic proteins, immunohistochemistry on 
TMA was performed according to standard laboratory procedures (11). Further 
details of the Bcl-2, Bcl-xL and Bcl-w antibodies are shown in Suppl table 3. 
Scoring was performed by two observers (MAdG and JVMGB) independently 
and discrepant cases were discussed to reach consensus. Both intensity 
(0=absent, 1=weak, 2=moderate and 3=strong expression) and percentage of 
positive tumour cells (0=0%, 1=1-24%, 2=25-49%, 3=50-74%, 4=75-100%) were 
assessed and scores were added up (12).
Cell viability assays 
To analyse the eff ect of treatment with doxorubicin and ABT-737, cell viability 
assays were performed with Alamar blue (Life Technologies, Bleiswijk, The 
Netherlands) according to the manufacturer’s instructions. Absorbance was 
measured with a light spectrometer (Victor V, 1420 Multilabel counter; Perkin 
Elmer, Groningen, The Netherlands).
The dose-response curves of single treatments with ABT-737 and 
doxorubicin were determined for each cell line in a range from 0.001 to 12.8μM. 
For doxorubicin, it is accepted that an in vivo range of 5 to 100 µM corresponds 
to an in vitro range from 1 to 10 µM (13). All cell lines were treated with ABT-
737 for 24 hours and subsequently doxorubicin for 48 hours. Because in only 
one of the four cell lines (LMS05) large eff ects could be observed, the other 
three cell lines were treated with doxorubicin and ABT-737 combined for 72 
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hours. The concentrations of doxorubicin used for the combination treatments 
were selected per cell line, based on the individual dose-response curves after 
48 hour (not shown) and 72 hour doxorubicin treatment. Cell viability was 
calculated relative to untreated cells, all experiments were repeated three 
times in triplicate. 
To evaluate whether the combination treatments of doxorubicin and 
ABT-737 were synergistic drug interactions, a simplified version of the Bliss 
independence model was applied (14). When two drugs exert their effects 
independent to one another, the resulting relative viability after drug treatment 
is expected to equal the product of the relative viability after treatment with 
the individual drugs. When the observed viability after combination treatment 
is lower than the expected viability, this is an indication of a synergistic drug 
interaction. When the observed viability is higher than the expected based 
on the individual drug effects, the compounds inhibit each other’s effects 
(antagonism).
Western blot 
To evaluate the expression of Bcl-2, Bcl-xL, Bcl-w, Mcl-1, PARP and α-tubulin 
before and after treatment we performed western blots according to the Cell 
Signaling Technology protocol enhanced chemiluminescence. Cell lysates 
were made from cultured cell lines LMS04, LMS05, IB133 and IB140 treated with 
doxorubicin (respectively 0.2, 0.6, 0.7 and 0.5μM) and with ABT-737 (5μM) for 
24 hours. In order to obtain cell lysates, hot SDS was added to the cells and the 
solution was heated up to 100ºC. Gels were loaded with 20µg lysate. Antibodies, 
described in detail in Suppl table 4, were dissolved in TPS Tween 0.05% in which 
the blots were also washed. As a positive control for all antibodies except for 
PARP, the HeLa cell line was included. For PARP, Jurkat apoptosis cell lysate (Cell 
Signaling Technology) was included as a positive control. 
Caspase assay 
To confirm that the decrease in cell viability was caused by apoptosis, caspase 
assays were performed according to the caspase-Glo 3/7 assay protocol of 
Promega. LMS04, LMS05, IB133 and IB140 cell lines were treated for 24 hours 
with ABT-737 (5μM), doxorubicin (0.2, 0.6, 0.7 and 0.5μM respectively) or a 
combination. A 1:1 ratio of Caspase-Glo ® 3/7 reagent volume per sample was 
used. As negative controls, untreated cells were included. For each condition, 
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Z-VAD-FMK, an irreversible pan-caspase inhibitor (25μM, Promega) was used. 
The luciferase units of each sample were measured by the VICTOR3 Label 
counter with emission fi lter D572 after 1 hour.
Statistics
GraphPad Prism for Windows version 6.02 (GraphPad Software, La Jolla 
California, USA) was used to analyze the results. The statistical diff erence 
between 2 groups was assessed by an unpaired t-test, P-values were considered 
statistically diff erent if P<0.05). Statistical diff erences in overall survival were 
calculated with the log-rank (Mantel-Cox) test. Also GraphPad was used for 
dose-response curves and calculation of IC
50
 values.
Results 
High expression of Bcl family proteins in leiomyosarcomas
Immunohistochemistry for anti-apoptotic proteins using tissue microarrays 
revealed that Bcl-xL and Bcl-w were higher expressed in leiomyosarcomas 
compared to uterine leiomyomas (Figure 1). Thirty three out of 43 (77%) 
leiomyosarcomas showed high Bcl-2 expression (IHC score >3). For Bcl-xL and 
Bcl-w this was 36 out of 43 (84%) and 18 out of 43 (42%), respectively (Table 
1). Interestingly, Bcl-xL and Bcl-w were expressed at signifi cantly lower levels 
in uterine leiomyomas (p=<0.001), while Bcl-2 expression was signifi cantly 
higher in leiomyomas, compared to leiomyosarcomas (p=0.042). The three 
uterine leiomyosarcomas showed a slightly higher Bcl-2 expression compared 
to the leiomyomas, although this is not statistically signifi cant (p=0.224) (Suppl 
fi gure 1A). The anti-apoptotic proteins were also expressed in other high grade 
sarcomas (myxofi brosarcoma and undiff erentiated pleomorphic sarcoma) 
(Table 1).
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Figure 1. Protein expression of Bcl-2, Bcl-xL and Bcl-w determined by immunohistochemistry. (A) In 
the top panel Bcl-2, Bcl-xL and Bcl-w expression of a representative leiomyosarcoma is displayed were 
the bottom panel shows expression of a representative uterine leiomyoma (20x magnification). 
Leiomyosarcomas showed overall higher expression of Bcl-xL and Bcl-w, whereas both leiomyosarcomas 
and uterine leiomyomas revealed a high expression of Bcl-2. (B) The difference in Bcl-2, Bcl-xL and Bcl-w 
protein expression of leiomyosarcoma (LMS), uterine leiomyoma (LM uterus), myxofibrosarcoma (MFS) 
and undifferentiated pleomorphic sarcoma (UPS) illustrated by dot plots confirmed an overall higher 
expression of Bcl-xL and Bcl-w in leiomyosarcomas as compared to uterine leiomyomas. 
There was no association between expression and histological grade 
(Suppl figure 1A). The Kaplan-Meier survival curve showed a trend for high 
expression of Bcl-2, Bcl-xL and Bcl-w to be associated with shorter overall 
survival time (Suppl figure 1B). However, the differences in overall survival 
between the groups of patients with an immunohistochemical score ≤3 or >3 
were not significant (p=0.5347 (Bcl-2), p=0.5490 (Bcl-xL) and p=0.2495 (Bcl-w)). 
Sixteen patients were diagnosed with a metastasis after a period of treatment. 
In the Kaplan-Meier survival curves no correction was added for metastasis or 
treatment. 
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Table 1. Expression of Bcl-2, Bcl-xL and Bcl-w in leiomyosarcomas, leiomyomas and sarcomas.
Expression LM LMS P-value MFS UPS/SCS
   LM vs LMS   
Bcl-2  
    Low 0/7 (0%) 10/43 (23%) 0.0419 2/16 (13%) 11/28 (39%)
    High 7/7 (100%) 33/43 (77%)  14/16 (87%) 17/28 (61%)
Bcl-xL      
    Low 7/7 (100%) 7/43 (16%) <0.0001 3/15 (20%) 7/28 (25%)
    high 0/7 (0%) 36/43 (84%)  12/15 (80%) 21/28 (75%)
Bcl-w  
   Low 7/7 (100%) 25/43 (58%) 0.0004 7/15 (47%) 14/28 (50%)
   High 0/7 (0%) 18/43 (42%)  8/15 (53%) 14/28 (50%)
Leiomyosarcoma (LMS), uterine leiomyoma (LM uterus), myxofi brosarcoma (MFS) and undiff erentiated 
pleomorphic/spindle cell sarcoma (UPS/SCS). Low = IHC score ≤ 3; high = IHC score > 3.
Doxorubicin and ABT-737 act synergistically in leiomyosarcoma cell 
lines 
Since Bcl-2, Bcl-xL and Bcl-w were highly expressed in the majority of 
leiomyosarcomas, four leiomyosarcomas cell lines (LMS04, LMS05, IB133 and 
IB140) were selected for further functional evaluation. Clinicopathological as 
well as genetic characteristics of these cell lines are shown in Suppl table 2. 
TP53 mutations were found in LMS04 and IB133, while IB140 demonstrated a 
CTNNB1 variation (Suppl table 2 and suppl fi gure 2).
The response to ABT-737 and doxorubicin were determined separately 
after 24, 48 and 72 hours of treatment. All cell lines showed maximal response 
at 72 hours of ABT-737 treatment. IB140 and IB133 demonstrated a slight 
decrease in cell viability compared to LMS04 and LMS05, however due to the 
limited sensitivity of single treatment with this drug, no reliable absolute IC50 
could be calculated (Figure 2A). The cell lines showed a maximal reduction 
in cell viability of 60-95% after single doxorubicin treatment (Figure 2B). The 
calculated absolute IC
50
 values of doxorubicin treatment for the four cell lines 
LMS04, LMS05, IB140 and IB133 were respectively: 0.198; 0.265; 1.314 and 
0.580 µM. 
To determine possible synergy of combination treatment, ABT-737 (1, 
5 and 10µM) was administered for the fi rst 24 hours, followed by the addition 
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of doxorubicin for 48 hours. A synergistic effect of ABT-737 was found, most 
pronounced in LMS05 (Figure 2C) and only a moderate effect was observed 
in IB140, IB133 and LMS04 (not shown). Therefore, these last three cell lines 
were treated simultaneously with ABT-737 and doxorubicin for 72 hours. 
The expected cell viability of combination treatment was calculated and 
compared with the observed viability. For five out of six tested sequential 
drug combinations in LMS05 a statistical significant difference (P<0.005) was 
found between the expected and observed cell viability, indicating synergism 
(Figure 2C). IB133 and IB140 both showed synergistic effects with pronounced 
reduction of cell viability in the three drug combinations with the higher 
doxorubicin concentration (p<0.005) after synchronous treatment for 72 hour 
(Figure 2E and 2F). In LMS04, on the other hand, the difference between the 
observed and expected effect of the synchronous combination treatment 
was most clear in the two combinations with the highest (10µM) ABT-737 
concentration (p=0.07 and p<0.005) (Figure 2D). 
Figure 2. Dose response curves of the four cell lines treated with ABT-737 and doxorubicin. (A) Dose 
response curves of ABT-737 ranging from 0.001-12.8µM after 72 hours of treatment showed limited 
effect of this single drug treatment. (B) Dose response curves of doxorubicin ranging from 0.001-12.8µM 
after 72 hours of treatment showed reductions till 5% cell viability. (C) Comparison of observed and 
expected relative cell viability of LMS05 after sequential treatment with ABT-737 for 24 hours followed 
by 48 hours treatment with doxorubicin. Strong synergism was seen in LMS05. (D-F) Comparison of 
observed and expected relative cell viability of the cell lines LMS04, IB140 and IB133 after synchronous 
combination treatment with ABT-737 and doxorubicin for 72 hours. A moderate synergistic effect was 
observed in IB140 and IB133, and LMS04 revealed a mild synergistic effect at ABT-737 10µM.
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Western blot performed on untreated cells confi rmed expression of all 
three anti-apoptotic proteins in the four cell lines. Among these, Bcl-xL was 
most abundantly expressed. Expression of Bcl-2 was highest in LMS05, followed 
by LMS04, while expression was almost absent in IB133 and IB140 (Figure 3). 
Mcl-1 was expressed in all cell lines, with a comparable intensity as the HeLa 
control. LMS04 even showed a stronger Mcl-1 expression. Treatment with ABT-
737 and/or doxorubicin did not signifi cantly alter the expression levels of Mcl-
1, Bcl-w, Bcl-xL or Bcl-2. 
Figure 3. Western blots performed on untreated, single agent treated or combination-agent treated 
cells. The expression of Mcl-1, Bcl-w, Bcl-xL, α-tubulin and Bcl-2 in four leiomyosarcoma cell lines 
showed that Bcl-2 was expressed in LMS05 and LMS04, while it was almost absent in the IB133 and 
IB140 cell lines. Bcl-xL was most abundantly expressed in all four cell lines. Mcl-1 was expressed in all cell 
lines. 
Combination treatment induces apoptosis
Using caspase Glo3/7 assays we demonstrated that reductions in cell viability 
were caused by apoptosis. All four cell lines showed a dramatic increase in 
caspase activity after combination treatment compared to single treatment 
(Figure 4A). Addition of the pan-caspase inhibitor Z-VAD-FMK blocked the 
increase in luciferase units, which indicates that the luciferase units correspond 
to apoptosis. Furthermore, induction of cleaved PARP, an indicator for apoptosis 
was greater in all 24 hour combination treated lysates, compared to the single-
agent treated or untreated samples (Figure 4B) (13). 
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Figure 4. Caspase Glo3/7 assay and PARP western blots to evaluate apoptosis after single-agent and 
combination treatments. (A) Amount of luciferase units measured in combined treated cells was 
significantly higher compared to single and untreated cells. For each condition also the pan-caspase 
inhibitor (Z-VAD-FMK) was included which show low or no expression of luciferase units. (B) Cleaved 
PARP expression was confirmed in all combined treated cells by western blot.
Discussion
In this study we found high expression of Bcl-2 family members in 
leiomyosarcomas and demonstrate a role for these proteins in the response 
of leiomyosarcomas to conventional chemotherapy. More specifically, 
inhibition of Bcl-2 family members using the ABT-737 BH3 mimetic rendered 
leiomyosarcoma cell lines more sensitive to doxorubicin, suggesting new 
therapeutic options for patients with metastatic or inoperable disease. 
We demonstrated a high protein expression of Bcl-xL and Bcl-w in 
leiomyosarcomas compared to benign uterine smooth muscle tumours. Bcl-2 
expression was higher in leiomyomas compared to leiomyosarcomas, which 
was also reported by others (15, 16). Some studies showed a correlation 
between high Bcl-2 expression and longer disease-specific survival in uterine 
leiomyosarcomas (15-18). In contrast, we observed a trend for high Bcl-2 
expression with shorter survival. The difference might be due to differences in 
biological behavior between uterine and soft tissue leiomyosarcomas as our 
series contains only three uterine leiomyosarcomas.
These results are consistent with observations in other tumour types, 
including sarcomas, in which in vitro studies have also demonstrated an 
important role for the Bcl-2 family members in chemoresistance, and that 
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tumour cells could be sensitized to doxorubicin by inhibition of these proteins, 
using ABT-737 (19). The addition of doxorubicin after ABT-737 treatment 
resulted in a complete loss of cell viability in chondrosarcoma. In other tumour 
cell lines, including castration-resistant prostate cancer (CRPC), malignant 
peripheral nerve sheath tumour (MPNST), acute promyelocytic leukemia 
(APL) and acute myeloid leukemia (AML), ABT-737 also showed synergy in 
combination with chemotherapeutic agents (20-23). 
Treatment with ABT-737 alone resulted only at a high concentration in a 
small reduction of the cell viability in the IB133 and IB140 cell lines. Therefore, 
we concluded that in vitro treatment with ABT-737 as single agent has almost no 
infl uence on the cell viability. Other studies in chondrosarcomas and small cell 
lung carcinomas also revealed limited activity of ABT-737 monotherapy (24). To 
explore a possible role of the Bcl-2 family members in response to conventional 
chemotherapy, we combined ABT-737 with doxorubicin, which is commonly 
used as single agent in the treatment of high grade soft tissue sarcomas (9, 10). 
Indeed, a synergistic eff ect was seen as cell viability decreased and apoptosis 
could be shown. Interestingly, single treatment with doxorubicin decreased 
cell viability, but had no impact on apoptosis. This suggests that even though 
cells stopped proliferating and lost their viability, they failed to activate their 
apoptotic machinery at the doses tested, most probably due to expression of 
Bcl-2 family members. This is in accordance with the low response rates and the 
poor impact of chemotherapeutic agents on overall survival of patients.
The four leiomyosarcoma cell lines were analyzed using the AmpliSeq™ 
Cancer Hotspot Panel v2. We detected a CTNNB1 S45C variation in IB140, with a 
coverage of 61 reads. Revision of the corresponding primary tumour confi rmed 
the diagnosis of leiomyosarcoma as well as the presence of the same mutation 
(Suppl fi g 2). Nuclear staining for β-catenin was absent, so the signifi cance 
of the S45C CTNNB1 alteration in this tumour remains unclear. Two cell lines 
showed alterations in TP53. The leiomyosarcoma cell lines which showed the 
highest synergy (LMS05 and IB140) have a wild type TP53 gene, whereas the 
cell line with the lowest synergy (LMS04) did not. TP53 is a major protein in the 
apoptotic signaling pathway and when TP53 is mutated the apoptotic response 
is impaired (25). Furthermore, wild type TP53 increases the responsiveness to 
chemotherapy by down-regulating multidrug resistance-1 expression (26). 
Even though the numbers are small, a mutation in this key protein might 
explain the diff erence in treatment response for LMS04 and IB133. 
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Furthermore, the cell lines showed Mcl-1 expression at the same level 
or stronger as compared to the HeLa control, and it has been reported that 
Mcl-1 in HeLa cells plays an important role in the sensitization to ABT-737 (27). 
High Mcl-1 levels are associated with resistance of cell lines to ABT-737 and 
downregulation of Mcl-1 sensitizes carcinoma cells to doxorubicin (27-29). 
This suggests that Mcl-1 expression might be important in the anti-apoptotic 
mechanisms in the LMS cell lines, and modulation of this protein level might be 
a target to increase the effect of ABT-737 and doxorubicin treatment. Treatment 
with ABT-737, doxorubicin or a combination did not change the expression 
levels of Bcl-xL, Bcl-w or Bcl-2. This is comparable to other studies in which there 
were only slight differences in the expression of Bcl-2 and Bcl-xL after treatment 
(21, 30). Thus, ABT-737 and doxorubicin do not down regulate the expression 
of the Bcl-2 family members at the protein level, and may instead block their 
inhibitory effect on Bak/Bax proteins in the mitochondrial membrane (31).
The effect of ABT-263 (navitoclax®, Abbott), a structural analogue of 
ABT-737, has been analyzed in toxicity phase I and II studies in small cell lung 
carcinomas. Thrombocytopenia was the most frequently observed adverse 
effect. However, marrow compensation platelet counts showed partial recovery 
when dosing was sustained, and in the week without dosing, recovery to 
baseline was seen. Diarrhea, vomiting, nausea and fatigue were other common 
adverse effects (24, 32). These adverse events are also frequently seen after 
chemotherapeutic treatment but are most of the time not life-threatening, 
suggesting that the preclinical evidence generated in this report may be 
realistically translated to clinical application. 
In conclusion, our results show that inhibition of Bcl-2 family members 
using ABT-737 renders leiomyosarcoma cell lines more sensitive to doxorubicin, 
especially in the presence of wildtype TP53, suggesting new potential therapeutic 
options for leiomyosarcoma patients with metastatic or inoperable disease.
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Supplementary Information
Supplementary fi gure 1. Immunohistochemistry score in relation with histological grade and overall 
survival. (A) The overall score was not correlated with histological grade. (B) Leiomyosarcoma patients 
were divided into two groups (high >3 and low ≤3) based on the immunohistochemical score of Bcl-2, 
Bcl-xL and Bcl-w. A shorter overall survival was seen for patients with a high expression of Bcl-2, Bcl-xL 
and Bcl-w, although the diff erence was not signifi cant. 
Supplementary fi gure 2. Histology, immunohistochemistry and NGS analysis of the IB140 cell line 
and the corresponding primary tumour. (A) H&E staining of the primary tumour showed high mitotic 
activity, (B) no nuclear β-catenin expression, and (C) a strong and diff use staining for caldesmon. The 
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morphology and immunohistochemistry are highly characteristic of leiomyosarcoma.  (D) NGS analysis 
of the primary tumour and the cell line showed CTNNB1 c.134C>G (p.S45C) variation in the cell line (total 
reads 61; 24 C (39%), 37 G (61%)) and primary tumour (total reads 2787; 1642 C (59%), 1135 G 41%)).
Supplementary table 1. Clinicopathological data of leiomyosarcoma patients.
Sample Age Gender P/R/M Tumour localisation Grade
1 39 M P Jejunum 1
2 60 F P Rectum 1
3 55 F P Retroperitoneum 1
4 76 F R Retroperitoneum 1
5 41 M P Soft tissue jaw 1
6 73 M R Duodenum 1
7 48 F P Rectus abdominis 1
8 32 M P Musculus psoas 1
9 23 M R Lower extremity 2
10 74 M P Upper extremity 2
11 56 F P Lower extremity 2
12 79 M P Subcutis back 2
13 43 M P Upper extremity 2
14 80 F P Lower extremity 2
15 30 M P Colon 2
16 76 F P Lower extremity 2
17 65 F P Lower extremity 2
18 55 M M Liver 2
19 80 F P Lower extremity 3
20 86 M P Lower extremity 3
21 43 F P Pelvis 3
22 67 F P Upper extremity 3
23 68 F P Lower extremity 3
24 70 M P Lower extremity 3
25 65 F P Lower extremity 3
26 70 M P Lower extremity 3
27 56 F P Lower extremity 3
28 75 M P Lower extremity 3
29 67 F P Upper extremity 3
30 41 F P Lower extremity 3
31 70 F P Retroperitoneum 3
32 84 F P Upper extremity 3
33 74 F M Pleura 3
34 50 F P Arteria femoralis 3
35 58 M P Lower extremity 3
36 52 F P Lower extremity 3
37 48 M P Stomach 3
38 76 F P Lower extremity 3
39* 50 F P Retroperitoneum 3
40* 50 F M Abdomen 3
41 39 F P Uterus NA
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Supplementary table 1. Continued
Sample Age Gender P/R/M Tumour localisation Grade
42 61 F P Uterus NA
43 52 F P Uterus NA
P=primary tumor; R=recurrence; M=metastasis; NA=non applicable; *primary and metastatic tumour 
sample from the same patient. None of the included samples were pretreated with chemotherapy or 
radiation.
Supplementary table 2. The characteristics of the four leiomyosarcoma cell lines.
Cell lines Passage 
number
Diagnosis and 
grade
Patient TP53$ Cancer Hotspot 
panel
LMS04 P45 LMS III F/54 Homozygous deletion KDR
LMS05 P34 LMS II ST M/76 Wild type: exon 4-9 No mutations
IB133 P21 LMS III RP F/56 Deletion: exon 2 and 3 No mutations
IB140 P22 LMS II ST M/51 Wild type: exon 1-11 CTNNB1 S45C#
# The mutation was also found in the primary tumour, which upon revision demonstrated abundant 
mitotic activity, strong expression of heavy caldesmon, and lack of nuclear staining for beta-catenin, 
consistent with the diagnosis of leiomyosarcoma (Suppl fi g 2).
$ determined by Sanger sequencing.
LMS: leiomyosarcoma, RP: retroperitoneum, ST: soft tissue.
Supplementary table 3. Details of antibodies used for immunohistochemistry.
Antibody Manufacturer Dilution Antigen retrieval
Bcl-2 Abcam  1/6 Citrate, pre-incubation 5% Elk milk
Bcl-xL Cell signaling  1/3 Citrate, DAB+
Bcl-w Abcam  1/3 Citrate, DAB+
Supplementary table 4. Details of antibodies used for western blot.
Antibody/clone Species Manufacturer Dilution
Bcl-2/50E3 Rabbit Cell signaling technology, Leiden, 
The Netherlands
1:1000
Bcl-xL/54H6 Rabbit Cell signaling technology 1:1000
Bcl-w/31H4 Rabbit Cell signaling technology 1:1000
Mcl-1 Rabbit Cell signaling technology 1:1000
PARP/46D11 Rabbit Cell signaling technology 1:1000
Alpha-tubulin/DM1A Mouse Abcam, Cambridge, UK 1:1000
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Abstract
New York esophageal squamous cell carcinoma 1 (NY-ESO-1, 
CTAG1B) is a cancer-testis antigen and currently a focus of several 
targeted immunotherapeutic strategies. We performed a large-scale 
immunohistochemical expression study of NY-ESO-1 using tissue microarrays 
of mesenchymal tumors from three institutions in an international 
collaboration. A total of 1132 intermediate and malignant, and 175 benign 
mesenchymal lesions were enrolled in this study. Immunohistochemical 
staining was performed on tissue microarrays using a monoclonal antibody 
for NY-ESO-1. Among mesenchymal tumors, myxoid liposarcomas showed 
the highest positivity for NY-ESO-1 (88%), followed by synovial sarcomas 
(49%), myxofibrosarcomas (35%) and conventional chondrosarcomas (28%). 
Positivity of NY-ESO-1 in the remaining mesenchymal tumors was consistently 
low, and no immunoreactivity was observed in benign mesenchymal 
lesions. Based on these findings, nearly 90% of myxoid liposarcomas, as well 
as a significant proportion of synovial sarcomas, myxofibrosarcomas and 
conventional chondrosarcomas are good candidates for immunotherapy 
targeting NY-ESO-1.
Keywords: 
NY-ESO-1, cancer-testis antigen, myxoid liposarcoma, mesenchymal tumor, 
sarcoma, immunohistochemistry, immunotherapy
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Introduction
New York esophageal squamous cell carcinoma 1 (NY-ESO-1), encoded 
by the CTAG1B gene, is a cancer-testis antigen that was identifi ed in 1997 
from the serum of a patient with esophageal squamous cell carcinoma (1). 
Cancer-testis antigens such as NY-ESO-1 have attracted increasing attention 
as immunotherapeutic targets because, among normal tissues, they are 
expressed only in adult testis germ cells and are atypically re-expressed in 
many malignancies (2, 3). NY-ESO-1 is of particular interest to researchers and 
clinicians because it is highly immunogenic and is expressed in a variety of 
carcinomas, melanomas and sarcomas (4). A recent clinical trial of adoptive 
immunotherapy, using genetically modifi ed T cells directed against NY-ESO-1, 
demonstrated objective clinical responses in a number of metastatic synovial 
sarcoma and melanoma patients with NY-ESO-1-positive tumors (5). The results 
of that clinical trial highlight the potential eff ectiveness of immunotherapy 
against tumors expressing NY-ESO-1, and several clinical trials (using antigen 
sensitization, adoptive T-cell transfer, and dendritic cell vaccine strategies) are 
currently underway.
Mesenchymal tumors arising from bone or soft tissues comprise many 
histologic subtypes, which even taken together occur at a much lower rate than 
the more common carcinomas, creating a practical barrier to developing new 
drug therapies. However, the well-defi ned biology of many sarcomas suggests 
they may be particularly susceptible to appropriate targeted strategies. Recent 
studies have reported NY-ESO-1 expression in an especially large proportion of 
myxoid liposarcomas and synovial sarcomas (2, 6-9). These studies also revealed 
the absence of NY-ESO-1 expression in their histologic mimics such as myxoma, 
myxofi brosarcoma, extraskeletal myxoid chondrosarcoma and low-grade 
fi bromyxoid sarcoma, and concluded that immunohistochemical staining of 
NY-ESO-1 is useful not only for candidate selection in immunotherapy, but also 
for histologic diff erential diagnosis. A limitation of these previous studies is 
that the sample sizes were too small to be conclusive and lacked independent 
external validation.
The goals of this study are to validate published reports of NY-ESO-1 
expression in myxoid liposarcoma and synovial sarcoma patients on a larger 
sample set, and to investigate NY-ESO-1 expression in other mesenchymal 
tumors not represented in previous studies. To do so, we undertook a multi-
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institutional NY-ESO-1 expression survey on tissue microarrays encompassing 
a wide variety of malignant, intermediate and benign bone and soft tissue 
tumors, seeking to determine if NY-ESO-1 is indeed useful in the differential 
diagnosis among mesenchymal tumors and to identify subtypes that are most 
likely to benefit from NY-ESO-1 immunotherapy.
Materials and Methods
Tumor samples and tissue microarrays
In this study, formalin-fixed paraffin-embedded tissue microarrays from 3 
institutions, the University of British Columbia (UBC), the MD Anderson Cancer 
Center (MDACC) and the Leiden University Medical Center (LUMC), with a 
diverse selection of benign, intermediate and malignant mesenchymal tumors 
were used. Each tissue microarray contains duplicate, triplicate or quadruplicate 
0.6 mm (UBC, LUMC), 1.5 mm (LUMC) or 2.0 mm (MDACC, LUMC) cores derived 
from representative viable diagnostic areas identified by a specialized bone 
and soft tissue tumor pathologist (TON, AJL, JVMGB). Tissue microarrays 
from UBC included in this study are TMA 01-003 (10), TMA 03-008 (11), TMA 
06-007 (12), TMA 06-001B (13), TMAs 08-019, 09-006, 10-009 (14), TMAs 12-
004, 12-005, 12-006, 12-010 (15) and TMA MPNST (16). From MDACC, myxoid 
liposarcoma tissue microarrays contained untreated tumors and tumors pre-
treated with chemotherapy, radiation or a combination of both (17, 18). From 
the LUMC, tissue microarrays were selected containing chondrosarcomas (19, 
20), osteosarcomas (21), myxoid liposarcomas and a variety of benign and 
malignant soft tissue tumors (22, 23).
Immunohistochemistry
Immunohistochemical staining was performed with an autostainer for 
tissue microarrays of the UBC and MDACC following protocols as described 
previously (24). Briefly, antigen retrieval was performed using the Standard 
Cell Conditioning 1 (CC1) protocol (Ventana, Tucson, AZ, USA). Sections were 
incubated with mouse anti-NY-ESO-1 monoclonal antibody (clone E978, 
Invitrogen, Carlsbad, CA, USA) at 1:25 dilution for 2 hours at room temperature, 
and then with UltraMap HRP-conjugated anti-mouse IgG secondary antibody 
for 16 min. The ChromoMap DAB Kit (Ventana) provided the visualization 
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chromogen. Slides were then counterstained with hematoxylin and mounted. 
Immunohistochemical staining of the tissue microarrays of the LUMC was 
performed manually; 4 µm sections were transferred to adhesive coated slides 
(Leica Biosystems, Rijswijk, The Netherlands) and dried overnight at 37°C. 
Next slides were deparaffi  nized in xylene, rehydrated and incubated in 0.3% 
methanol/H
2
O
2 
at room temperature for 20 min to block the endogenous 
peroxidase activity. Antigen retrieval was performed by 10 min microwave 
treatment in tris/EDTA-solution (pH=9.0), followed by the addition of the 
primary NY-ESO-1 / CTAG1B antibody (1:100, clone E978, Invitrogen) and 
overnight incubation in a moist chamber at room temperature. Next, slides 
were incubated with PowerVision Poly-HRP (Leica), visualized with DAB+ 
Substrate Chromogen System (DAKO, Heverlee, Belgium) and counterstained 
with hematoxylin. All wash steps were done in PBS.
In both protocols the staining was preceded by a titration series on 
normal testis, and during the actual staining testis was included as a positive 
control, and as the tissue present in the negative control reaction (without the 
addition of the primary antibody).
Digital Images
Digital images of immunostained and H&E-stained tissue microarrays of UBC 
were acquired using a BLISS imager (Bacus Laboratories, Lombard, IL, USA). A 
relational database was constructed that correlates scoring and identifi cation 
information with images of each core. This information is publicly accessible at 
http://www.gpecimage.ubc.ca (username: nyeso1; password: nyeso1).
Evaluation of immunohistochemistry
The tissue microarray slides were evaluated under a light microscope or on the 
scanned images by two to fi ve independent observers (ME, MAG, TON, JVMGB, 
AJL), including three experienced bone and soft tissue tumor subspecialty 
pathologists (TON, JVMGB, AJL). NY-ESO-1 immunopositivity was scored in a 
semiquantitative manner for the intensity (0 = negative, 1 = weak positive, 2 = 
moderate positive, 3 = strong positive) and the percentage of positive tumor 
cells (0 = 0%, 1 = 1-25%, 2 = 26-50%, 3 = 51-75%, 4 = 76-100%). Each core on 
the tissue microarrays was scored separately and the average score from cores 
of the same tumor were calculated. Tumor samples with more than 50% of 
positive tumor cells and a staining intensity of moderate or strong (2 or 3) were 
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defined as “positive”. This cutoff value was chosen to be consistent with criteria 
used in an ongoing clinical trial of NY-ESO-1 immunotherapy (5). In addition, 
cross comparison of manual and autostaining revealed the manual method 
generated a weak background stain not seen with the automated platform. 
However, the scoring system, which considered weak (intensity 1) staining 
as negative meant that the cases defined as “positive” were consistently 
categorized and equally discernible with both staining methods. Comparison 
of TMA to whole section was performed on a comparison set of eleven cases, 
and the staining results were found to be concordant.
Statistical Analysis
A chi-square test was used to assess the differences between histological 
subtypes; statistical significance was defined as p < 0.05. Data analysis was 
performed with JMP software (version 9.0.2, JMP Software, Cary, NC, USA).
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Table 1. Immunohistochemical NY-ESO-1 (CTAG1B) expression in intermediate and malignant bone 
and soft tissue tumors. 
TMAs UBC and MDACC TMAs LUMC Total
Malignant and intermediate bone 
and soft tissue tumors ca
se
s
N
 p
os
it
iv
e
%
 p
os
 c
as
es
ca
se
s
N
 p
os
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%
 p
os
 c
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e
%
 p
os
 c
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es
SOFT TISSUE    
Adipocytic tumors    
Liposarcoma, dediff erentiated 5 0 0.0 2 1 50.0 7 1 14.3
Liposarcoma, myxoid 128 110 85.9 30 29 96.7 158 139 88.0
Liposarcoma, myxoid, post-treatment 43 18 41.9  43 18 41.9
Liposarcoma, pleomorphic 7 0 0.0 4 0 0.0 11 0 0.0
Liposarcoma, well-diff erentiated 13 1 7.7 8 0 0.0 21 1 4.8
    
Fibroblastic / myofi broblastic tumors    
Desmoid-type fi bromatosis 8 0 0.0  8 0 0.0
Dermatofi brosarcoma protuberans 17 2 11.8 1 0 0.0 18 2 11.1
Solitary fi brous tumor 15 0 0.0 2 0 0.0 17 0 0.0
Fibrosarcoma 8 1 12.5  8 1 12.5
Myofi broblastic sarcoma  2 0 0.0 2 0 0.0
Myxofi brosarcoma  17 6 35.3 17 6 35.3
Low grade fi bromyxoid sarcoma 5 0 0.0  5 0 0.0
Sclerosing epithelioid fi brosarcoma 1 0 0.0  1 0 0.0
    
Smooth muscle tumors    
Leiomyosarcoma 5 0 0.0 50 8 16.0 55 8 14.5
    
Skeletal muscle tumors    
Rhabdomyosarcoma, alveolar 9 0 0.0  9 0 0.0
Rhabdomyosarcoma, embryonal 12 0 0.0 2 1 50.0 14 1 7.1
Rhabdomyosarcoma, pleomorphic  3 1 33.3 3 1 33.3
    
Vascular tumors of soft tissue    
Angiosarcoma  1 0 0.0 1 0 0.0
Epithelioid angiosarcoma 4 0 0.0  4 0 0.0
Epithelioid hemangioendothelioma 1 0 0.0  1 0 0.0
    
Gastrointestinal stromal tumors    
Gastrointestinal stromal tumor 143 0 0.0 3 0 0.0 146 0 0.0
    
Nerve sheath tumors    
Malignant peripheral nerve sheath 
tumor
75 2 2.7 7 0 0.0 82 2 2.4
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Table 1. continued. 
TMAs UBC and MDACC TMAs LUMC Total
Malignant and intermediate bone 
and soft tissue tumors ca
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 c
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 c
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Tumors of uncertain differentiation    
Alveolar soft part sarcoma 8 0 0.0  8 0 0.0
Angiomatoid fibrous histiocytoma 2 0 0.0  2 0 0.0
Chondrosarcoma, extraskeletal myxoid 5 0 0.0  5 0 0.0
Clear cell sarcoma 8 0 0.0  8 0 0.0
Desmoplastic small round cell tumor 2 0 0.0  2 0 0.0
Epithelioid sarcoma 7 0 0.0  7 0 0.0
Malignant myoepithelioma 1 0 0.0  1 0 0.0
Synovial sarcoma 63 30 47.6 6 4 66.7 69 34 49.3
    
Undifferentiated / unclassified sarcomas    
Undifferentiated pleomorphic sarcoma 5 1 20.0 22 2 9.1 27 3 11.1
Undifferentiated spindle cell sarcoma  5 0 0.0 5 0 0.0
    
Endometrial stromal sarcoma    
Endometrial stromal sarcoma 58 3 5.2  58 3 5.2
    
BONE    
Chondrogenic tumors    
Chondrosarcoma, conventional 29 2 6.9 113 38 33.6 142 40 28.2
Chondrosarcoma, clear cell  18 0 0.0 18 0 0.0
Chondrosarcoma, dedifferentiated 4 0 0.0 26 3 11.5 30 3 10.0
Chondrosarcoma, mesenchymal 3 0 0.0 15 0 0.0 18 0 0.0
    
Osteogenic tumors    
Osteosarcoma 4 1 25.0 76 4 5.3 80 5 6.3
    
Miscellaneous tumors    
Ewing sarcoma 21 0 0.0    21 0 0.0
Bold indicates entities with a significant fraction of positive cases.
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Table 2. Immunohistochemical NY-ESO-1 expression in benign bone and soft tissue tumors.
TMAs UBC and MDACC TMAs LUMC Total
Benign bone and soft tissue tumors
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SOFT TISSUE    
Atypical fi broxantoma 2 0 0.0  2 0 0.0
Congenital mesoblastic nephroma 2 0 0.0  2 0 0.0
Fetal rhabdomyoma 2 0 0.0  2 0 0.0
Fibroma/fi bromatosis 36 0 0.0 4 0 0.0 40 0 0.0
Granuloma annulare 1 0 0.0  1 0 0.0
Leiomyoma  6 0 0.0 6 0 0.0
Lipoma 7 0 0.0 7 0 0.0 14 0 0.0
Lipoma, spindle cell 10 0 0.0  10 0 0.0
Myofi broma and Myofi bromatosis 6 0 0.0  6 0 0.0
Myositis ossifi cans 2 0 0.0  2 0 0.0
Myxoma  3 0 0.0 3 0 0.0
Neurofi broma 33 0 0.0  33 0 0.0
Nodular fasciitis 1 0 0.0  1 0 0.0
Perineurioma 3 0 0.0  3 0 0.0
Schwannoma 21 0 0.0 3 0 0.0 24 0 0.0
Tenosynovial giant cell tumor  1 0 0.0 1 0 0.0
    
BONE    
Chondroblastoma 4 0 0.0  4 0 0.0
Chondromyxoid fi broma 3 0 0.0  3 0 0.0
Enchondroma 6 0 0.0 5 0 0.0 11 0 0.0
Osteochondroma  6 0 0.0 6 0 0.0
Synovial chondromatosis    1 0 0.0 1 0 0.0
Table 3. Immunohistochemical NY-ESO-1 expression in non-mesenchymal tumors and in several non-
tumorous lesions. 
TMAs UBC and MDACC TMAs LUMC Total
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Non-mesenchymal tumors      
Hepatoblastoma 2 0 0.0   2 0 0.0
Melanoma 7 0 0.0   7 0 0.0
Melanoma, desmoplastic 10 1 10.0   10 1 10.0
Squamous cell carcinoma 8 0 0.0   8 0 0.0
Wilms tumor 23 0 0.0   23 0 0.0
     
Non-tumorous lesions     
Granuloma annulare 1 0 0.0   1 0 0.0
Reumatoid nodule 5 0 0.0   5 0 0.0
Normal fat 8 0 0.0    8 0 0.0
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Results
In total, specimens from 1132 malignant and intermediate bone and soft 
tissue tumors, 175 benign bone and soft tissue tumors, 50 non-mesenchymal 
tumors, 6 non-tumorous lesions and 8 samples of normal fat were available for 
evaluation (Tables 1 - 3). There were 38 subtypes of malignant and intermediate 
tumors and 21 different benign mesenchymal lesions in this cohort. The 
subtypes with more than 50 samples available included myxoid liposarcoma 
(n=201 in total; 158 untreated cases and 43 tumors which received treatment 
prior to resection), gastrointestinal stromal tumor (n=146), conventional 
chondrosarcoma (n=142), malignant peripheral nerve sheath tumor (n=82), 
osteosarcoma (n=80), synovial sarcoma (n=69), endometrial stromal sarcoma 
(n=58) and leiomyosarcoma (n=55).
Figure 1. Immunohistochemical staining of NY-ESO-1 (CTAG1B) in myxoid and round cell 
liposarcomas. 
Myxoid liposarcoma without treatment prior to resection revealed strong nuclear immunoreactivity in 
the majority of the tumor cells: (A) H&E, (B) NY-ESO-1 immunohistochemistry. Myxoid liposarcoma after 
neo-adjuvant treatment (with both radiation and chemotherapy) showed typical histologic changes of 
hyalinization (C) but retained nuclear and cytoplasmic staining (D).
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Among a wide variety of mesenchymal tumors, myxoid liposarcomas 
that had not received neoadjuvant treatment prior to resection showed the 
highest positivity for NY-ESO-1 (CTAG1B): 88.0% (139/158). The high number 
of positive cases was observed both in the autostained cohort cases from 
UBC and MDACC (85.9%; 110/128) and in the manually stained cohort cases 
from LUMC (96.7%; 29/30). Even among myxoid liposarcomas which received 
chemotherapy or radiation prior to resection, NY-ESO-1 expression was still 
detectable in 41.9% (18/43) of cases, although this was signifi cantly lower 
(p<0.0001) compared to the cases without preoperative treatment. Expression 
was seen both in myxoid as well as round cell areas. In an additional 37.2% 
(16/43) of these neoadjuvantly-treated tumors, weak staining in a small subset 
of the tumor cells was present; the remaining 20.9% (9/43) did not reveal any 
residual immunoreactivity. In comparison, the other liposarcomas – including 
well-diff erentiated (4.8% positivity; 1/21) and dediff erentiated (14.3%; 1/7) 
subtypes – showed NY-ESO-1 expression in only a minor subset of the cases; 
none of the tested pleomorphic liposarcomas revealed NY-ESO-1 expression 
(0%; 0/11). NY-ESO-1 positivity in myxoid liposarcomas was signifi cantly higher 
than in the other liposarcomas (p<0.0001) or in the other malignant and 
intermediate bone and soft tissue tumors (p<0.0001).
NY-ESO-1 expression was observed in almost half (49.3%; 34/69) of 
the synovial sarcomas. In addition, positivity was found in conventional 
chondrosarcoma (28.2%; 40/142) and dediff erentiated chondrosarcoma (10.0%; 
3/30). In the conventional chondrosarcomas there was no correlation of NY-
ESO-1 expression and histological grade. Two of the positive dediff erentiated 
chondrosarcomas revealed NY-ESO-1 expression only in the dediff erentiated 
component and the third positive case showed immunoreactivity in the well-
diff erentiated component. 
Other sarcomas with a substantial percentage of positive tumors 
include myxofi brosarcoma (35.3%; 6/17), leiomyosarcoma (14.5%; 8/55), 
dermatofi brosarcoma protuberans (11.1%; 2/18 – including one of nine cases 
with fi brosarcomatous change) and undiff erentiated pleomorphic sarcoma 
(11.1%; 3/27). Pleomorphic rhabdomyosarcoma (33.3%; 1/3) and fi brosarcoma 
(12.5%; 1/8) also presented positivity in a minority of the cases, although the 
sample size was small. The 175 benign bone and soft tissue tumors, the 6 non-
tumorous lesions and the 8 normal fat samples were all negative for NY-ESO-1. 
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In the group of the non-mesenchymal tumors 10% (1/10) of the desmoplastic 
melanomas and none of the other melanomas showed NY-ESO-1 positivity.
Positive controls of formalin-fixed, paraffin-embedded testis sections 
revealed strong NY-ESO-1 expression among spermatogonia and spermatocytes 
in the seminiferous tubules. No immunoreactivity was observed in any of the 
negative controls. Representative results of a selection of malignant bone and 
soft tissue tumors are shown in Figures 1 - 3.
Figure 2. Other sarcomas with positive immunohistochemical staining for NY-ESO-1. 
A+B: Synovial sarcoma with strong staining of all tumor cells. C+D, incl. inset: Conventional 
chondrosarcoma with prominent cytoplasmic staining. E+F: Myxofibrosarcoma with moderate 
immunoreactivity.
Discussion
To the best of our knowledge, this is the largest-scale NY-ESO-1 (CTAG1B) 
expression study in bone and soft tissue tumors, including over 1300 specimens 
representing 38 malignant and borderline and 21 benign histologic subtypes. 
Of special note is the inclusion in our study of 201 myxoid liposarcomas and 
69 synovial sarcomas – two sarcoma subtypes that have been considered to 
be potentially good candidates for NY-ESO-1 immunotherapy. We employed a 
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cut-off  value for immunohistochemical positivity by reference to the eligibility 
of an antecedent clinical trial of immunotherapy targeting NY-ESO-1 (5).
Myxoid liposarcoma represents 20-30% of all liposarcomas, mostly 
occurs in young adults and is characterized by a translocation t(12;16)(q13;p11) 
or, in a few percent of the cases, a t(12;22)(q13;q12), leading to the chimeric 
fusion product FUS-DDIT3 or EWSR1-DDIT3, respectively (25, 26). According 
to the literature, one third of myxoid liposarcoma patients develop distant 
metastases (18, 27, 28), so eff ective systemic therapy is needed to improve the 
prognosis of many patients. Previous studies reported NY-ESO-1 expression in 
95% to 100% of myxoid liposarcomas; these results were based on sample sizes 
ranging from 25 to 38 cases (6, 9). Our larger study revealed that 139 out of the 
158 (88.0%) untreated myxoid liposarcomas were positive for NY-ESO-1, and 
concurs with the rate of positivity reported in the previous studies. The slightly 
lower rate of positivity might be attributable to the fact that some tumors 
only display a focal NY-ESO-1 positivity, which might be missed due to the 
use of tissue microarrays. Hemminger et al. reported that other liposarcoma 
subtypes, lipomas and other myxoid mesenchymal tumors were negative 
for NY-ESO-1, suggesting that NY-ESO-1 could be a sensitive and specifi c 
immunohistochemical marker to diff erentiate myxoid liposarcoma from 
tumors with overlapping histomorphological features (9). In this study several 
mesenchymal tumors with myxoid or lipogenic diff erentiation were evaluated, 
including well-diff erentiated liposarcoma (4.8%; 1/21), dediff erentiated 
liposarcoma (14.3%; 1/7), spindle cell lipoma (0%; 0/10), lipoma (0%; 0/14), 
normal fat tissue (0%; 0/8), myxoma (0%; 0/3) and myxofi brosarcoma (35.3%; 
6/17). Comparing those mimics, myxoid liposarcoma shows remarkably strong 
immunoreactivity for NY-ESO-1 (88.0%) and therefore its expression helps to 
discriminate myxoid liposarcoma from tumors in the diff erential diagnosis.
Interestingly, chemotherapy- or radiation-pretreated myxoid 
liposarcomas showed a lower positivity for NY-ESO-1. The biological mechanism 
behind the decreasing NY-ESO-1 positivity after the preoperative treatment is 
unknown; however, some of these samples at histological examination showed 
a low tumor cell density with hyalinization, reactive matrix and weak NY-ESO-1 
staining below the intensity required to label the tumor as positive. NY-ESO-1 
expression is still more frequent even in treated myxoid liposarcomas than in 
other sarcomas; therefore NY-ESO-1-targeted immunotherapy combined with 
established therapies remains an attractive potential strategy. This observed 
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reduction in NY-ESO-1 positivity in post-treatment myxoid liposarcoma was 
not seen in a set of eight additional synovial sarcoma specimens, in which 
all retained strongly positive expression following neoadjuvant treatment 
(radiation +/- chemotherapy).
Synovial sarcoma is a translocation-associated sarcoma characterized by 
the fusion gene, SS18-SSX1, -SSX2 or -SSX4 (29). More than half of the patients 
are teenagers and young adults. The development of novel systemic therapies 
is important because metastasis of synovial sarcoma is common (overall 5-year 
metastasis-free survival rate 51.1%)(30). Jungbluth et al. first investigated 
NY-ESO-1 expression in synovial sarcoma and found that 80% (20/25) of the 
samples expressed NY-ESO-1 (31). Recently, Lai et al. investigated 50 synovial 
sarcomas and reported that 76% (38/50) of synovial sarcomas expressed NY-
ESO-1 in a strong and diffuse pattern (7). Our study revealed 49.3% positivity 
across 69 cases of synovial sarcoma, somewhat lower than that of the previous 
papers, possibly due to decreased sensitivity using the tissue microarray 
platform. Considering the combined results from our and previous studies, 
approximately half to three quarters of synovial sarcomas show NY-ESO-1 
expression.
In a recent clinical trial using genetically engineered autologous 
T lymphocytes reactive with NY-ESO-1, four of the six advanced synovial 
sarcoma patients who received immunotherapy showed documented partial 
responses (5); worth noting is that this response lasted at least 18 months 
in one patient. This result has encouraged the development of NY-ESO-1-
targeted immunotherapy not only for synovial sarcomas, but also for other NY-
ESO-1 expressing sarcomas including myxoid liposarcomas. Public information 
on clinicaltrials.gov lists at least fourteen clinical trials employing vaccine, 
autologous T-cell or dendritic cell transduction immunotherapy strategies that 
test patients with NY-ESO-1 expressing sarcomas, mostly in active recruitment 
phases in 2014. Some vaccine studies use a low NY-ESO-1 positivity cutoff 
value of >5%, hoping that the vaccine can still elicit a immune response in 
these patients.
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5Figure 3. Soft tissue sarcomas without NY-ESO-1 immunoreactivity.A+B: Myxoid liposarcoma. C+D: Gastrointestinal stromal tumor. E+F: malignant peripheral nerve sheat 
tumor.
Primary central chondrosarcoma is a bone sarcoma, accounting for 
approximately 20% of malignant bone tumors (28). As it is highly resistant 
to existing chemotherapeutic agents, the search for new targeted therapies 
is ongoing. Our study revealed positivity for NY-ESO-1 in 28.2% (40/142) 
of conventional chondrosarcoma and 10.0% (3/30) of dediff erentiated 
chondrosarcoma specimens, while clear cell and mesenchymal 
chondrosarcomas were all negative. Lai et al. reported that one out of two tested 
chondrosarcomas showed immunoreactivity for NY-ESO-1, and a relatively 
low NY-ESO-1 mRNA expression level was found in four out of eleven cases in 
another study (7, 32). Although the number of positive cases is relatively low, 
immunotherapy may be of signifi cance in a subset of these patients, who are 
not included in the eligibility criteria for some of the existing clinical trials. 
Apart from six of seventeen tested myxofi brosarcomas and one of three 
pleomorphic rhabdomyosarcomas, the other tested types of mesenchymal 
tumors were almost uniformly negative for NY-ESO-1 expression. Although our 
study included over 1132 cases, the numbers of some rare sarcomas are too 
limited to draw fi nal conclusions on NY-ESO-1 expression in these subtypes. 
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In summary, we confirm that NY-ESO-1 can be reliably detected by 
immunohistochemistry. Using previously described scoring criteria, but based 
on much larger numbers of samples than have been assessed previously, we 
confirm very high frequencies of NY-ESO-1 expression in myxoid liposarcomas, 
high frequencies in synovial sarcomas, and we find similar levels of expression 
in 28.2% of conventional chondrosarcomas. Clinical trials of NY-ESO-1 targeted 
therapies should be open to patients with positive histologies, and NY-ESO-1 
expression by immunohistochemistry should be considered as a potential 
entry criteria or integrated stratification as a potential predictive marker for 
such therapeutic strategies. NY-ESO-1 positivity in the remaining subtypes of 
mesenchymal tumors was rare. Benign bone and soft tissue lesions showed 
no positivity for NY-ESO-1, supporting the limited level of expression of this 
biomarker in normal tissues and the possibility that targeted therapies will 
have limited side effects. 
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Abstract
Myxoid liposarcoma has the pathognomonic fusion oncogene FUS-DDIT3 
encoding a chimeric transcription factor. Metastatic risk is higher with an 
increased round cell component and has been linked to aberrations involving 
the IGFR/PI3K/AKT pathway. These molecular insights have yet to translate to 
targeted therapies and the lack of experimental models is a major hindrance. 
We describe the initial in-depth characterization of a new cell line (DL-221) and 
establishment of a mouse xenograft model.
The cell line DL-221 was derived from a metastatic pleural lesion 
showing myxoid and round cell histology. This newly established cell line was 
characterized for phenotypic properties and molecular cytogenetic profile, 
using PCR, COBRA-FISH and western blot. Next-generation whole exome 
sequencing was performed to further characterize the cell line and the parent 
tumor. NOD-SCID-IL2R gamma knockout mice were xenograft hosts.
DL-221 cells grew an adhering monolayer and COBRA-FISH showed an 
aneuploid karyotype with t(12;16)(q13;p11) and several other rearrangements; 
RT-PCR demonstrated a FUS-DDIT3 fusion transcript type 1. Both the cell line 
and the original tumor harbored a TP53 compound heterozygous mutation in 
exon 4 and 7 and were wild type for PIK3CA. Moreover, among the 1254 variants 
called by whole exome sequencing, there was 77% concordance between the 
cell line and parent tumor. The recently described hotspot mutation in the 
TERT promoter region in myxoid liposarcomas was also found at C228T in DL-
221. Xenografts suitable for additional pre-clinical studies were successfully 
established in mice after subcutaneous injection.
The established DL-221 cell line is the only published available myxoid 
liposarcoma cell line that underwent spontaneous immortalization, without 
requiring SV40 transformation. The cell line and its xenograft model are unique 
and helpful tools to study the biology and novel potential targeted treatment 
approaches for myxoid liposarcoma.
Keywords: 
Myxoid liposarcoma, round cell liposarcoma, translocation, FUS-DDIT3, TP53, 
PIK3CA, HDAC, TERT, CTAG1B, exome sequencing, targeted therapy. 
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Introduction
Myxoid liposarcoma (MLS) is a malignant mesenchymal neoplasm, 
representing one third of the liposarcomas and accounting for 5% of all adult 
soft tissue sarcomas (1). Histologically MLS is composed of a variably cellular 
ovoid cell proliferation with signet-ring lipoblasts set in a myxoid matrix with 
characteristic plexiform vasculature. Areas of undiff erentiated small round cells 
with scarce cytoplasm and no matrix (round cell variant) are associated with a 
higher metastatic potential and a worse prognosis (2-8). Other poor prognostic 
factors are the presence of necrosis, male gender, increasing age and multifocal 
disease (2, 8-10).
Localized MLS can be eff ectively treated with surgery or the combination 
of surgery and radiation, but 35-50% of patients develop recurrence or 
metastases. The metastatic pattern is unconventional with spread to sites in 
soft tissue or bone sometimes occurring before the tumor metastasizes to the 
lungs (1, 6, 11). Although MLS is relatively sensitive to radiotherapy and certain 
chemotherapeutic agents, treatment of extensive disease is challenging (12).
MLS is characterized by a reciprocal translocation generating a fusion 
transcription factor oncogene. In >95% a translocation t(12;16)(q13;p11) is 
present, fusing FUS (fused in sarcoma; a.k.a. TLS) with DDIT3 (DNA-damage-
inducible transcript 3; a.k.a. CHOP) (13, 14). At least eleven diff erent FUS-DDIT3 
fusion types have been described and the fusion type does not impact clinical 
outcome (2, 13, 15). Less than 5% of the cases harbour a t(12;22)(q13;q12) 
leading to an EWSR1-DDIT3 fusion, of which four diff erent transcripts are 
described (1, 15, 16).
Although the exact mechanism via which the chimeric transcription 
factor exerts its oncogenic eff ects remains to be elucidated, it is postulated 
that it acts as an aberrant transcriptional regulator, stimulating proliferation 
while inhibiting adipogenic diff erentiation (17-19). The chimeric product is 
highly expressed and interferes with heterodimerization of DDIT3 with CCAAT/
enhancer-binding protein-β (C/EBPβ). The activity of the transcription factors 
C/EBPα and PPARγ is inhibited and fat diff erentiation is blocked (19).
Exome sequencing and biomarker analysis of MLS specimens has 
identifi ed alterations in the IGF/Akt/mTOR axis, implicated in cellular processes 
such as cell survival, proliferation and growth. Overexpression of the receptor 
tyrosine kinases AXL, RET and IGF1R, and the ligand IGF1, are negative 
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prognostic biomarkers (8, 20, 21). Activating mutations in PIK3CA are found in 
14-18% of MLS and loss of expression of PTEN is found in 12% of the tumors 
and is mutually exclusive from PIK3CA mutations (22, 23). Increased PI3K/Akt 
signalling has been demonstrated by high expression of downstream targets 
like phosphorylated 4EBP1, PRAS40 and S6. The PIK3CA mutation rate, IGFR 
expression and loss of PTEN were higher in tumors with a round cell component 
suggesting that this pathway might be involved in round cell transformation 
and tumor progression. TP53 mutations and reduced protein expression of 
p16INK4/p14ARF have been identified in a subset of tumors, most frequently in 
round cell components (24). Hotspot mutations in the TERT (telomerase reverse 
transcriptase) promoter region were recently reported in MLS (23% to 74%)
(25, 26). These mutations led to increased protein expression of TERT and have 
been implicated in telomerase dysregulation and the resultant proliferative 
capability of tumor cells (27). The cancer-testis antigen NY-ESO-1 (a.k.a. 
CTAG1B) has recently shown to be almost universally expressed in MLS (89-
100%)(28-30). NY-ESO-1 expression is normally limited to germ cells making it 
a good cancer immunotherapeutic target (31, 32).
Over the last few years, we have gained increasing insight into the 
molecular pathogenesis of MLS; however, translating this knowledge into 
specific therapies has been challenging. Reliable in vitro and in vivo models are 
crucial to investigate novel therapies and to study the mechanisms of action. 
Although MLS is a common sarcoma subtype, so far only two MLS cell lines 
(402-91 and 1765-92) were established, both immortalized by transfection with 
the SV40 large T-antigen, and have been made available worldwide (33, 34).
In this study, we present the establishment and characterization of a 
new MLS cell line (DL-221), which to our knowledge is the first spontaneously 
immortalized cell line of this tumor type. This was undertaken as part of the 
International Myxoid Liposarcoma Consortium and our motivation was to 
facilitate preclinical research by having representative models to test new 
therapies.
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Materials and Methods
Myxoid liposarcoma primary culture and cell lines
With approval of the Institutional Review Board (IRB) of The University of Texas 
MD Anderson Cancer Center and with patient’s written informed consent, 
isolation of tumor cells was performed as described previously (35). Cells were 
cultured in DMEM supplemented with 10% fetal bovine serum (FBS) (Gemini 
bio-products, West Sacramento, CA) and 1% penicillin-streptomycin (100U/ml), 
and placed in a humidifi ed 5% CO
2
 incubator at 37ºC. The previously established 
human MLS cell lines 402-91 and 1765-92 were cultured in RPMI1640 (Thermo 
Fisher Scientifi c, Waltham, MA) supplemented with FBS and antibiotics. The 
population doubling time was calculated during the exponential growth 
phase using the algorithm provided by Doubling Time software (http://
www.doubling-time.com). All cell lines were tested on a regular basis for 
mycoplasma infection. Short Tandem Repeat (STR) DNA fi ngerprinting was 
performed on the cell lines, the metastatic tumor tissue from which the DL-221 
cell line was derived and from xenografted tissue (AmpFLSTR Identifi ler PCR 
Amplifi cation kit; Applied Biosystems, Foster City, CA). The data was analyzed 
with GeneMapper (v4.0, Applied Biosystems).
Fluorescence in situ hybridization (FISH)
Two color FUS split apart FISH was performed on interphase cells using a probe 
mix containing bacterial artifi cial chromosome (BAC) clone RP11-196G11 direct 
labeled with FITC (FITC-dUTP) (Roche diagnostics GmbH, Mannheim, Germany) 
and clone RP11-120K18 direct labeled with Cy3 (Roche). Both clones fl ank the 
FUS gene and are separated by 120 kbp. Scoring of the split-apart FISH was 
done by counting at least 100 nuclei; signals were considered split-apart when 
their distance was larger than the size of a single hybridization signal. Harvested 
metaphase cells were used for COBRA-FISH. Pictures were taken with a DMRA 
microscope (Leica, Rijswijk, The Netherlands) and karyotypes analyzed with 
Colorproc (v2.0, LUMC, Leiden, The Netherlands). A detailed description of the 
harvesting, hybridization, probe labeling and COBRA-FISH protocols has been 
published (36, 37).
43717 Marieke de Graaff 100% ZW.indd   121 30-12-16   11:46
Chapter 6
122
FUS-DDIT3 fusion type characterization
Total RNA was extracted from cells using RNeasy Mini Kit (Venio, The 
Netherlands) as per manufacturer instructions. cDNA was generated using 
the SuperScript III reverse transcriptase kit (Life Technologies, Carlsbad, CA) 
and PCR was performed with Taq polymerase (Life Technologies). Sanger 
sequencing of the amplified product was performed; Chromas (Technelysium, 
South Brisbane, QLD, Australia) and the BLAST Multiple Alignment tool (NCBI) 
were used to depict the sequence and analyze the breakpoints, respectively 
(23). A detailed description of PCR conditions has been published previously 
(see Table S1 for primers)(13).
Immunoprecipitation, SDS-PAGE and western blot
Immunoprecipitation was performed on protein lysates from near-confluent 
cells. The cells were washed twice with ice-cold phosphate-buffered saline 
(PBS) and harvested by scraping in ice-cold lysis buffer containing 15 mM Tris 
(pH 8.0), 100 mM NaCl, 1% Triton X-100, supplemented with protease inhibitor 
cocktail (P2714, Sigma-Aldrich, St. Louis, MO). Lysates were incubated on ice 
for 30 min, clarified by centrifugation at 4°C, followed by protein estimation 
using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Overnight 
immunoprecipitation with anti-DDIT3 (sc-793, Santa Cruz Biotechnology, 
Dallas, TX) was performed using Dynabeads® Protein G (Life Technologies, 
Carlsbad, CA) as per manufacturer instructions. Next, SDS-PAGE separation 
and western blot were performed using anti-FUS (sc-373698, Santa Cruz) and 
anti-DDIT3 (ab10444, Abcam, Cambridge, UK) for detection. The following Cell 
Signaling Technology (Danvers, MA) antibodies were also used for western 
blot: anti-AKT (#2920), anti-phospho-AKT (Ser473) (#9271), anti-AXL (#4566) 
and PTEN (#9559). Antibodies of Abcam were used for western blot analysis of 
HDAC1 (ab19845), HDAC2 (ab32117) and HDAC3 (ab32369)(38).
Molecular characterization: mutation analysis and myxoid 
liposarcoma associated biomarkers
Mutation analysis was performed for exon 4 to 10 of TP53, exons 9 and 20 of 
PIK3CA and the TERT promoter region by conventional Sanger sequencing 
as described elsewhere (Table S1)(23). Detailed procedures of NY-ESO-1 
immunohistochemistry have been described previously (30).
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Cell viability assay
In vitro cell viability assays were performed as described previously (39). Briefl y, 
metabolic activity was measured by a WST-1 colorimetric assay as read-out for 
the cell viability after doxorubicin treatment. Cells were treated with increasing 
doxorubicin concentrations for 72hr in quadruplicates and experiments were 
performed 2 to 4 times. GraphPad Prism (v6.05, La Jolla, CA) was used to 
calculate the IC
50
-values.
In vivo animal model
All animal procedures and care were approved by the MD Anderson Cancer 
Center Institutional Animal Care and Usage Committee. Animals received 
humane care as per the Animal Welfare Act and the NIH “Guide for the Care 
and Use of Laboratory Animals”. Mouse studies were performed as described 
previously (40). Briefl y, 3x106 cells were injected subcutaneously in the fl ank 
of (n=2/cell line) 6 weeks old female NOD-SCID-ILR2 gamma mice (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ, The Jackson Laboratory, Bar Harbour, ME). Tumor growth 
was assessed twice weekly with a digital caliper (Mitutuyo, Chicago, IL); tumor 
volume was calculated by using the formula (tumor volume (mm3) = length x 
width x height x 0.5). Mice injected with DL-221 cells were sacrifi ced at 79 and 92 
days post injection due to ulcerated tumor burden. The tumors were resected, 
weighed (Ohaus Adventurer® Pro Scale), fi xed in formalin and embedded in 
paraffi  n. Sections were H&E stained to evaluate tumor histology. FUS split-apart 
FISH was performed to confi rm the presence of the translocation.
Sequencing
Whole exome sequencing was performed on DNA isolated from the DL-221 
metastatic tumor tissue and its derivative cell line at passage 33/34. Coding 
regions were captured with baits from the Agilent SureSelect Human All 
Exon V4 (Agilent Technologies, Inc., Santa Clara, CA). After selecting for 200 
bp median fragment sizes, the samples were run on an Illumina HiSeq 2000 
(Illumina Inc., CA) to generate 76 bp paired-end reads. Duplicate reads were 
removed using Picard and mapping was done using BWA (41), giving an overall 
mean coverage of 69X for the metastatic tumor and 62X for the derived cell 
line. The percentages of reads having at least 50X mean coverage were 75% 
and 65%, respectively.
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Variants were called separately for each sample using VarScan1 (42) 
against the human reference genome. Further comparisons between samples 
were done by using MuTect (43) and Pindel (44) with each one of either the 
tumor or cell line being set as the “reference” with 3% allele frequency cutoff 
for making calls. To confirm the translocation, Breakdancer (45) and Meerkat 
(46) were used. Visual comparisons of allele frequency patterns were made 
using R: Vioplot (47) scatterplot, and 2D kernel density plots. Annotations were 
obtained using AnnoVar, including protein predictors Mutation Assessor and 
Polyphen2. Pathway analysis was performed using DAVID (48, 49). The exome 
sequence data has been deposited in the European Genome-phenome Archive 
(EGA). 
 
Results
Patient history and establishment of the DL-221 cell line
The cell line was generated from a metastatic tumor deposit from the pleura of a 
42-year-old male patient (Figure 1A). The patient was originally diagnosed with 
myxoid liposarcoma of the right anterior thigh that was treated with surgical 
resection and adjuvant radiation therapy. One year later he was diagnosed 
with metastatic disease involving the right periorbital area and chest wall 
(10th rib) for which he received adriamycin/ifosfamide followed by right lateral 
orbitotomy and chest wall resection. Subsequently, the patient developed 
multiple metastatic lesions involving the thoracic, lumbar spine and sacrum 
for which he received multiple chemotherapy regimens. The pleural lesion 
that was utilized to establish the cell line had been treated with trabectedin 
prior to resection. The pathology report indicated that the metastatic lesion 
was found to have a myxoid and sclerotic component. In addition, round cell 
change was identified. He developed additional metastatic disease involving 
the lungs, pleura, posterior diaphragmatic region, pelvic muscles and presacral 
space for which he was again treated with trabectedin followed by single agent 
doxorubicin. He ultimately succumbed to the disease.
Isolated tumor cells from the metastatic pleura tumor were originally slow 
growing and passaged once a month, until after 14 months they underwent 
spontaneous immortalization and a fast growing clone emerged. This clone 
was isolated and expanded, and after 24 consecutive months of culturing, the 
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cell line has reached over 90 passages. The cell line has a population doubling 
time of 30 hours calculated at passage 62; this was stable at least through 
passage 90. Tumor cells grow in an adherent monolayer fashion; phase contrast 
microscopy revealed spindle cell morphology in monolayer culture (Figure 1B). 
Cells are mononuclear and the enlarged nuclei contain one or more clearly 
discernible nucleoli. The cells do not exhibit contact inhibition when reaching 
confl uence. A genetic profi le of the cell line was generated by STR typing and 
was consistent with the metastatic lesion (Table S2). 
Figure 1. Establishment of the myxoid liposarcoma DL-221 cell line with the characteristic 
translocation t(12;16)(q13;p11). 
(A) Representative H&E-section of the tumor of the pleura of which the tumor cells were isolated for the 
establishment of the DL-221 cell line (magnifi cation 40x). (B) Tumor cells in culture showing spindle-
shaped morphology and nuclei with large nucleoli. (C) COBRA-FISH karyogram of DL-221 cell line 
showing a near triploid karyotype with several numerical and structural aberrations.
COBRA-fl uorescence in situ hybridization
The presence of the diagnostic FUS-DDIT3 translocation was monitored with 
FUS split-apart FISH at several times during the culture process to assure a 
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pure culture of tumor cells. The composite karyotype of the DL-221 cell line 
at passage p31 and p68 was 71~75<3n±>,der(X)t(X;15)(q;q)x2,-Y,der(2)t(X;2)
(q;p)t(2;3)(q;p)x2,-4,+5,der(7)t(7;X)(q;q),+i(7)(q10),+7,+8,+8,-9,+11,t(12;16)
(q13;p11),-13,+14,-15,der(17)t(10;17)(p;p),+18,+19,+20,+21,idic(22)[10]/ 
71~75<3n±>,der(X)t(X;15)(q;q)x2,-Y,der(2)t(X;2)(q;p)t(2;3)(q;p)x2,der(4)t(2;4)
(q;p),-4,+5,der(7)t(5;7)(p;q),der(7)t(7;X)(q;q),+8,+8,-9,+10,+11,t(12;16)(q13;p11)
x2,-13,+14,-15,+18,+19,+20,+21,+22[6] (Figure 1C). Several additional 
non-clonal rearrangements were found. The cell line has at least two main 
subpopulations based on the presence of one or two copies of the translocation 
t(12;16)(q13;p11) and with two or one copies of chromosome 12 and 16 to 
complement the triploid genome, respectively. The two different clones are 
still present in the same proportion, two copies of the translocation versus 
one copy of the translocation in a ratio of 1.0:1.7, after long term in culture. All 
chromosomal aberrations that are found at least two times are included in the 
composite karyotype. The karyotypes are made according to the guidelines of 
the International System for Human Cytogenetic Nomenclature (50).
Fusion-type characterization
The FUS-DDIT3 fusion type was determined with reverse transcriptase-PCR and 
sequencing. A type 1 fusion was found in the DL-221 cell line, fusing the first 
seven exons of FUS to the entire reading frame of the DDIT3 gene. The 402-91 
and 1765-92 cell lines were included as positive controls in Figure 2A and show 
as expected type 1 and type 8 fusions, respectively. After electrophoresis the 
chimeric products reveal a band at the position corresponding to the size of 
the fusion product. A band was observed around 136 bp in 402-91 and DL-221, 
consistent with a type 1 fusion product, whereas a larger band at 730 bp was 
found for 1765-92 due to additional FUS exons in the type 8 fusion product.
Immunoprecipitation
To prove the presence of the FUS-DDIT3 chimeric fusion oncoprotein in 
the myxoid liposarcoma cell lines, immunoprecipitation experiments were 
performed with a DDIT3 antibody on protein lysates from 402-91, 1765-92 and 
DL-221. Further analysis with SDS-PAGE and immunoblotting with antibodies 
against DDIT3 and FUS revealed one band for DDIT3 and two bands picked 
up by the FUS antibody in all samples. The estimated molecular weight of the 
protein detected with anti-DDIT3 is around 75 kDa in 402-91 and DL-221 and 
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around 100 kDa in 1765-92, corresponding to the estimated weight of the 
chimeric fusion proteins of 75 kDa and 100 kDa for type 1 and 8 fusion proteins, 
respectively. Two bands picked up by the anti-FUS antibody were detected in 
all three cell lines; one band was present at the same level as the DDIT3 band 
(i.e. FUS-DDIT3) whereas the other band with a weight of 68 kDa represents 
native FUS protein. The abundant presence of normal FUS is expected based 
on the high transcriptional activity of this gene; as expected, no expression of 
the stress-induced native DDIT3 was detected (Figure S1)(51). Merging of the 
immunoblots of FUS (green) and DDIT3 (red) revealed a yellow band in each of 
the three cell lines, confi rming that it represents the fusion oncoprotein (Figure 
2B). 
Figure 2. Fusion type characterization of the DL-221 cell line and proving the presence of the FUS-
DDIT3 chimeric fusion oncoprotein. 
(A) RT-PCR was performed on the three myxoid liposarcoma cell lines. This confi rms a type 1 fusion 
product (136 bp) in both DL-221 and 402-91, while the longer fusion product of 730 bp in 1765-92 
was consistent with the type 8 fusion product. (B) Immunoprecipitation of FUS-DDIT3 from the myxoid 
liposarcoma cell lines 402-91, 1765-92 and DL-221 using an anti-DDIT3 antibody. FUS-DDIT3 (arrow) was 
detected in all three cell lines at around 75 kDa in 402-91 and DL-221 (expressing type 1 FUS-DDIT3) and 
around 100 kDa (expressing the larger type 8 FUS-DDIT3).
Molecular characterization: mutation analysis and myxoid 
liposarcoma associated biomarkers
Target panel sequencing revealed two diff erent TP53 mutations in the cell line, 
c.374C>G, p.T125R in exon 4 and c.715A>G, p.N239D in exon 7. The original 
tumor also harbored these pathogenic variations (52). Mutational analysis of 
the hotspot regions in exons 9 and 20 of PIK3CA did not identify an aberration 
in the tumor or cell line, nor any other mutations in this gene as confi rmed 
with whole exome sequencing. No TP53 nor PIK3CA aberrations were found in 
402-91 or 1765-92. Mutational analysis of the TERT promoter region revealed a 
C228T mutation in DL-221 (Figure S2). Next, we confi rmed the presence of the 
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previously reported C228T hotspot mutation in 402-91 and 1765-92. None of the 
cell lines harbored the second reported hotspot mutation in MLS, C250T (26). 
Figure 3. PTEN and pAKT protein expression. 
Western blot analysis of (A) PTEN and AXL expression, with GAPDH expression as a loading control, and 
(B) pAKT (ser473) expression relative to total AKT expression in the myxoid liposarcoma cell lines. The 
bottom panel shows the merged image of the pAKT (ser473) signal in red and total AKT signal in green. 
An overlap of both signals produces a yellow band
PTEN expression was retained in all three cell lines (Figure 3A). Analysis 
of the expression of MLS associated biomarkers with western blots showed a 
strong expression of total Akt in all three cell lines, while phospho-Akt (pAkt-
473) was only found in 402-91 and 1765-92 (Figure 3B). The presence of p53 
protein in DL-221 was confirmed with western blot analysis, which must be 
a mutated protein. The p53 protein was abundantly present in 402-91 and 
1765-92, but the expression levels are not necessarily relevant in these two cell 
lines due to the SV40-immortalisation, as reported previously (53). AXL was 
highly expressed in 1765-92, moderately expressed in DL-221 and minimally 
expressed in 402-91 (Figure 3A). The protein expression of HDAC-1, -2 and -3 
was evaluated. All three histone deacetylase family members were expressed 
in 402-91, all except HDAC-3 in 1765-92 and, HDAC-2 and -3 in DL-221 (Figure 
S3). The 402-91 had a moderate immunohistochemical expression of NY-ESO-1; 
both DL-221 and 1765-92 showed strong expression. The biomarker status of 
the three MLS cell lines is shown in Table 1. 
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Table 1. Molecular biomarkers in myxoid liposarcoma cell lines (402-91, 1765-92, DL-221). 
Cell line FUS-
DDIT3 
fusion
TP53 P53 
(WB)
PIK3CA TERT p-AKT473/ 
Total AKT 
(WB)
AXL 
(WB)
HDAC 
1/2/3 
(WB)
NY-
ESO-1 
(IHC)
402-91 Type 1 WT Positive WT C228T +/++ + +/++/+ +
1765-92 Type 8 WT Positive WT C228T +/++ +++ +/+/- ++
DL-221 Type 1 T125R, 
N239D
Positive WT C228T -/++ ++ -/+/+ ++
WB = western blot; WT = wild type; IHC = immunohistochemistry
Cytotoxicity experiments with colorimetric assays were performed 
to determine the eff ect of treatment on cell viability. The conventional 
chemotherapeutic doxorubicin was highly toxic for all three MLS cell lines. For 
DL-221 the IC
50
 values were in a range of 35 to 89 nM (average 62 nM) and the 
IC
50
 values for 402-91 and 1765-92 were 24 nM (range 21-29 nM) and 47 nM 
(range 31-55 nM) respectively after 72 hour treatment (Figure 4). 
Figure 4. Dose-response curves of MLS cell lines to doxorubicin treatment in vitro. 
All three cell lines were treated with doxorubicin for 72 hour. For each cell line, one representative 
experiment of consecutive experiments is depicted.
Mouse studies
DL-221 cells from passage 15 were injected subcutaneously in the fl ank of two 
NOD-SCID-ILR2 gamma mice. Tumor development was observed in both mice 
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and they were sacrificed at day 79 and 92 post-injection, due to ulcerated tumor 
burden (Figure 5A). No metastatic lesions were found. Histological evaluation 
of the xenografts revealed a similar morphology, consisting of a moderately 
cell-rich, myxoid lesion with short spindle-shaped, moderately pleomorphic 
tumor cells. Marked nuclear atypia with hyperchromatic and heterogeneous 
nuclei was present and large nucleoli were visible in the majority of the cells 
(Figure 5B). A FUS-split apart FISH assay was performed on FFPE sections from 
both xenografts and revealed a segregation of the signals, consistent with the 
expected rearrangement at the FUS locus (Figure 5C). Cells obtained from both 
first generation resections were successfully passaged. The STR profile of the 
xenografts revealed the same profile as the original tumor and the cell line 
(Table S2). Injection of the two other available MLS cell lines, 402-91 and 1765-
92, did not lead to tumor formation in vivo in 16 months.
Figure 5. Xenograft model of DL-221 cell line. 
(A) tumor growth in two mice, (B) H&E picture of xenograft tumor (magnification 40x) and (C) FUS split-
apart FISH reveals a break in the FUS gene in the tumor cells in mice, the gain of the green signal was 
consistent with the karyotype image shown in figure 1.
Next generation sequencing
The metastatic tumor and its derivative cell line both underwent whole exome 
sequencing to an average mean coverage of 60X. Using Varscan1 to compare 
each sample to the hg19 reference genome, a total of 1254 exonic variants 
were called (1230 nonsynonymous, 23 stopgains, 1 stoploss), 960 of which 
were shared between the two samples. Among those shared, 38 genes overlap 
with the Sanger Cancer Gene Census, 10 of which were “Probably damaging” 
by Polyphen2 and 7 with “Medium Impact” by Mutation Assessor. Analysis of 
these alleles using DAVID showed significant p-values from both Panther (p = 5.2 
X 10-5) and KEGG (p = 4.8 X 10-4) for the Wnt signaling pathway, which includes 
Polyphen2-predicted “probably damaging” variants in APC (p.R99W), APC2 
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(p.G323R), and TP53 (p.N239D, p.T125R) (Table S3). Ninety percent (863/960) of 
the alleles retained insignifi cant allele frequency changes of <0.2 between the 
metastatic tumor and cell line (Figure S4). Driver mutations such as the two TP53 
missense mutations p.T125R and p.N239D that were characterized in the primary 
tumor were confi rmed in both samples and retained consistent allele frequencies 
(metastatic p.T125R 0.43 allele freq, depth = 54, cell line 0.46 allele freq, depth 
= 54; p.N239D metastatic 0.4 allele freq, depth = 37, cell line 0.32 allele freq, 
depth = 50). These two variants are not found in any of the population databases 
ESP6500 and 1000G. As well, the FUS-DDIT3 translocation was confi rmed from 
split reads found using Meerkat and a call found with Breakdancer that was ~1 
kb away from the actual breakpoint (Table S4 and S5)(46).
By MuTect, 63 exonic variants were found in the metastatic tumor that 
were absent from the cell line, while 32 exonic variants were present in the 
cell line but not in the tumor. A small group of 28 nonsynonymous alleles 
were selected for during cell line establishment, as evidenced by increases in 
allele frequencies of >0.5 (Table S6). There are several possible explanations 
for these frequency changes. First, all of these alleles come from just three 
chromosomes: chr2 (9/28), chr4 (6/28), and chr9 (13/28), which could be due 
to copy number events. The losses of both chromosomes 4 and 9 seen by FISH 
karyotyping of the cell line would explain the loss of heterozygosity eff ects that 
resulted in allele frequencies of 1.00 in the cell line for these two chromosomes. 
Other possibilities are that clonal selection or purifi cation of the tumor from 
normal cell contamination resulted in higher allele frequencies, which may 
explain those alleles from chromosome 2. Of these 28 alleles, fi ve are predicted 
“Probably damaging” by Polyphen2 (FAT4 p.P1313S; DSPP p.D1152N; SP140L 
p.C181R; IFIH1 p.L125M; and IPPK p.R130W).
Discussion
Myxoid liposarcoma is a relatively common sarcoma subtype, yet there are only 
two previously established cell lines that are widely available (33). Representative 
models for preclinical testing, including cell lines and functioning xenografts, 
are essential to understanding the underlying molecular determinants of round 
cell and metastatic progression in this disease and to identify and develop 
targeted therapeutic strategies.
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Here we report the establishment of a new MLS cell line (DL-221) and 
demonstrate that this cell line can be successfully used in a xenograft model. The 
cell line was grown from isolated myxoid liposarcoma cells from a metastatic 
pleura lesion. After 14 months of culturing, a fast growing clone emerged 
and was expanded. DL-221 has been cultured for more than 24 months and 
shows a stable doubling time of around 30 hours. In contrast to the two other 
established MLS cell lines, 402-91 and 1765-92, which were both immortalized 
by induction of the large T-cell SV40 antigen (33), DL-221 is the first published 
MLS cell line that underwent spontaneous immortalization. SV40 suppresses 
the transcriptional activity of the tumor suppressor p53 and hence affects the 
p53 pathway in the cells. SV40 immortalization also involves the inactivation of 
other growth suppressors as pRB and SEN6 (54). This has to be kept in mind when 
studying the in vitro effect of new treatment options in these cell lines, as it is 
not fully representative of the oncogenic process that occurs in human patient 
tumors. One of the reasons for the limited MLS models could be the difficulty 
of culturing them in vitro, which has been our experience as well. This might 
be related to a lack of necessary cytokines, growth factors, adhesion molecules 
or endothelial cells in the extracellular environment, difficulty in adjusting to 
a monolayer culture or a combination of these factors. Most primary cultures 
from MLS tumor tissues slow down after several weeks or months in culture, 
and finally result in terminal fat differentiation or senescence. 
Exome sequencing of the original tumor and the DL-221 cell line was 
performed to search for new genetic aberrations that are common between 
the cell line and original tumor and those that arise in the cell line specific to 
the stress of growing in culture. The FUS-DDIT3 translocation and the TP53 
mutations were present in both samples. 
The DL-221 cell line was regularly tested for the presence of the 
chimeric fusion oncogene, which was confirmed by FUS-split apart FISH on 
interphase cells. COBRA-FISH karyotyping of metaphase cells revealed a near 
triploid karyotype with several numerical and structural aberrations including 
the characteristic balanced t(12;16)(q13;p11). The tumor cell population 
consists of two clones, which differ in the number of copies per cell of this 
translocation. The most common clonal cell population contains one copy of 
the translocation and the other clone two (with the ratio of the clones being 
1.7:1.0), and this was stable across multiple passages. It is as yet unknown if this 
has any consequences on the level of FUS-DDIT3 fusion product in the different 
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clones. Fusion type characterization revealed a type 1 product, fusing exon 7 of 
FUS to the complete coding sequence of DDIT3. This is the same fusion as in the 
cell line 402-91; while the 1765-92 cell line carries the longer type 8 fusion. No 
cell line is available with the most common (65%) type 2 fusion; by comparison 
type 1 fusions are encountered in 22% of patients, whereas type 8 fusions are 
rare (2, 13).
MLS can contain several additional molecular genetic alterations, like 
TP53, PIK3CA and TERT mutations, which directly infl uence tumor cell biology 
and might be involved in round cell transformation, migration capacity and 
diff erential response to drugs. Alterations of the p53 pathway have been 
described in several studies on MLS and the percentage of cases with an 
alteration varies from <5% to 83% (2, 8, 24, 55, 56). Whole exome sequencing 
of the DL-221 cell line revealed two TP53 missense mutations, T125R in exon 4 
and N239D in exon 7; both mutations lead to the substitution of an amino acid 
of a diff erent class and are expected to be deleterious. Sanger sequencing of 
exon 4 to 10 did confi rm the mutations in exons 4 and 7. TP53 alterations are 
most frequently encountered in the hotspot exons 5 to 8; these two mutations 
have both been reported before in carcinomas (cosmic database). PIK3CA 
mutations have been identifi ed in 14-18% of the MLS cases and are associated 
with round cell progression and shorter disease-specifi c survival (22, 23). Loss 
of PTEN expression, which is mutually exclusive with PIK3CA mutations, and 
IGF1R overexpression are other mechanisms to activate the PI3K/Akt pathway. 
Immunohistochemical expression of the downstream pathway member, 
phosphorylated 4EBP1, is signifi cantly correlated to pathway activating events, 
and p-4EBP1 is highly expressed in 60% of MLS. All three cell lines are wildtype 
for PIK3CA and retain PTEN expression. Total-Akt was expressed in all three 
cell lines, whereas p-Akt473 was only present in 402-91 and 1765-92, possibly 
implying that the PI3K pathway is activated in the 402-91 and 1765-92 cell lines 
but not in the DL-221 cell line. A minor response has been reported in two 
MLS patients treated with mTOR inhibitors (everolimus and temsirolimus), a 
downstream target of the PI3K pathway (57). These fi ndings warrant testing of 
the several new inhibitors of PI3K, Akt and mTOR in the preclinical and clinical 
setting for MLS. Expression of the receptor tyrosine kinase AXL is associated 
with metastasis and worse outcome in several malignancies, and has been 
identifi ed as a prognosticator of disease-specifi c survival in MLS patients (8). 
AXL was present in DL-221 and 1765-92 but is only weakly expressed in 402-91. 
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This might indicate that AXL inhibition is a candidate treatment in a subset of 
MLS. Point mutations in the telomerase reverse transcriptase (TERT) promotor 
region have been identified in 23% (3/13) to 74% (29/39) of MLS (25, 26). This 
broad range in the mutation rate warrants investigation of more patients 
to elucidate the role of TERT mutations in MLS. The mutation creates a new 
transcription factor-binding site leading to an upregulation of TERT and finally 
lengthening of the telomeres. DL-221 carries the C228T mutation, as do both 
the other cell lines we tested. NY-ESO-1, a cancer testis antigen expressed in 
the majority of the myxoid liposarcomas (30), is strongly expressed in 1765-
92 and DL-221 cells. The patients from whom these cell lines originated could 
have been candidates for NY-ESO-1 directed immunotherapeutic approaches 
and the cell lines might serve as good models to test its efficacy (58).
HDAC inhibitors have shown inhibitory and cytotoxic effects on several 
soft tissue sarcoma tumor cell models grown in vitro and in vivo, including 
the 402-91 cell line (59). The MLS fusion gene can affect gene transcription 
processes by interacting with C/EBP family members; in addition, the EWSR1-
DDIT3 fusion gene has shown to act on at an epigenetic level and enhance 
histone deacetylation and DNA methylation (60). Epigenetic alterations might 
be involved in the transcriptional regulation of MLS. Expression of HDAC 
members -1, -2 and -3 was investigated. HDAC-2 was the only one showing 
moderate to strong expression in all three cell lines, thereby making this a 
potential target for treatment (61). HDAC-1 and -3 were moderately expressed 
in 2 out of 3 cell lines. A recent phase II trial with a pan-HDAC inhibitor SB939 
as a single agent tested in 22 translocation associated sarcoma patients (5 
of whom had MLS) revealed no objective responses but 2 out of 4 evaluable 
MLS patients achieved stable disease (62). Those patients with high HDAC-2 
expression appeared to benefit the most (61-63); however extensive pre-
clinical selection of the most promising HDAC-inhibitors might be worthwhile 
in specific soft tissue sarcoma subtypes. DL-221, similar to the other two cell 
lines displays sensitivity to the commonly used chemotherapeutic doxorubicin; 
we are in the process of performing a high throughput drug screen to look for 
activity with novel targeted agents.
In summary, DL-221, a new spontaneously immortalized myxoid 
liposarcoma cell line and generated xenograft, represents a much-needed 
addition to the in vitro and in vivo models available to study this disease. We 
also report whole exome sequencing to reflect the concordant abnormalities 
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between the cell line and original tumor, data informative for preclinical testing 
and selecting novel targeted therapeutics that might be translated to the clinic. 
We hope this cell line and xenograft model will serve to accelerate the pace of 
preclinical and translational research in MLS, leading to new treatment options 
to prevent or treat metastatic disease.
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Supplementary Information
Supplementary Table 1: Primers for PIK3CA, TERT and TP53 mutational analysis and FUS-DDIT3 fusion 
variant determination.
Gene Exon Forward sequence Reverse sequence 
PIK3CA 9 TGACAAAGAACAGCTCAAAGC TTAGCACTTACCTGTGACTCCA
PIK3CA 20 TGATGACATTGCATACATTCG TGTGTGGAAGATCCAATCCA
TERT Pro-moter GTAAAACGACGGCCAGCAGCGCT 
GCCTGAAACTC
GTCCTGCCCCTTCACCTT
TP53 4a CCATCTACAGTCCCCCTTG ATGATGACAGGGGCCAGGAG
TP53 4b GCACCAGCAGCTCCTACAC ATGAGCCCCTCAGGGCAACTG
TP53 5 TTTCAACTCTGTCTCCTTCCTCTT AGCCCTGTCGTCTCTCCAG
TP53 6 AGGCCTCTGATTCCTCACTG ATGAGAGACCCCAGTTGCAAACC
TP53 7 CTTGGGCCTGTGTTATCTCC ATGAGTGTGCAGGGTGGCAAG
TP53 8 TGCTTCTCTTTTCCTATCCTGAG ATGAGCTTCTTGTCCTGCTTGC
TP53 9 ACCTTTCCTTGCCTCTTTCC ATGAAGAAAACGGCATTTTGAGTG
TP53 10 CTTCTCCCCCTCCTCTGTTG ATGAGAAGGGGCTGAGGTCACTC
FUS 5 GCAGAACCAGTACAACAGCA NA
FUS 6 GAACCCAGAGGTCGTGGAG NA
FUS 7 GGTGGCTTCAATAAATTTGG NA
FUS 12 ATGAATGCAACCAGTGTAAGGCCC NA
FUS 13 TAAACCAGATGGCCCAGGAG NA
DDIT3 2 NA TGCTTTCAGGTGTGGTGATG
DDIT3 3 NA GGAGAAAGGCAATGACTCAG
NA = not applicable.
Supplementary Table 2. STR typing results of metastatic tumor, xenograft tumor, DL-221 cell line and 
402-91 and 1765-92 cell lines.
Sample AMEL CSF1PO D13S317 D16S539 D5S818 D7S820 TH01 TPOX vWA
DL-221 Tumor X,Y 10,13 8,11 12,13 12 10,12 8,9 8 14,17
DL-221 
Xenograft
X 10,13 8,11 12,13 12 10,12 8,9 8 14,17
DL-221 Cell line X 10,13 8,11 12,13 12 10,12 8,9 8 14,17
402-91 X,Y 11,12 11,12 11,12 11,14 10,12 6,9.3 8,11 14,18
1765-92 X 11,12 11,12 12 11,12 9,13 7,9.3 8 15,18
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Figure S1. DDIT3 expression. 
Myxoid liposarcoma cell lines 402-91, 1765-92 and DL-221 do not express the 29 kDa native DDIT3 
under regular culture conditions. Tunicamycin treatment at 5 mg/ml was included as a positive control 
to cause endoplasmic reticulum stress, and induce DDIT3 protein expression. The higher molecular 
weight FUS-DDIT3 fusion proteins were also observed in all three cell lines at a higher level of expression 
compared to native DDIT3.
Figure S2. TERT hotspot mutation in DL-221. 
Mutational analysis for promoter hotspot mutations in TERT, showing the C228T mutation in DL-221.
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Figure S3. HDAC expression. 
Expression levels of the HDAC-1, -2 and -3 proteins in the three myxoid liposarcoma cell lines.
Figure S4. Comparison of the VarScan1 variant calls between DL-221 and the parental metastatic 
lesion. 
(A) The R packag  vioplot was used to graph violin density plots of all VarScan1 calls from both the 
metastatic tumor and the derivative cell line. The similarity of the plots indicates high identity between 
the two samples. 960/1255 variants are shared between the two, with 63 exonic variants present in 
the metastatic tumor but not in the cell line and 32 exonic variants present in the cell line but not in 
the metastatic tumor. (B) 2D allele frequency plot showing that 90% of changes in allele frequency 
between the metastatic lesion and the cell line are small (<0.2). The two samples have a high correlation 
in variants (r2 = 0.623).
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Abstract
Myxoid liposarcoma is a soft tissue sarcoma characterized by a recurrent 
t(12;16) translocation. Although tumours are initially radio- and 
chemosensitive, the management of inoperable or metastatic MLS can be 
challenging. Therefore, our aim was to identify novel targets for systemic 
therapy. We performed an in vitro high-throughput drug screen using 
three myxoid liposarcoma cell lines (402-91, 1765-92, DL-221), which were 
treated with 273 different drugs, including various targeted inhibitors, FDA 
approved drugs, natural products and chemotherapeutic agents, at four 
different concentrations. Cell lines and tissue microarrays were used for 
validation. As expected, all cell lines revealed a strong growth inhibition 
to conventional chemotherapeutic agents, such as anthracyclines and 
taxanes. A good response was observed to compounds interfering with Src 
and the mTOR pathway, which are known to be affected in these tumours. 
Moreover, we identified survivin (BIRC5) as a potential novel target, since 
a strong inhibitory effect was seen at low concentration using the survivin 
inhibitor YM155. Sensitivity was confirmed in 402-91 and 1765-92 cells in 
dose response curves and siRNA for BIRC5 decreased cell viability. Survivin 
is multifunctional protein involved in the correct segregation of sister 
chromatids during mitosis. Secondly, it has an anti-apoptotic function. 
Interestingly, immunohistochemistry revealed abundant expression of 
survivin restricted to the nucleus in all 32 tested primary tumor specimens. 
Inhibition of survivin in 402-91 and 1765-92 by YM155 increased the 
percentage S-phase but did not induce apoptosis. In conclusion, using a 273 
compound drug screen we confirmed previously identified targets (mTOR, 
Src) in myxoid liposarcoma. In addition, we identified survivin as a potential 
novel target for therapy. However, although a strong decrease in cell viability 
is observed using the survivin inhibitor YM155, the increased percentage 
S-phase combined with the lack of apoptosis warrant further investigation 
before application in the treatment of metastatic myxoid liposarcoma.
Keywords: myxoid liposarcoma, soft tissue sarcoma, drug screen, survivin, 
YM155, mTOR, targeted therapy
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Introduction
Myxoid liposarcoma (MLS) is a malignant soft tissue tumour accounting for 20-
30% of the liposarcomas and roughly 5% of all soft tissue sarcomas (1). These 
tumours are histopathologically characterized by a proliferation of stellate 
spindle cells with monomorphic ovoid nuclei, embedded in a myxoid matrix 
with a plexiform vasculature (1). High grade tumours are defi ned by having more 
than 5% of closely packed small blue round cells with high nuclear/cytoplasm 
ratio and scant stroma. Myxoid liposarcoma is genetically characterized by a 
reciprocal translocation t(12;16)(q13;p11), generating a fusion product of FUS 
and DDIT3. The chimeric fusion oncoprotein acts as an aberrant transcription 
factor, and is known to infl uence the expression of several genes, including 
inhibition of adipogenic transcription factors C/EBPα and PPARγ (2, 3).
MLS tumours are initially sensitive to conventional chemo- and radiation 
therapy, but despite adequate local treatment, up to 40% can progress to local or 
distant relapse (4-7). Myxoid liposarcoma exhibits a unique metastatic pattern, 
as tumour cells tend to spread to other soft tissue sites, before metastasizing 
to the lungs. The disease can become quite extensive and management 
of metastatic or otherwise inoperable tumours often is challenging. This is 
refl ected by the variable 5-year survival rates reported in several studies, which 
range from 8% for advanced disease to around 83% to 93% for cases with 
purely myxoid and localized tumours (5-9). 
In addition to doxorubicin and ifosfamide, recently eribulin, a 
microtubule-dynamics inhibitor, was shown to off er a survival benefi t when 
compared with dacarbazine in the third-line setting in liposarcomas and is now 
FDA approved(10). Moreover, myxoid liposarcoma was shown to be sensitive 
to trabectedin (ET-743, Ecteinascidin), a natural alkylating agent derived from 
a marine tunicate (11). The drug has a complex mechanism of action that 
is not entirely elucidated, but involves binding to the DNA-minor groove, 
interaction with DNA repair complexes and additional eff ects on the tumour 
microenvironment (12). Unfortunately, similar to other systemic therapies, 
resistance develops and the antitumour eff ect of trabectedin has been shown 
to diminish after some time on treatment (13). Therefore new therapeutic 
approaches are warranted to improve the outcome of advanced or metastatic 
myxoid liposarcoma.
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Over the past decades, therapeutic progress has been hampered by the 
sparse availability of representative preclinical models. For many years only two 
published cell lines (403-91 and 1765-92) were widely available, both of which 
were SV40 immortalized (14, 15). Recently, we reported on the generation of 
a novel myxoid liposarcoma cell line (DL-221) and ancillary mouse xenograft 
model (16). This newly established cell line is so far the only known myxoid 
liposarcoma cell line that underwent spontaneous immortalization.
Here we used all three available myxoid liposarcoma cell lines in an in 
vitro high-throughput drug screen to search for novel therapeutic agents that 
have the potential to enter future clinical trials. Drug screens are regularly used 
and contribute to the discovery of new candidate targets in cancer therapies 
(17, 18); furthermore, the pathways targeted by effective drugs can yield 
insights into tumor biology. In addition to the conventional chemotherapeutic 
agents used in daily practice, such as anthracyclines and taxanes, we found 
that YM155, a survivin inhibitor, also strongly decreased tumour growth. 
Strong nuclear accumulation of survivin was observed in 100% of myxoid 
liposarcomas, and confirmed to be essential for tumour growth. Inhibitors of 
survivin may therefore represent novel and promising therapeutic options in 
myxoid liposarcoma.
Materials and Methods
Cell culture
The myxoid liposarcoma cell lines 402-91 and 1765-92 (both kindly provided 
by Pierre Åman, Sahlgrenska Cancer Centre, Department of Pathology, 
Institute of Biomedicine, University of Gothenburg, Sweden) were cultured 
in RPMI supplemented with 10% fetal bovine serum (FBS) (Fisher Scientific, 
Landsmeer, The Netherlands) and 1% penicillin-streptomycin (100U/ml). DL-
221 was cultured with DMEM supplemented with 10% FBS and 1% pen/strep. 
All included cell lines have been well characterized for possible alterations 
in myxoid liposarcomas. All three cell lines are PIK3CA wild type, 402-91 and 
1765-92 are TP53 wild type and only DL-221 has two TP53 mutations (T125R 
and N239D)(16). Cells were maintained in a humidified 5% CO2 incubator at 
37°C. Cell lines were tested on a regular basis for mycoplasma infections. STR 
(short tandem repeat) typing was performed before and after the experiments 
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to confi rm cell line identity using the Cell ID GenePrint 10 system (Promega, 
Leiden, The Netherlands).
Drug screen
A high throughput drug screen was performed in which a selection of 273 
drugs (Suppl. Table S1) out of 2100 of the Bioactive Compound Library L1700 
(Selleckchem, Houston, TX, USA) were tested on the three myxoid liposarcoma 
cell lines. Selection was based on potential clinical relevance of drugs. Drug 
stocks were dissolved in DMSO and stored in aliquots at -80°C. Cells were 
seeded in 96-well plates 24 hour before treatment. Addition of the drugs 
was performed with the Freedom EVO® 200 liquid handling platform (Tecan, 
Männedorf, Switzerland) and fi nal treatment concentrations were 1, 10, 100 
and 1000 nM, each in triplicate. Cells were treated for 72 hours and thereafter 
CellTiter-Blue Cell Viability Assay (#G8081, Promega, Madison, WI) was added 
and incubated for 3 or 4 hours. Plates were read at room temperature using 
Fluoroskan Ascent™ FL fl uorometer (Thermo Fisher Scientifi c Inc., Pittsburgh, 
PA), measuring the fl uorescence at 530 Ex/604 Em. Data was analyzed by 
Tableau (Tableau, Seattle, WA, USA). A compound was considered eff ective if 
able to reduce the cell viability >50% at a drug concentration of 100 nM in at 
least two cell lines.
Compounds and cell viability assays
For single agent validation studies, the survivin suppressant YM155, 
sepantronium bromide (S1130, Selleckchem), everolimus (S1120, 
Selleckchem), panobinostat (LBH-589, 13280, Cayman Chemical, Ann Arbor, 
MI, USA) and trabectedin (ET-743, PharmaMar, Madrid, Spain) were dissolved 
in DMSO according to the manufacturers’ instructions. Z-vad-FMK (550377, 
BD bioscience) was used as a general caspase inhibitor and also dissolved 
in DMSO. Myxoid liposarcoma cell lines were plated in 96-well plates 24 hr 
before treatment. Cells were treated with YM155 using concentrations from 
0.01 till 5000 nM, in 11 steps, for 72 hours. Cell viability experiments were 
performed three times, in triplicate. As myxoid liposarcomas are known 
to respond well to trabectedin, combination treatments with YM155 were 
performed to investigate possible synergism or antagonism of both drugs. 
Concentrations used for combination treatment were for both drugs selected 
around the IC25, IC50 and IC75 values of single drug treatment for each cell line. 
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This resulted in nine different dose combinations per cell line, and drugs were 
added simultaneously. After 72 hours incubation a Presto blue assay (Life-
Technologies, Scotland, UK) was performed. Fluorescence was measured at 
590nm on a fluorometer (Victor3V 1420 multilabel reader, Perkin Elmer, The 
Netherlands). Combination experiments were performed twice, in triplicate. 
To evaluate whether the combination treatments were synergistic, a simplified 
version of the Bliss independence model was applied (19).
siRNA knockdown
For siRNA knockdown experiments, validated smartpool siRNAs targeting BIRC5 
and control siRNAs (siGAPDH and siPLK1) were purchased from Dharmacon 
(GE Life Sciences, Landsmeer, the Netherlands). Reversed siRNA (50nM) 
transfection was carried out using DharmaFECT3 transfection reagent (Thermo 
Fisher Scientific Inc.) in triplo using 5000-10000 cells/well, the experiments 
were performed twice. After 24 hours evaluation of gene knockdown qRT-PCR 
were performed and expression levels were normalized towards housekeeping 
genes CPSF6, GPR108 and CYPA (20). After 72 hours Presto Blue assay and 
protein analysis by Western blot analysis were performed.
Immunohistochemistry
Survivin expression was investigated in myxoid liposarcoma tissue samples 
using a previously constructed tissue micro-array with tumour samples from 32 
patients diagnosed in the Leiden University Medical Center (21). The tumours 
of 15 patients consisted of a purely myxoid (M), intermediate cell density (I) or 
round cell (RC) morphology. The other 17 patients had tumours containing a 
combination of two histological areas (M+I, M+RC or I+RC); in these cases both 
areas were included, resulting in a total of 49 tumour samples. All samples were 
handled in a coded fashion, and all procedures were performed according to 
the ethical guidelines, “Code for Proper Secondary Use of Human Tissue in the 
Netherlands” (Dutch Federation of Medical Scientific Societies). Cell pellets 
of the three untreated myxoid liposarcoma cell lines were fixed in formalin 
and embedded in paraffin by using Shandon™ Cytoblock™ (Thermo Fisher 
Scientific Inc.). Sections were incubated with rabbit anti-survivin monoclonal 
antibody (71G4B7, #2808, Cell Signaling Technology, Leiden, The Netherlands) 
in a 1:100 dilution. Staining was visualized with DAB+ substrate Chromogen 
System (DAKO, Heverlee, Belgium). Placenta tissue was included as a control. 
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Both nuclear and cytoplasmic expression was scored separately by two 
independent observers (JVMGB, MAG). A semi-quantitative scoring system 
was used, combining the staining intensity (0=negative, 1=weak, 2=moderate, 
3=strong) and the percentage of positive tumour cells (0=0%, 1=1-25%, 2=25-
50%, 3=51-75% and 4=76-100%) as described previously (22). 
RNA isolation and quantitative real-time PCR
RNA was isolated from myxoid liposarcoma cell lines using TRIzol (Invitrogen, 
Carlsbad, CA, USA) followed by a purifi cation procedure using the RNeasy mini 
kit (Qiagen, Venlo, The Netherlands) according to manufacturer’s instructions. 
Q-PCR was performed for the isoforms wild-type (WT) survivin, survivin 2b and 
survivin Δex3 with primers described previously (23). Expression levels were 
normalized towards housekeeping genes HPRT, GAPDH and TBP. Results are 
depicted relative to survivin WT expression for each cell line. 
Apoptosis
Induction of apoptosis was assessed using the Caspase-Glo® 3/7 assay 
(Promega, Madison, WI, USA) according to the manufacturer’s instructions. 
Briefl y, MLS cells were plated into white walled 96 well plates (Corning, Fisher 
Scientifi c, Landsmeer, The Netherlands) and incubated with YM155 at the IC
75 
concentrations, as determined by cell viability assays. After 24 hr treatment the 
substrate was added in a 1:1 dilution and incubated for 30 minutes at room 
temperature. Luminescence was measured with a luminometer (Victor3V 1420 
multilabel reader). Experiments were performed twice. 
Western blot
After 24 hours YM155 treated and untreated MLS cells or 72 hours after siRNA 
transfection MLS cells were collected in hot-SDS buff er (1% SDS, 10 mM Tris/
EDTA with complete inhibitor and phosSTOP) for protein analysis as described 
previously (24). Briefl y, 5ug or 10 µg protein of each sample was size-fractioned 
on 12% (TGX Stain-Fast Cast Acrylamide kit, BIO-RAD Laboratories)  separating 
gels. Jurkat cell lysate treated with 25 µM etoposide (Cell Signaling (#2043)) 
was used as positive control for PARP and cleaved PARP detection. Proteins 
were transferred to a PVDF membrane and incubated overnight at 4°C with 
primary antibodies (all from Cell Signalling); PARP antibody (clone 46D11), 
survivin antibody (clone 71G4B7) or GAPDH antibody (clone D16H11). As a 
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loading control, α-tubulin staining (clone DM1A, Sigma-Aldrich, Zwijndrecht, 
The Netherlands) was included. After incubation with the secondary HRP-
conjugated antibody for 30 minutes at room temperature, membranes were 
treated with ECL2 substrate (Pierce™, Thermo Scientific) as per manufacturer’s 
instructions, and chemiluminescence was captured using ECL hyperfilm 
(Amersham, GE Healthcare Life Sciences, Eindhoven, The Netherlands).
Cell cycle analysis
Cell lines were cultured in T25 flasks in amounts ensuring 70%-90% confluency 
when harvested and treated with the YM155 IC
50
 concentrations. After 48hr 
treatment cells were  prepared for flow cytometric analysis.  In short, cells 
were harvested, counted and fixed in ice-cold methanol. Next, cells were 
washed, treated with RNase and stained for DNA using propidium iodide 
(PI) and stored one over night at 4oC. Next day, cells were analysed using an 
LSRII flowcytomer (BD biosciences). A blue 488 nm, 20 mW laser was used for 
excitation. PI fluorescence was collected using a 610/20 band pass filter. Data 
analysis was performed by using WinList 8 remotely connected to ModFit LT 
4 (Verity Software House, Topsham, ME) (25). Each data file contained at least 
10,000 single cell events. A one-compartment polynomial model was used for 
calculating the percentage G
1
, S and G
2
M phase of the cell cycle. This statistical 
model showed the best fit.
Statistical analysis
Dose response curves and IC
50
 values were determined using GraphPad Prism 
(version 6.05, GraphPad Software, La Jolla, CA). Mann-Whitney testing was 
performed to investigate differences in survivin expression (GraphPad Prism).
Results
Identification of 27 compounds effective against myxoid liposarcoma 
tumour cells 
Out of 273 tested compounds, 27 drugs were shown to be effective in myxoid 
liposarcoma tumour cell lines in vitro, which was defined as a loss of >50% 
cell viability in two or all three cell lines at a drug concentration of 100 nM 
(Figure 1, Supplementary Table 1). All three myxoid liposarcoma cell lines 
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showed a strong response (>80% loss of cell viability) to treatment with the 
anthracyclines doxorubicin and epirubicin at dose concentrations of both 100 
nM and 1000 nM (402-91 and 1765-92) and 1000 nM (DL-221) (Figure 1). The 
tested taxanes, docetaxel and paclitaxel, as well as a member of another class 
of mitotic inhibitors, vincristine, revealed a strong decrease in cell viability at 
the lowest concentration of 1 nM (average cell viabilities of the three cell lines 
respectively ~22%, ~24% and ~19% after 72 hours of treatment). In the drug 
screen YM155, a survivin suppressant, showed in the 402-91 and 1765-92 cell 
Figure 1. Hits of high throughput in vitro drug screen of three MLS cell lines. 
List of 27 drugs with a reduction in cell viability of >50% in two or all three cell lines at a drug 
concentration of 100 nM. Strong inhibitory eff ect of the survivin inhibitor YM155 is observed in two out 
of three MLS cell lines. Also a good response is observed to several conventional chemotherapeutics, 
like doxorubicin, gemcitabine and paclitaxel. Per drug four concentrations (1, 10, 100 and 1000 nM) are 
tested, green boxes correspond to a high cell viability (~100%) and red boxes to a loss of cell viability 
(~0%). For comparison, at the bottom, four compounds are randomly shown that did not meet the 
criteria.
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line a very strong decrease in cell viability (average ~13% cell viability) at all four 
drug concentrations. In the DL-221 cell line there was a moderate reduction of 
the cell viability after treatment with YM155 at concentrations of 10, 100 and 
1000 nM (ranging from 81% to 30% cell viability). Other interesting agents in 
the list are 17-DMAG HCl, geldanamycin, SNX-5422 and SNX-2112, all targeting 
HSP90. The list also contains several drugs affecting the PI3K/AKT/mTOR 
pathway, including omipalisib, gedatolisib and WYE-132. The HDAC inhibitors 
quisinostat, dacinostat and panobinostat showed a strong inhibitory effect in 
all three cell lines. KX2-391, an agent interfering with the proto-oncogene Src, 
also was effective in all three cell lines.
Validation of selected hits using cell viability assays
We selected the the survivin inhibitor YM155, the mTOR inhibitor everolimus, 
and the broad-spectrum HDAC inhibitor panobinostat (LBH-589) for further 
validation using cell viability assays. YM155 was of particular interest because 
this was the drug with the best antitumor effect at the lowest treatment dose 
in 2 of the 3 cell lines. The 402-91 and 1765-92 cell lines were confirmed to 
be highly sensitive to YM155 and showed IC
50
 values of 6.3 nM and 5.1 
nM respectively (Figure 2A). The IC
50
 value of DL-221 was 194 nM, which is 
consistent with the results observed in the drug screen. In all three cell lines an 
inhibition of cell viability (~50%) was observed at a low dose concentration (~5 
nM) of everolimus (Supplementary Figure 1A). However, with increasing dose 
no further decrease of cell viability was observed. The tested cell lines 402-91 
and DL-221 demonstrated an IC50 value of 28 nM and 49 nM respectively after 
treatment with panobinostat (Supplementary Figure 1B).  
To confirm the importance of BIRC5 in myxoid liposarcoma cell survival, 
siRNA experiments were performed. Knockdown of the survivin gene by 
smartpool siBIRC5 resulted in a partial decrease of viability in all three cell lines 
(402-91 69%, 1765-92 55% and DL-221 69% ). The transfection was successful as 
all three myxoid liposarcoma cell lines and the control siRNA GAPDH showed a 
minor reduction of cell viability, whereas transfection with the positive control 
siPLK1 resulted in all three cell lines in a pronounced decrease in cell viability. 
Moreover, western blot analysis after transfection with siBIRC5 confirmed a 
decrease in survivin protein in all three cell lines (Supplementary Figure 2).
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Figure 2. Role of survivin in myxoid liposarcoma cell lines. 
Dose response curves for YM155 (72 hours) in myxoid liposarcoma cell lines. Error bars represents three 
experiments performed in triplicates (a). Normalised RNA expression of three survivin isoforms in cell 
lines showing relative abundance of the Δex3 isoform (b). Survivin immunohistochemistry of FFPE cell 
pellets revealed a strong nuclear survivin expression in the cell lines 402-91 (c), 1765-92 (d) and DL-221 
(e) (20x magnifi cation).
No synergistic eff ect of everolimus or YM155 and trabectedin
As trabectedin (ET-743) is eff ective and therefore often used in the treatment 
of myxoid liposarcoma, we investigated possible synergy between trabectedin 
and two of the validated screen hits, YM155 or Panobinostat. Combination 
treatment of trabectedin with YM155 showed no statistically signifi cant 
diff erence between the expected and the observed cell viability in all three 
tested cell lines, indicating absence of synergism or antagonism for this drug 
combination (Supplementary Figure 3A, C, E). The combination of trabectedin 
and panobinostat was evaluated in the 402-91 and DL-221 cell lines, but again no 
statistical signifi cant synergism or antagonism was observed (Supplementary 
Figure 3B, D). 
Strong nuclear survivin expression in all myxoid liposarcoma cell lines 
and primary tumours 
Since YM155 was most effi  cient in decreasing myxoid liposarcoma cell viability, 
we evaluated the protein expression of survivin in the myxoid liposarcoma cell 
lines. The FFPE cell pellets of the three cell lines showed strong nuclear survivin 
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expression and a weak cytoplasmic expression in all three cell lines (Figure 2C-
E). No difference in the expression levels was observed. 
Moreover, we examined the relative distribution of the three most common 
survivin isoforms: survivin WT, survivin 2b and survivin Δex3 by qRT-PCR. All 
cell lines revealed a similar mRNA expression pattern, with survivin Δex3 being 
most highly expressed, followed by survivin WT, while the lowest expression 
was found for survivin 2b (Figure 2B).
Next we studied a cohort of myxoid liposarcoma primary tumour 
samples. The tumour samples of all 32 patients (100%) on the tissue microarrays 
demonstrated strong nuclear expression of survivin protein (Figure 3A). 
No statistically significant differences were observed between the myxoid, 
intermediate and round cell components (p>0.05) (Figure 3B,C). Cytoplasmic 
staining was absent, with the exception of a single round cell liposarcoma with 
moderate cytoplasmic staining. 
Figure 3. High nuclear expression of survivin in myxoid liposarcomas.
Immunohistochemical analysis of nuclear survivin expression in 32 MLS patients showing high 
expression in tumour components with myxoid, intermediate and round cell morphology (a). High 
nuclear survivin expression in tumour with myxoid morphology (b). High nuclear survivin expression in 
tumour with round cell morphology (c)(20x magnification).
YM155 does not induce apoptosis but increases the S-phase in two 
out of three MLS cell lines
To further evaluate the mechanism of action of YM155 in myxoid liposarcoma 
cell lines, we evaluated PARP expression in all three myxoid liposarcoma cell 
lines using Western blot analysis, but no cleaved PARP was found in the cell 
lines (Figure 4A) after 24 hours of YM155 treatment. Caspase 3/7 activity after 
treatment with the survivin inhibitor YM155 at IC
75
 concentration also revealed 
no significant increase in caspase 3/7 activity after 24 hours (data not shown). 
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These results indicate that YM155 does not induce apoptosis in myxoid 
liposarcoma. 
We subsequently performed cell cycle analysis to evaluate a possible 
eff ect of YM155 on cell cycle regulation. After 48 hours, YM155 treated cells 
revealed an increase in the S-phase fraction and a decrease in the G1-fraction 
as compared to untreated 402-91 and 1765-92 cells. In DL-221 no clear changes 
were observed in cell cycle distribution after YM155 treatment (Figure 4B). 
Figure 4. Eff ect of YM155 on apoptosis and cell cycle. 
YM155 does not cause PARP dependent apoptosis, but increases S-phase in 2 of the myxoid liposarcoma 
cell lines. Western blot analysis for PARP and cleaved PARP expression in myxoid liposarcoma cell lines 
(a). FACS cell cycle analysis of myxoid liposarcoma cell lines treated with YM155 for 48 hours, measured 
in two independent experiments. Two cell lines, 402-91 and 1765-92, show a decrease in G
1
 and an 
increase in S-phase after treatment. DL-221 does not show a diff erence in cell cycle distribution (b).  
Discussion
Myxoid liposarcoma initially often responds well to treatment with radiotherapy, 
conventional chemotherapeutics, or trabectedin, however after several 
treatment cycles, the eff ect of treatment is observed to decrease. Therefore, 
for patients with locally advanced or metastatic disease new therapeutic 
options are highly warranted in order to improve survival. In this study our aim 
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was to identify novel candidate targets for treatment by performing a high 
throughput drug screen with multiple targeted (tyrosine kinase) inhibitors as 
well as substances of other classes. 
The 27 most effective compounds (Figure 1) include the conventional 
chemotherapeutic agents used in daily practice, such as anthracyclines and 
taxanes, as anticipated. In addition, the results included three potent inhibitors 
of the PI3K/AKT/mTOR pathway (omipalisib, gedatolisib and WYE-125132). A 
subset of myxoid liposarcomas demonstrate dysregulation of this pathway by 
either PIK3CA mutation, loss of PTEN expression or Akt activation (26-28). No 
large series on mTOR inhibition in myxoid liposarcoma patients are available, 
although in two cases a minor response has been observed (29) and a clinical 
trial is ongoing (COSYMO www.clinicaltrials.gov NCT02821507). In the current 
study we found a decrease of cell viability down to 50% at low dose treatment 
with everolimus. As a plateau phase was reached, this drug is only able to kill a 
part of the cell population, suggesting that in clinical studies the drug will need 
to be combined with another (chemotherapeutic) drug. 
The Src inhibitor KX2-391 is another interesting hit confirming previous 
preclinical results, as two previous studies reported that the Src pathway 
is highly active in myxoid liposarcoma (30, 31).  KX2-391 is the first clinical 
Src inhibitor targeting the peptide substrate-binding site, with higher in 
vitro potency than dasatinib (32). In a small phase I study with several solid 
malignancies favourable pharmacokinetics and antitumour activity were 
observed (33). 
We demonstrate that inhibition of survivin by YM155 results in a 
significant decrease of cell viability in two out of three cell lines (402-91 and 
1765-92). YM155 blocks BIRC5 at the promoter region. In addition to this 
inhibition at the transcriptional level, also at the post-transcriptional level 
survivin can be downregulated by the addition of CDK or HSP90 inhibitors 
which are known to interact with the expression of BIRC5 in the cells (34). 
Interestingly, four of the 27 hits emerging from the compound screen target 
HSP90 (Figure 1), and demonstrate a strong inhibitory effect on cell viability. A 
recent study also demonstrates an important role for HSP90 inhibitor 17-DMAG 
resulting in decreased phosphorylation of several receptor tyrosine kinases 
and demonstrating massive tumour cell death in a xenograft model (35). 
Survivin (BIRC5) is a member of the inhibitor of apoptosis family and is a 
multifunctional protein that is involved in several important cellular processes 
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in both the nucleus and the cytoplasm. Survivin interacts with aurora B kinase 
and both are part of the chromosomal passenger complex, which forms at the 
kinetochore in the nucleus and regulates microtubule-kinetochore attachment 
ensuring proper segregation of the sister chromatids during mitosis (36, 37). 
Cytoplasmic survivin is involved in two processes, on one hand the binding of 
XIAP, which inhibits caspase-9 and prevents activation of the apoptotic pathway. 
In addition, survivin is able to activate AKT and to upregulate α5 integrin, 
resulting in stimulation of cell motility. Normally, survivin is expressed during 
fetal development and also in certain diff erentiated tissues. High expression of 
survivin has been found in several malignancies, including sarcomas such as 
malignant peripheral nerve sheath tumor, pleomorphic liposarcoma, uterine 
leiomyosarcoma, chondrosarcoma and Ewing sarcoma (38-43). 
All primary myxoid liposarcoma tumor samples, as well as the three 
cell lines, showed high nuclear expression of survivin. There are multiple 
survivin isoforms described. Several studies show a particular overexpression 
of survivin Δex3 in several malignancies, including for example breast and 
colon carcinoma and soft tissue sarcomas (44, 45). The expression of this 
isoform is also associated with a worse prognosis. We here show that also in the 
myxoid liposarcoma cell lines the survivin Δex3 isoform is relatively abundant. 
Successful knockdown of BIRC5 by siRNA resulted in a decreased cell viability 
which confi rms that survivin is indeed important for the survival of myxoid 
liposarcoma tumor cells.
In a previous study, p53 overexpressing chondrosarcomas displayed 
higher levels of nuclear survivin expression and TP53 mutant chondrosarcoma 
cell lines were more sensitive to YM155 compared to TP53 wild-type 
chondrosarcoma cell lines (40). The myxoid liposarcoma cell line DL-221 is the 
only one carrying a TP53 mutation while 402-91 and 1765-92 are TP53 wild-
type (16). Also, we did not observe a diff erence in survivin expression among 
the three myxoid liposarcoma cell lines, and as such the mechanism in myxoid 
liposarcoma might be diff erent as compared to chondrosarcoma. Inhibition 
of survivin by p53 is regulated via several signal transduction pathways and 
alterations in one of these pathways might underlie a possible diff erence (46). 
A possible explanation for the observed diff erence might be the interaction 
between HDAC proteins and p53 at the promoter region of survivin. Also the 
presence of methyl residues on the survivin promoter block binding of p53, 
resulting in induced survivin expression. Next, survivin expression is also 
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influenced by other transcription factors, of which NF-kB is an important one as 
NF-kB is deregulated in myxoid liposarcoma as it is influenced by the FUS-DDIT3 
fusion protein. However, as there is only one TP53 mutant myxoid liposarcoma 
cell line available, this number is too small to draw any conclusions.
Previously we and others showed that inhibition of survivin by YM155 
is effective in vitro in several other malignancies, including squamous cell 
carcinoma, gastrointestinal stromal tumor and chondrosarcoma (40, 47, 48). 
Evaluation of the effect of YM155 in in vivo models for gastric carcinoma and 
osteosarcoma demonstrated a suppression of tumor growth in mice (49, 50). 
Interestingly, dual treatment with YM155 and temsirolimus, an inhibitor of 
mTOR, demonstrated an improved antitumor effect in a renal cancer model 
(51). However, in most of these carcinoma models survivin inhibition induces 
apoptosis, while for myxoid liposarcoma as well as for chondrosarcoma (40) 
survivin expression was predominantly nuclear. This can be contributed to 
its role in maintaining proper sister chromatid segregation during mitosis. 
Strikingly, after treatment with YM155 we observed an increase in percentage 
of cells in S-phase in 402-91 and 1765-92 (wild-type TP53). In DL-221 (TP53mut) 
phases of the cell cycle were left unchanged while the caspase 3/7 pathway 
seems not to be activated, possibly associated with the lack of cytoplasmic 
survivin staining. This should be further explored since a high S-phase is 
significantly associated with a poor prognosis (52, 53). Furthermore, survivin 
knock-downs by shRNA increased chromosomal instability, irrespective of p53 
(54). As together with a high S-phase this might lead to clonal selection and 
outgrowth of resistant clones, this warrants further investigation. 
In conclusion, using a large compound screen we identified 27 
compounds that are effective in decreasing cell viability of myxoid liposarcoma 
cells. We identified survivin as a potential novel target in myxoid liposarcoma. 
The survivin protein is expressed in 100% of tumour samples and two of three 
tumour cell lines are highly sensitive for treatment with YM155. However, 
despite a strong decrease in cell viability, the S-phase increased, which warrants 
further investigation before treating advanced myxoid liposarcoma patients 
with YM155 targeting survivin.
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Supplementary Information
Supplementary Figure 1. 
Dose response curves of myxoid liposarcoma cell lines after monotherapy with everolimus (a) and 
panobinostat (b) afther 72 hours of treatment. 
Supplementary Figure 2. Knockdown BIRC5. 
BIRC5 and PLK1 siRNA show a decrease in cell viability, whereas the transfec€tion agent alone or control 
siGAPDH hardly affect cell viability (a). A reduction in GAPDH and survivin protein expression was found 
after transfection with respectively siGAPDH and siBIRC5 in all three cell lines (b).
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Supplementary Figure 3. Combination treatment of cell line 402-91 and DL-221 with panobinostat and 
trabectedin (a and b) showed no synergism or antagonism. Combination therapy of three MLS cell lines 
with trabectedin and YM155 also demonstrated no synergism or antagonism (c-e). 
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Summary and concluding remarks 
This thesis focusses on the molecular pathology of two specifi c subtypes of 
soft tissue sarcomas, leiomyosarcoma of soft tissue and myxoid liposarcoma. 
As described in detail in the introduction, these malignant tumours each have 
their unique clinical features, histopathology and genetic profi le. Soft tissue 
leiomyosarcomas are often high grade and generally have an aneuploid 
karyotype with multiple diff erent and non-recurrent translocations. This 
complex genomic profi le makes it hard to identify a common alteration that 
can be targeted in the search for new treatment strategies. Therefore, to gain 
insight in the aetiology of tumorigenesis the focus of research should be on 
the identifi cation of genes and pathways driving and promoting tumour 
formation. The identifi ed pathway alterations can be candidate targets for 
new therapeutic options interfering with members of these pathways. Myxoid 
liposarcomas, on the other hand, harbour a recurrent genetic aberration, most 
frequently resulting in the fusion protein FUS-DDIT3. This oncogenic fusion 
product acts as an aberrant transcription factor and infl uences gene expression 
resulting in malignant transformation and tumour growth. The presence of a 
specifi c genetic alteration makes the translocation product an ideal candidate 
for targeted treatment, however this is complicated by the fact that targeting a 
transcription factor is diffi  cult and that probably not all target genes have been 
identifi ed yet. 
Mutations in exon 2 of the mediator complex subunit 12 (MED12), located 
on chromosome Xq13.1, were fi rst described in around 50%-70% of benign 
uterine smooth muscle tumours in 2011 (1). In chapter 2 we investigated the 
presence of MED12 exon 2 mutations in extra-uterine leiomyomas, including 
piloleiomyomas, abdominal leiomyomas and angioleiomyomas, and both 
soft tissue and uterine leiomyosarcomas, aiming to obtain more insight in 
the pathogenesis of these tumours. In line with the previously published 
study (1), we found a mutation rate of 58% in uterine leiomyomas. In contrast, 
only one abdominal leiomyoma harboured a MED12 mutation and based on 
the expression of the oestrogen receptor, this lesion was most likely derived 
from the uterus. The absence of MED12 mutations in all other extra-uterine 
leiomyomas highly suggests a diff erent pathogenesis (2). Recently MED12 
mutations have been found in fi broadenomas of the breast and phyllodes 
tumours (3). As these mutations tend to occur in particular in hormone 
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sensitive tumours, it might be probable that MED12 is only involved in 
tumours with activated hormone receptor signalling. We identified one uterine 
leiomyosarcoma with a MED12 mutation, this low mutation rate is similar to 
what is described in literature (ranging from 2% to 30%) and supports the 
hypothesis that the majority of uterine leiomyosarcomas arise de novo while 
only rarely a leiomyosarcoma develops in a benign smooth muscle tumour 
(4). It has been postulated that in rare cases uterine leiomyomas create an 
environment that facilitates wild-type smooth muscle cells to acquire other 
genetic alterations and develop into a malignant phenotype, as has been 
described for EXT-mutated osteochondroma (5). We found nuclear β-catenin 
in half of the MED12-mutated uterine leiomyomas. When translocated to the 
nucleus, β-catenin directly interacts with MED12 and regulates transcription of 
target genes of the canonical Wnt-signalling pathway. In addition, in the same 
series we investigated fumarate hydratase (FH)-deficiency, which is mutually 
exclusive with MED12 mutations. One uterine leiomyoma and one cutaneous 
leiomyoma from a patient with suspected hereditary leiomyomatosis and 
renal cell carcinoma syndrome, and 2 sporadic leiomyosarcomas were positive 
for S-(2-succinyl)cysteine (2SC) immunohistochemistry, which is a robust 
biomarker for FH mutations (6). Moreover, these FH deficient tumours showed 
increased H3K9me3 methylation compared to FH-wild type tumours, which 
was expected since alterations in several genes of the tricarboxylic acid cycle 
affect histone demethylases. The role of these epigenetic alterations, is not yet 
clarified in smooth muscle tumours.
Soft tissue leiomyosarcomas have a complex genetic profile with 
numerous non-recurrent aberrations resulting from a high degree of 
chromosomal instability. In the search for a better understanding of the 
pathogenesis of this tumour and to identify candidate targets for treatment, 
we performed COBRA-FISH karyotyping and found a t(6;14) in two cases, 
as described in chapter 3. Interestingly we identified in one of the tumours 
cryptic rearrangements around HMGA1 and RAD51L1, genes that are also 
involved in a subset of leiomyomas. Detailed breakpoint mapping and in depth 
characterization with array-CGH profiling of both cases revealed different 
translocation breakpoints which, once more, underlines the complex and 
heterogeneous genetic profile of leiomyosarcomas. In this study a high grade 
leiomyosarcoma was encountered with a relatively simple karyotype, also 
in literature this has been described in a subset of tumours. Combination of 
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modern sequencing techniques might identify diff erent subgroups in these 
complex heterogeneous tumours, like for example the ‘muscle-enriched’ group 
characterized by enhanced expression of muscle diff erentiation related genes. 
The recent discovery of the expression of LMOD1 in the ‘muscle-enriched’ 
group and ARL4C in another subgroup, associated with a better and worse 
disease specifi c survival, respectively, might be helpful in determination of 
the prognosis (7). However, additional research is needed to translate these 
fi ndings into subtype-specifi c targeted therapy.
Soft tissue leiomyosarcomas are frequently resistant to chemotherapy 
and therefore the number of treatment options for this aggressive disease is 
limited. To gain insight in the mechanisms involved in chemoresistance and to 
search for new therapeutic targets, we investigated the role of the Bcl-2 family 
proteins in leiomyosarcomas, in chapter 4. The anti-apoptotic protein Bcl-2 was 
highly expressed in the majority of tumours and moreover a substantial number 
of tumours showed expression of Bcl-xL and Bcl-w. Single-agent treatment 
of leiomyosarcoma cell lines with ABT-737, a BH3 mimetic, resulted in only 
a slight reduction of cell viability. However, combination treatment with the 
conventional chemotherapeutic agent doxorubicin demonstrated synergism 
in all tested cell lines by inducing apoptosis. Therefore, inhibition of anti-
apoptotic proteins by a BH3 mimetic sensitizes soft tissue leiomyosarcomas to 
chemotherapy. Before the results of this study can be translated to the practice 
of the clinical oncologist for the benefi t of leiomyosarcoma patients, further 
validation in in vivo models need to be done. In case of positive and promising 
results, combination treatment with a Bcl-2 inhibitor and conventional 
chemotherapeutic agent might be a therapeutic option for patients with 
Bcl-2 positive tumours. The Bcl-2 inhibitor navitoclax has shown a favourable 
safety profi le in several phase I trials. The antitumour eff ect of navitoclax 
monotherapy was disappointing in for example patients with small cell lung 
cancer and therefore clinical studies tend to focus on the combination with 
other chemotherapeutic agents (8, 9). A limited treatment eff ect might be 
attributed to expression MCL1 or galectin-3, which are both also antiapoptotic 
proteins, able to mimic the function of Bcl-2 and acts as a bypass mechanism 
to avoid apoptosis. A specifi c sphingosine kinase 2 inhibitor (ABC294640) 
promotes MCL1 degradation and induced apoptosis in combination with a Bcl-
2 inhibitor in multiple myeloma (10). Therefore tumours expressing both Bcl-2 
proteins as well as MCL1 or galectin-3, needs to be treated with a combination 
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of a Bcl-2 inhibitor and a compound that leads to a reduced function of MCL1 
or galectin-3 to ensure successful suppression of the antiapoptotic function 
(11).
In chapter 5 we investigated the protein expression of the cancer-testis 
antigen NY-ESO-1 (CTAG1B) in a large series of myxoid liposarcomas as well 
as its expression in several other benign and malignant bone and soft tissue 
neoplasms using immunohistochemical staining. Cancer-testis antigens are 
currently under the magnifying glass due to their unique combination of 
properties, which include expression exclusively in the testis in adults, aberrant 
expression in certain tumours and highly immunogenic features, rendering 
them an interesting target for immunotherapy. Strong expression of NY-ESO-1 
was found in 88% of myxoid liposarcomas, which was the tumour with the 
highest proportion of positive cases. In the myxoid liposarcomas pre-treated 
with chemo- or radiotherapy prior to resection, NY-ESO-1 could be detected 
in 42% of cases. NY-ESO-1 was also positive in a subset of synovial sarcomas, 
myxofibrosarcomas and conventional chondrosarcomas, while all benign 
mesenchymal lesions were negative. Clinical trials investigate the effect of NY-
ESO-1 targeted vaccine, autologous T-cell or dendritic cell immunotherapies 
strategies and these studies should be open to patients with NY-ESO-1 
expression. A pilot clinical trial demonstrated an antitumour effect of NY-
ESO-1 reactive T-cells in synovial sarcoma patients (12). At this moment several 
clinical trials are recruiting patients, including myxoid liposarcoma patients, to 
investigate NY-ESO-1 vaccine or T-cell therapy, either alone or in combination 
with another drug.
Establishing a cell line from primary myxoid liposarcoma tumour samples 
is a daunting task reflected by the presence of only two cell lines generated by 
SV40 virus transformation available world-wide, which hampers the research to 
this malignant tumour. Chapter 6 focusses purely on myxoid liposarcoma and 
here we report the establishment and characterization of a new human myxoid 
liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. The new cell 
line is studied in detail for mutations and pathway alterations frequently 
encountered in this tumour type, like for example the mutation status of 
PIK3CA, TERT and TP53 and the protein expression of NY-ESO-1. Both the cell 
line as well as the ancillary xenograft model underwent next-generation whole 
exome sequencing and they are of pivotal importance to study the biology and 
novel potential-targeted treatment approaches for myxoid liposarcoma.
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In chapter 7 we continue the search for new candidate targets for 
the treatment of myxoid liposarcoma. A high-throughput drug screen was 
performed using three myxoid liposarcoma cell lines, including the one 
presented in chapter 6. As expected, a strong response to the chemotherapeutic 
agents of the classes of the anthracyclines and taxanes was observed. Survivin 
(BIRC5) was identifi ed as an interesting novel target in the screen, as a strong 
decrease in cell viability was observed after treatment with the survivin inhibitor 
YM155. Survivin has a dual function in the cell; in the nucleus it is involved in 
cell cycle regulation and in the cytoplasm in the inhibition of apoptosis. We 
demonstrated that survivin is highly expressed in the nuclei of tumour samples 
supporting its role in cell cycle regulation in myxoid liposarcoma. Other 
interesting targets from the drug screen were drugs aff ecting mTOR, HDAC 
and HSP90. Further in vivo studies are required to investigate whether YM155 
can be a promising therapeutic strategy for patients with advanced myxoid 
liposarcoma. 
Concluding remarks and future perspectives
This thesis presents molecular data for soft tissue leiomyosarcoma, a tumour 
known for its complex genome and, as a consequence, the diffi  culty to identify 
targets for treatment. We here show that MED12 mutations are restricted to 
uterine smooth muscle tumours, and describe the occurrence of non-recurrent 
translocations in two cases of soft tissue leiomyosarcomas. How these 
alterations relate to the three molecular subtypes that have recently been 
proposed (7) remains to be investigated. In addition, we show high expression 
of the Bcl family members in leiomyosarcomas, and using cell lines we could 
demonstrate that these proteins play a role in chemoresistance. Also here it 
would be interesting to see how the expression of other Bcl family members 
is related to the molecular subtype. Moreover, we show that treatment with 
a Bcl-2 inhibitor overcomes the chemoresistance of leiomyosarcoma cells. 
This combination strategy should be further explored in vivo to investigate 
whether it might be a promising therapeutic approach for leiomyosarcoma 
patients. Next, the ongoing research of Next Generation Sequencing in 
combination with functional studies as metabolomics and proteomics might 
help in the identifi cation of cellular processes in leiomyosarcomas which 
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might be used in diagnostics or for therapy. The identification of new, and 
potential immunogenic, proteins might provide new candidate targets for 
immunotherapy. A recent study demonstrates that concurrent targeting of the 
PI3K/AKT/mTOR pathway in combination with doxorubicin treatment results in 
reduced tumour growth in vivo in leiomyosarcoma xenografts (13).
Myxoid liposarcoma, genetically belonging to the group of tumours with 
a recurrent translocation, is generally sensitive to conventional chemotherapy 
and radiation. Trabectedin is initially quite effective in a substantial part of 
the patients, but this effect might cease after some time. We show expression 
of the cancer-testis antigen NY-ESO-1 in a large proportion of tumours, 
providing options for immunotherapy. The use of a dendritic cell vaccine 
with the NY-ESO-1 protein may teach the patient’s immune system to target 
and kill tumour cells expressing the NY-ESO-1 protein. Another promising 
option is the adoptive transfer of autologous T-lymphocytes transduced with 
a NY-ESO-1-reactive T-cell receptor. As the first myxoid liposarcoma patients 
have entered clinical trials exploiting NY-ESO-1, soon we will learn whether 
this is a promising strategy for patients with advanced or metastatic myxoid 
liposarcoma. So far, preclinical studies on myxoid liposarcoma were hampered 
by the lack of representative preclinical models. In this thesis we present a 
novel, spontaneously immortalized myxoid liposarcoma cell line, DL-221, 
which was used together with the other two available cell lines for a large-
scale drug screen. We identified survivin as a promising novel target, which is 
expressed in 100% of myxoid liposarcomas, and future in vivo studies should 
reveal whether the surviving inhibitor YM155 is an effective therapeutic option 
for patients with advanced myxoid liposarcoma.
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Nederlandse samenvatting
Sarcomen vormen een heterogene groep maligne tumoren die uit gaan van 
mesenchymale of neuroectodermale weefsels, zoals bot, kraakbeen, glad en 
dwarsgestreept spierweefsel, vet, endotheel en zenuwweefsel. Ondanks dat 
sarcomen verantwoordelijk zijn voor minder dan 1% van alle maligniteiten, zijn 
er inmiddels meer dan 50 verschillende histologische subtypes beschreven. De 
verschillende sarcomen worden gekenmerkt door hun verschillen in klinische 
presentatie, hun sterk uiteenlopende biologische gedrag en prognose. 
Een correcte diagnose is dan ook uiterst belangrijk voor het kiezen van de 
optimale behandelstrategie. Het stellen van de juiste diagnose wordt door veel 
pathologen als lastig ervaren omdat sarcomen zeldzaam zijn en door het grote 
aantal verschillende subtypes. Daarnaast hebben sommige tumoren meerdere 
overlappende histopathologische kenmerken. De World Health Organisation 
(WHO) heeft een internationale consensus richtlijn opgesteld voor de 
classifi catie van bot- en wekedelentumoren die handvaten biedt bij het stellen 
van de juiste diagnose. Geadviseerd wordt om patiënten met (verdenking op) 
een mesenchymale tumor te verwijzen naar een gespecialiseerd centrum waar 
een multidisciplinair team betrokken is bij de diagnostiek en behandeling 
van deze patiënten. Hier werken gespecialiseerde oncologisch chirurgen, 
orthopeden, radiologen, oncologen, radiotherapeuten en pathologen nauw 
samen. Sarcomen zijn bij uitstek tumoren waarbij niet alleen de histologie en 
moleculaire diagnostiek van belang zijn, maar ook het klinisch beeld, zoals de 
leeftijd van presentatie en het radiologisch beeld van de verschillende tumoren 
dienen bij het maken van de diff erentiaal diagnose meegenomen te worden in 
de overweging. 
De groep van bot- en wekedelentumoren kan op basis van hun biologisch 
gedrag worden onderverdeeld in vier subgroepen, namelijk benigne, lokaal 
agressief, zelden metastaserend en maligne. Een bekend voorbeeld van 
een benigne tumor is een lipoom, een goedaardige vettumor, histologisch 
opgebouwd uit mature adipocyten. Dermatofi brosarcoma protuberans (DFSP) 
is een wekedelentumor die op de plaats waar deze ontstaat vooral schade 
veroorzaakt door zijn lokaal destructieve groei waardoor chirurgische resectie 
met tumorvrije marges moeilijk te bereiken kan zijn. Tijdige herkenning, 
diagnose en instellen van de goede behandeling is van groot belang bij 
sarcomen, omdat sommige subtypen een slechte prognose hebben. Bij de 
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diagnostiek is de histomorfologie van de tumor van belang, daarnaast kan 
immuunhistochemisch onderzoek bij met name de wekedelentumoren 
bijdragend zijn, omdat hiermee de differentiatielijn van de tumor vaak kan 
worden aangetoond. Zo zijn er bijvoorbeeld markers voor zenuw-, vaat- en 
spierdifferentiatie. Daarnaast is moleculair genetisch onderzoek in sommige 
gevallen van groot belang omdat van de 117 verschillende benigne en 
maligne wekedelentumoren die zijn beschreven in de WHO er 49% een unieke/
specifieke genetische of moleculaire afwijking heeft.
Op basis van de genetische achtergrond kunnen sarcomen ingedeeld 
worden in drie hoofdgroepen, te weten tumoren met een specifieke genetische 
verandering op het niveau van één gen, zoals KIT mutaties in gastro-intestinale 
stromaceltumoren, tumoren met een karakteristieke chromosomale 
translocatie en een verder normaal karyotype, zoals de FUS-DDIT3 translocatie 
in myxoid liposarcomen en de laatste groep bestaat uit tumoren met een 
complex karyotype zonder een terugkerende specifieke afwijking, zoals 
leiomyosarcomen. De ontdekking van specifieke afwijkingen in tumoren op 
niveau van het DNA heeft in sommige gevallen bijgedragen tot een begrip 
van het pathologische mechanisme wat leidt tot ongeremde celdeling en 
dus tumorgroei. Ook draagt het bij aan de diagnostiek van deze tumoren 
omdat met verscheidene moleculaire technieken de pathognomonische DNA 
afwijking vastgesteld kan worden. Zo kunnen mutaties in hot-spot gebieden 
met verschillende sequencetechnieken snel in kaart gebracht worden en 
fusieproducten van translocaties kunnen aangetoond worden door middel 
van fluorescentie in situ hybridisatie (FISH) of q-PCR van het fusieproduct. Ook 
is er onderzoek gaande naar het ontwikkelen van medicijnen die speciaal 
gericht zijn tegen de genetische afwijking in sommige tumoren en op die 
wijze mogelijk kunnen leiden tot een nieuwe therapeutische optie die bij de 
behandeling van patiënten toegepast kan worden. 
Dit proefschrift richt zich op twee verschillende wekedelensarcomen, 
het myxoid liposarcoom en het leiomyosarcoom van de wekedelen. Wekedelen 
leiomyosarcomen tonen gladde spierceldifferentiatie en zijn verantwoordelijk 
voor ongeveer 10 tot 20% van de wekedelensarcomen. De tumoren komen 
het vaakst voor in de 5de en 6de decade en zijn iets frequenter bij vrouwen dan 
bij mannen. Op basis van de locatie kunnen deze tumoren verder worden 
verdeeld in vijf groepen, te weten gladde spierceltumoren van de diepe 
wekedelen, het retroperitoneum, de uterus, de bloedvaten en de superficiële 
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dermis. In dit proefschrift worden de leiomyosarcomen van de wekedelen 
en het retroperitoneum onderzocht. Aangezien deze tumoren in de diepe 
wekedelen ontstaan zijn ze vaak al groot op het moment dat ze ontdekt worden. 
De tumoren bestaan uit spoelvormige cellen met eosinofi el cytoplasma en 
langgerekte kernen die in elkaar kriskras kruisende bundels gelegen zijn. 
Hooggradige tumoren worden gekenmerkt door uitgesproken cytonucleaire 
atypie en necrose. De tumoren hebben een wisselende mate van gladde 
spierceldiff erentiatie die kan worden aangetoond met immuunhistochemisch 
onderzoek waarbij er minimaal enige desmine of h-caldesmon expressie 
aanwezig moet zijn. Leiomyosarcomen hebben een instabiel, complex 
karyotype en tot op heden is er geen genetische afwijking bekend die in al deze 
tumoren voorkomt. Mutaties in TP53, verlies van de tumor suppressorgenen 
PTEN en RB1 en veranderingen in MYOCD, ATRX en ROR2 komen in een 
substantieel deel van de tumoren voor en zijn soms gecorreleerd met de 
prognose. Leiomyosarcomen worden behandeld met chirurgie en daarnaast 
met conventionele chemotherapie zoals doxorubicine en dacarbazine. Naast 
de maligne gladde spierceltumor bestaat er ook een benigne gladde spiercel 
tumor, het leiomyoom. Een veelvoorkomende variant van deze tumor is het 
leiomyoom van de uterus, welke bij ongeveer 70% van de vrouwen in de 
reproductieve leeftijd voorkomt. Benigne gladde spierceltumoren kunnen ook 
elders in het lichaam voorkomen, zo zijn er bijvoorbeeld de piloleiomyomen 
die in de huid ontstaan. De leiomyomen van de uterus kunnen genetisch in vier 
hoofdgroepen verdeeld worden, waarbij tussen de 50-70% van deze tumoren 
een mediator complex subunit 12 (MED12) mutatie heeft. In hoofdstuk 2 
wordt het voorkomen van MED12 mutaties in leiomyomen van de uterus 
en wekedelen onderzocht. In overeenstemming met de literatuur wordt in 
58% van de uterine leiomyomen een MED12 mutatie aangetroff en. In de 
onderzochte angioleiomyomen, piloleiomyomen en abdominale leiomyomen 
wordt in slechts één abdominale tumor een MED12 mutatie aangetroff en. Deze 
specifi eke tumor toont ook oestrogeenreceptor expressie wat er op duidt dat 
deze laesie mogelijk afkomstig is van een leiomyoom van de uterus. MED12 
mutaties zijn meer recent ook aangetroff en in fi broadenomen van de borst en 
phyllodestumoren wat suggereert dat MED12 mogelijk vooral van belang is 
in hormoongevoelige tumoren. De afwezigheid van MED12 mutaties in extra-
uteriene leiomyomen duidt op een andere pathogenese van deze laesies. In 
deze studie was er één leiomyosarcoom van de uterus met een MED12 mutatie, 
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wat overeenkomt met het lage percentage (2 tot 30%) leiomyosarcomen met 
MED12 mutaties wat is beschreven in de literatuur. Dit ondersteunt de hypothese 
dat het merendeel van de leiomyosarcomen van de uterus de novo ontstaat 
in plaats van dat ze zich ontwikkelen in een leiomyoom. Het is wel mogelijk 
dat leiomyomen een omgeving creëren waarin wild-type gladde spiercellen 
verschillende genetische veranderingen kunnen opbouwen die uiteindelijk 
resulteren in de ontwikkeling van een leiomyosarcoom, dit mechanisme is 
bekend van EXT-gemuteerde osteochondromen. De helft van de leiomyomen 
van de uterus met een MED12 mutatie toont nucleaire β-catenine expressie. 
Normaal komt β-catenine in het cytoplasma voor, maar als de afbraak wordt 
voorkomen kan het naar de celkern gaan en daar binden aan MED12 wat 
resulteert in stimulatie van de Wnt-signaalpathway. In deze serie tumoren is 
ook gekeken naar fumaraathydratase (FH) deficiëntie, wat ‘mutually exclusive’ is 
met MED12 mutaties. Een leiomyoom van de uterus en een cutaan leiomyoom 
van dezelfde patiënt, met mogelijk het HLRCC (hereditary leiomyomatosis 
and renal cell carcinoma) syndroom, waren sterk positief voor S-(2-succinyl)
cysteïne (2SC) immuunhistochemie. 2SC is een robuuste biomarker voor FH 
mutaties omdat de afwezigheid van functioneel FH leidt tot hoge levels van 
eiwitsuccinatie. Daarnaast werden nog twee leiomyosarcomen met hoge 2SC 
expressie gevonden, deze tumoren vertonen een toegenomen H3K9me3 
methylering in vergelijking met FH-wild type tumoren, dit is te verklaren 
doordat mutaties in genen van de citroenzuurcyclus een effect hebben op 
histon demethylasen. 
Zoals hierboven beschreven worden leiomyosarcomen gekenmerkt 
door hun complexe genetische profiel en chromosomale instabiliteit. Om de 
pathogenese van leiomyosarcomen beter te proberen te begrijpen en om 
mogelijke kandidaat genen te identificeren zijn in hoofdstuk 3 tumorcellen 
van enkele tumoren gekaryotypeerd met COBRA-FISH. Twee tumoren hebben 
een translocatie tussen de chromosomen 6 en 14 (t(6;14)). Interessant is 
dat één van de tumoren rearrangements toonde van de genen HMGA1 en 
RAD51L1, die ook bij een deel van de leiomyomen betrokken zijn. De exacte 
breekpunten van de translocaties zijn in kaart gebracht met FISH en array-CGH. 
Hierbij bleek dat de twee tumoren met de t(6;14) verschillende breekpunten 
in de chromosomen hadden. Dit illustreert weer het complexe en heterogene 
genetische profiel van leiomyosarcomen. In deze studie werd ook een tumor 
aangetroffen met een relatief simpel karyotype en in de literatuur is beschreven 
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dat een minderheid van de tumoren een vrij simpel karyotype heeft. Recent 
onderzoek naar een grote groep leiomyosarcomen laat zien dat de tumoren 
op basis van hun diff erentiatie in verschillende subgroepen onderverdeeld 
kunnen worden. Zo is er een groep waarbij relatief veel genen tot expressie 
komen die betrokken zijn bij spieraanleg en –diff erentiatie. Een hoge expressie 
van LMOD1 in deze groep is geassocieerd met een betere ziekte specifi eke 
overleving. Aanvullend onderzoek is nodig om te onderzoeken of de genen 
met een veranderde expressie als target voor therapie gebruikt kunnen gaan 
worden. 
Leiomyosarcomen worden behandeld met sommige varianten 
van conventionele chemotherapie, helaas zijn sommige tumoren echter 
resistent voor deze medicijnen. Daarom wordt in hoofdstuk 4 gefocusseerd 
op de mechanismen die betrokken zijn bij chemoresistentie. Bcl2 speelt een 
belangrijke rol in dit proces in, omdat dit eiwit een lid is van een familie van 
anti-apoptotische eiwitten, net als Bcl-xL en Bcl-w. Bcl2 komt hoog tot expressie 
in leiomyosarcomen wat er op duidt dat in de tumorcellen het mechanisme 
van cellen om in apoptose te gaan geremd wordt, waardoor de tumorcel dus 
kan overleven. Behandeling van tumorcellen met een BH3-mimeticum (een 
remmer van eiwitten van de Bcl2 familie) resulteerde slechts in een kleine 
reductie van de overleving van tumorcellen in vitro. Daarentegen resulteerde 
de combinatiebehandeling van de tumorcellen met een BH3-mimeticum en 
het conventionele chemotherapeuticum doxorubicine tot synergie waarbij er 
apoptose van de tumorcellen optreedt. De inhibitie van Bcl2 door een BH3-
mimeticum maakt de tumorcellen gevoelig voor de chemotherapie. Dit zijn 
veelbelovende resultaten waarbij de volgende stap zou zijn om de combinatie 
van deze twee geneesmiddelen in in vivo modellen te testen. In de toekomst 
kan deze combinatie misschien gebruikt worden bij de behandeling van 
patiënten met Bcl2 positieve tumoren. 
Het myxoid liposarcoom is verantwoordelijk voor ongeveer 5% van 
alle wekedelensarcomen. De tumor gaat uit van het vetweefsel en komt het 
vaakst voor bij patiënten in het 4e of 5e decade. Deze tumor is in tweederde van 
de gevallen in de wekedelen van het bovenbeen gelokaliseerd. Histologisch 
zijn het tumoren met een myxoide matrix met korte spoelvormige cellen 
met beperkte cytonucleaire atypie en tussen de tumorcellen een delicaat 
patroon van kleine bloedvaatjes. Als de tumor voor meer dan 5% bestaat uit 
een component van monomorfe, kleine cellen met weinig cytoplasma en 
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donker chromatinepatroon die dicht opeen gepakt liggen, de zogenaamde 
‘small blue round cells’ dan wordt de tumor als hooggradig beschouwd. Het 
myxoid liposarcoom heeft een translocatie t(12;16)(q13;p11), wat betekent dat 
de lange arm van chromosoom 12 fuseert met de korte arm van chromosoom 
16, resulterend in een fusieproduct van de genen FUS en DDIT3. Het exacte 
mechanisme waarbij het fusieproduct resulteert in ongeremde tumorgroei 
is niet compleet opgehelderd, waarschijnlijk werkt het fusieproduct als een 
aberrante transcriptiefactor en zet het andere genen aan tot proliferatie terwijl 
tegelijkertijd de lipogene differentiatie wordt geremd. 
In hoofdstuk 5 wordt de expressie van NY-ESO-1 onderzocht in 
verschillende benigne en maligne wekedelentumoren. NY-ESO-1 is een eiwit 
wat normaal alleen in de testis tot expressie wordt gebracht en behoort tot de 
groep van ‘cancer testis antigenen’. Het immuunsysteem van de patiënt kan 
tegen een dergelijk eiwit een immuunreactie opwekken waardoor de cellen die 
dit eiwit tot expressie brengen worden vernietigd. In deze studie blijkt dat NY-
ESO-1 in 88% van de myxoid liposarcomen tot expressie komt. Ook in sommige 
andere maligne tumoren, zoals synoviosarcomen en myxofibrosarcomen, 
komt dit eiwit in een deel van de gevallen voor. NY-ESO-1 expressie was 
niet aanwezig in de benigne mesenchymale tumoren. Aangezien het eiwit 
immunogeen is, is het mogelijk om een immuunrespons tegen de tumorcellen 
uit te lokken. Dit kan door patiënten een vaccin te geven tegen NY-ESO-1, 
waarbij het immuunsysteem van de patiënt wordt getraind om dit eiwit te 
herkennen en om de tumorcellen op te ruimen. Ook kan geselecteerd worden 
op T-cellen van de patiënt die gericht zijn tegen NY-ESO-1 of dendritische 
celtherapie waarbij monocyten uit het bloed van de patiënt worden gehaald 
en worden opgewerkt tot dendritische cellen die bijdragen aan een effectieve 
immuunrespons van het lichaam. Deze vormen van immuuntherapie worden 
in trial verband onderzocht. Een nieuwe therapie tegen myxoid liposarcomen 
is van groot belang omdat ondanks dat patiënten in eerste instantie vaak goed 
reageren op conventionele chemo- en/of radiotherapie, patiënten in een later 
stadium moeilijk te behandelen zijn mede omdat deze tumor zich diffuus kan 
uitbreiden naar andere wekedelen verspreid door het hele lichaam.
Om meer onderzoek naar myxoid liposarcomen mogelijk te maken is het 
van belang om voldoende tumormodellen te hebben. Myxoid liposarcomen 
zijn bij uitstek tumoren die moeilijk te kweken zijn in tweedimensionale 
kweekflesjes met medium. Daarom zijn er wereldwijd slechts twee cellijn 
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modellen beschikbaar. In hoofdstuk 6 wordt de ontwikkeling van een nieuwe 
myxoid liposarcoomcellijn (DL-221) beschreven. De tumorcellen zijn geïsoleerd 
van de tumor van een patiënt en daarna in kweekmedium opgegroeid. Op 
veel momenten in het traject zijn de tumorcellen getest voor de aanwezigheid 
van het FUS-DDIT3 fusieproduct om te controleren of het daadwerkelijk 
tumorcellen zijn en geen andere celtypen zoals bindweefselcellen. De 
nieuwe cellijn is spontaan geïmmortaliseerd waarmee deze zich onderscheid 
van de andere twee cellijnen (402-91 en 1765-92) die door middel van 
SV40 virus transformatie onsterfelijk zijn gemaakt. De DL-221 is uitgebreid 
gekarakteriseerd waarbij gekeken is naar de mutatie status van PIK3CA, TERT en 
TP53 en de eiwitexpressie van NY-ESO-1. Ook is van zowel de cellijn als van het 
ontwikkelde xenograft model Next Generation Sequencing (NGS) verricht om 
de biologie en mogelijke kandidaat targets voor de behandeling van myxoid 
liposarcomen te bestuderen. 
In hoofdstuk 7 is een uitgebreide ‘drug screen’ gedaan, waarbij in alle 
drie de beschikbare myxoid liposarcoomcellijnen is onderzocht hoe gevoelig 
de tumorcellen zijn voor de behandeling met verschillende medicijnen. 
Er zijn in totaal 273 medicijnen getest, waarbij zowel reeds geregistreerde 
medicijnen alsook nieuwe stoff en en specifi eke (tyrosine kinase) inhibitors 
zijn geïncludeerd. Hieruit bleek dat de tumorcellen, zoals verwacht, 
gevoelig zijn voor behandeling met conventionele chemotherapeutica zoals 
anthracyclines en taxanen. Daarnaast werd survivin (BIRC5) geïdentifi ceerd als 
nieuwe kandidaat target omdat de tumorcellen van twee cellijnen al bij lage 
concentratie een sterke afname van de viabiliteit liet zien. Intracellulair heeft 
survivin twee belangrijke functies, in de kern is het betrokken bij de regulering 
van de celcyclus en in het cytoplasma remt het de apoptose. Een hoge nucleaire 
survivin expressie werd gevonden in myxoid liposarcomen wat er op duidt dat 
dit eiwit een rol heeft in de regulatie van de celcyclus in myxoid liposarcomen. 
Verder onderzoek naar het eff ect van survivin inhibitie in vivo is nodig en dit 
kan in de toekomst mogelijk leiden tot een nieuwe behandelmogelijkheid 
voor myxoid liposarcomen.
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2SC  S-(2-succino)-cysteine
ABC  Aneurysmal bone cyst
a-CGH  array-Comparative Genomic Hybridization
ACTN1   Alpha-actinin-1
ADCK1  AarF Domain Containing Kinase 1
AKT  AKT Serine/Threonine Kinase
ARL4C  ADP-Ribosylation Factor-Like 4C
ATRX  Alpha thalassemia/mental retardation syndrome X-linked
AXL  AXL receptor tyrosine kinase
BAC  Bacterial artificial chromosome
BCL  B-Cell CLL/Lymphoma 2
BH3  Bcl-2 homology (BH) domain 3 
BIRC5  Baculoviral IAP Repeat Containing 5
BRAF  B-Raf Proto-Oncogene, Serine/Threonine Kinase 
CCR  Complex chromosomal rearrangement
CDH11  Cadherin 11, type 2, OB-cadherin
CDK4  Cyclin-dependent kinase 4
C/EBP  CCAAT-enhancer-binding protein
CHOP  C/EBP homologous protein
COBRA FISH Combined binary ratio labeling fluorescence in situ 
hybridization
COL1A1  Collagen, type I, alpha 1
COL4A5  Collagen, type IV, alpha 5
COL4A6  Collagen, type IV, alpha 6
CT  Computed tomography
CTA  Cancer/testis antigen 
CTAGB1  Cancer testis antigen 1B (NY-ESO-1)
CTNNB1 Beta-catenin
DAPK  Death associated protein kinase
DDIT3  DNA-damage-inducible transcript 3
DPF3  Double PHD Fingers 3
DSB  Double strand breaks
DSS  Disease specific survival
ER  Estrogen receptor
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EXT  Exostosin glycosyltransferase
EWSR1  Ewing sarcoma RNA-binding protein 1
FBS  Fetal bovine serum
FFPE  Formalin-fi xed paraffi  n-embedded
FH  Fumarate hydratase
FIGO  Federation of Gynaecology and Obstetrics
FISH  Fluorescence in situ hybridization
FNCLCC  Fédération Nationale des Centres de Lutte Contre le Cancer
FUS  Fused in sarcoma
GIST  Gastrointestinal stromal tumour
HDAC  Histone deacetylase
H&E  Haematoxylin and eosin
HHF35  Actin
HLRCC  Hereditary leiomyomatosis and renal cell cancer
HMGA1/2 High-mobility group AT-hook 1/2
HRR  Homologous recombination repair
IC50  Half maximal inhibitory concentration
IGF1R  Insulin-like growth factor 1 receptor
KIT  proto-oncogene c-Kit
LM  Leiomyoma
LMOD1  Leiomodin 1
LMS  Leiomyosarcoma
MDM2  Mouse double minute 2 homolog/E3 ubiquitin-protein 
ligase Mdm2 
MED12  Mediator complex subunit 12
MFS  Myxofi brosarcoma
MLS  Myxoid liposarcoma
MPNST  Malignant peripheral nerve sheath tumor
MRI  Magnetic resonance imaging
mTOR  Mammalian target of rapamycin
MYOCD  Myocardin
NFKBIZ  NF-kappa-B inhibitor zeta
NGS  Next Generation Sequencing
NK-cell  Natural killer cell
NY-ESO-1 New York esophageal squamous cell carcinoma 1 (a.k.a. 
CTAG1B)
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OMD  Osteomodulin
OS  Overall survival
PCR  Polymerase chain reaction
PDGFRA/B Platelet Derived Growth Factor Receptor A/B
PI3K  Phosphatidylinositol 3-kinase
PIK3CA  Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic 
Subunit Alpha
PPARγ  Peroxisome proliferator activated receptor gamma 
PR  Progesterone receptor
PTEN  Phosphatase and tensin homolog
q-PCR  quantitative Polymerase Chain Reaction
RAD51L1 RAD51 Paralog B
RB1  Retinoblastoma 1
REST  Repressor element 1 silencing transcription factor
RET  Rearranged during transfection proto-oncogene
RMS  Rhabdomyosarcoma
ROR2  Receptor tyrosine kinase-like orphan receptor 2
RT-PCR  Reverse Transcriptase Polymerase Chain Reaction
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SMA  Smooth muscle actin
SNP  Single nucleotide polymorphism
SSX  Synovial sarcoma X
STR-typing Short tandem repeat typing
STS  Soft tissue sarcoma
SUPT3H Transcription initiation protein SPT3 homolog
SV40  Simian vacuolating virus 40
TAPBP  Transporter associated with antigen processing (TAP) 
binding protein
TC-NER  Transcription-coupled nucleotide-excision repair
TERT  Telomerase reverse transcriptase
TLS  Translocated in Sarcoma
TMA  Tissue microarray
TRAP150 Thyroid hormone receptor-associated protein complex 150 
KDa component
UPS  Undifferentiated pleomorphic sarcoma
USP6  Ubiquitin specific peptidase 6 (Tre-2 oncogene)
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List of abbreviations
WB  Western Blot
WD/DDLPS Well-diff erentiated/dediff erentiated liposarcoma
WHO  World Health Organisation
ZNF9  Zinc fi nger protein 9
WNT4  Wingless-type MMTV integration site family, member 4
WT1  Wilms tumour protein
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